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Nothing in life is to be feared, it is only to be understood. 
Now is the time to understand more, so that we may fear 
less. 
Marie Curie 
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IV. Summary 
 
 
IV. Summary 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder affecting 
around 1% of the population over the age of 65 worldwide. While the majority of cases are 
sporadic, groundbreaking genetic research over the last two decades has revealed a 
complicated network of genes underlying susceptibility and pathology of PD.  Mutations in 
Parkin are the most common cause of early onset Parkinson’s disease. Parkin encodes a 
RING-In Between RING-RING E3 ligase that normally resides in the cytoplasm and is 
regulated by autoinhibitory intramolecular interactions. PINK1 is a mitochondrial Ser/Thr 
kinase that is unique in possessing a N-terminal mitochondrial targeting sequence and three 
loop insertions within its kinase domain. At the outset of my PhD, PINK1 was discovered to 
phosphorylate Parkin at Serine 65 (Ser65), however, little was known about how this 
phosphorylation affected Parkin function and E3 ligase activity. The work described in this 
thesis aims to address in detail the molecular interactions between these proteins.  
In Chapter 3, I describe the development of novel tools and assays to study the PINK1-
Parkin interaction. I demonstrate that PINK1 robustly phosphorylates Parkin at Ser65 in vitro 
as well as in cells. I further show that Parkin is activated via PINK1 mediated 
phosphorylation of Ser65. I validate the mitochondrial GTPase Miro1 as a direct substrate of 
Parkin and employ this novel substrate-based assay to demonstrate a multitude of effects 
conferred by Parkin disease mutations on its phosphorylation and E3 ligase activity. 
In Chapter 4, I describe work that revealed a novel PINK1 substrate – ubiquitin. I 
demonstrate that Ubiquitin gets phosphorylated at a homologous Ser65 residue and this is 
critical for PINK1-mediated Parkin activation. I provide further evidence that both 
phosphorylation events are necessary for optimal Parkin E3 ligase activity.  
Following up on this work, in Chapter 5, I investigate the mechanism by which 
phosphorylated ubiquitin contributes to Parkin activation. I demonstrate that binding of 
phosphorylated ubiquitin to Parkin significantly enhances its phosphorylation by PINK1 and 
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thereby its activation. I further identify Histidine 302 and Lysine 151 as Parkin residues 
critically involved in binding phosphorylated ubiquitin and confirm their importance for 
Parkin phosphorylation and activation in vitro as well as in cells.    
Overall, the work described in this thesis elaborates the mechanism by which Parkin is 
regulated by PINK1-dependent phosphorylation. In parallel this work provides the 
PINK1/Parkin field with a set of valuable tools to evaluate this mechanism. My work not 
only reveals PINK1-dependent Parkin activation via direct phosphorylation of the Parkin 
Ser65 residue, but goes on to identify a new key player in this pathway – Ser65 phosphorylated 
ubiquitin. Finally my studies provide novel and original insights into the interplay of these 
three proteins towards driving Parkin activation. 
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1 Chapter 1 Introduction 
1.1 Parkinson’s Disease  
1.1.1 Historical overview  
The first mentions of an akinetic movement disorder date back to 5000 BC in Indian practice 
of medicine, known as Ayurveda. However, it was not until 1817 when the first formal 
description and classification of the clinical features  was reported in the famous essay by 
physician James Parkinson, entitled ‘An essay on the shaking palsy’ wherein he describes 6 
cases bearing a syndrome that now bears his name Parkinson’s disease (Pearce, 1989, 
Parkinson, 1817): 
‘SHAKING PALSY (Paralysis Agitans) 
Involuntary tremulous motion, with lessened muscular power, in parts not in action 
and even when supported; with a propensity to bend the trunk forwards, and to pass from a 
walking to a running pace: the senses and intellects being uninjured.’ 
The initial description of the illness was greatly expanded by French physician Trousseau 
who recognised muscle rigidity, displacement of the centre of gravity, bradykinesia as well as 
eventual damage to the patient’s intellect as symptoms associated with PD in his 15th Lecture 
on Clinical Medicine (Trousseau, 1868). While James Parkinson had wrongly suggested that 
the cause of the disease might lie in the ‘ medulla spinalis’  (spinal cord), it was not until 
the early 20th century that the substantia nigra located in the midbrain was firmly established 
as the major site of pathology. The very first mention of substantia nigra as the potential 
‘anatomical basis of Parkinson’s disease’ is attributed to Brissaud (Brissaud, 1895), however 
it was admittedly speculative and further validation was needed. It was the doctoral work of 
Russian student Tretiakoff, who examined the substantia nigra in post mortem brains of 9 
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individuals with paralysis agitans and 3 with postencephalitic Parkinsonism and observed 
lesions, loss of pigmented nigral neurons and the appearance of Lewy bodies in the surviving 
neurones, that indicated that the substantia nigra was the primary anatomical place of origin 
for PD (Trétiakoff, 1919, Lewy, 1912). 
In the 1950s and 1960s seminal discoveries set the stage for the current understanding of 
dopamine involvement in PD as well as its modern treatment with L-3,4-
dihydroxyphenylalanine (L-dopa)– a natural dopamine precursor (Riederer et al., 2006). 
First, dopamine as a neurotransmitter was discovered to have a biological function distinct 
from noradrenaline and other known catecholamines (Blaschko, 1957), followed by the finding 
of its involvement in regulation of movement control as well as central motoric function 
(Bertler and Rosengren, 1959, Sano et al., 1959). Clear demonstration of the reduction in 
dopamine levels in PD brains (Ehringer and Hornykiewicz, 1960) combined with the 
knowledge that L-dopa is a natural precursor to dopamine, encouraged Hornykiewicz to start 
the first clinical trials of L-dopa as a treatment for PD, leading to the ‘dopamine miracle’ and 
later its adaptation as common medical treatment for PD: 
‘Bed-ridden patients who were unable to sit up, patients who could not stand up when seated, 
and patients who when standing could not start walking performed all these activities with 
ease after L-dopa [levodopa]. They walked around with normal associated movements and 
they could even run and jump. The voiceless, aphonic speech, blurred by palilalia and unclear 
articulation, became forceful and clear as in a normal person’ (Birkmayer and Hornykiewicz, 
1961). 
1.1.2 Clinical symptoms and pathology of Parkinson’s Disease 
Parkinson’s disease is the second most common neurodegenerative disorder, characterised by 
progressive loss of neurons from substantia nigra pars compacta, dopamine loss in striatum 
and accumulation of pathogenic cytoplasmic inclusion bodies known as Lewy bodies. Lewy 
bodies are rich in ubiquitin, α-synuclein, neurofilaments and molecular chaperones (Spillantini 
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et al., 1998, Forno, 1996). The main risk factor associated with PD is age and positive family 
history. As the average life expectancy continues to increase in developed countries, so does 
the incidence and prevalence of Parkinson’s - the current life-time risk of developing the 
disease being 1.5% (Bower et al., 1999) – and this is expected to rise exponentially therefore 
increasing socioeconomical burden (Dorsey et al., 2007) 
PD is characterised by two classes of symptoms – motor and non-motor. Motor symptoms 
encompass resting tremor, bradykinesia (slowness of movement), rigidity and postural 
imbalance –  also known as the PD quartet. The onset of the symptoms is typically unilateral 
and continues to progress and persist asymmetrically. It was estimated that the manifestation 
of motor symptoms occurs only after 50-60 % of dopaminergic neurons have been lost 
(Riederer and Wuketich, 1976) and therefore marks a relatively late stage of disease 
progression. While the non-motor symptoms are less well known, they can be equally, if not 
more so, debilitating - these include loss of sense of smell, constipation, alterations in REM 
behaviour, mood disorders, orthostatic hypotension as well as a range of neurobehavioral 
disturbances - and can appear well before the motor symptoms (Beitz, 2014). 
1.1.3 Genetics of Parkinson’s disease 
While the aetiology of Parkinson’s at large remains a mystery, the majority of cases are 
believed to be caused by a combination of environmental and genetic factors. Over 90 % of 
the cases are believed to be sporadic, however, a long-acknowledged high prevalence of 
positive family history in PD patients has led to exploration of possible genetic causes. It was 
not until 1997 that the first gene causing the illness was identified (Polymeropoulos et al., 
1997). Since then at least 10 other monogenic forms of PD with both autosomal dominant 
and recessive forms of inheritance have been discovered and have opened a path for 
exploration of the molecular pathways underlying the illness (Bras et al., 2015). The genes 
were denoted with PARK to mark their putative association with PD and numbered in a 
chronological order of discovery. Table 1.1 summarises the genes known to cause monogenic 
PD. 
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Gene Gene locus Disorder Inheritance Protein 
SNCA 4q21-22 EOPD AD -synuclein 
Parkin 6q25.2-q27 EOPD AR Parkin 
PINK1 1p35-36 EOPD AR PINK1 
DJ1 1p36 EOPD AR DJ1 
LRRK2 12q12 Classical PD AD LRRK2 
ATP13A2 1p36 
juvenile 
parkinsonism 
AR ATP13A2 
PLA2G6 22q13.1 
juvenile 
parkinsonism 
AR PLA2G6 
FBXO7 22q12-q13 
juvenile 
parkinsonism 
AR FBOX7 
VPS35 16q11.2 Classical PD AD VPS35 
DNAJC6 1p31.3 
juvenile 
parkinsonism 
AR DNAJC6 
SYNJ1 21q22.2 
juvenile 
parkinsonism 
AR SYNJ1 
EOPD-early onset PD; AD-autosomal dominant; AR-autosomal recessive 
1.1.4  Autosomal dominant Parkinson’s Disease 
Three genes are confirmed to cause autosomal dominant Parkinson’s disease – -synuclein, 
leucine rich repeat kinase 2 (LRRK2) and vacoular protein sorting-associated protein 35 
(VPS35). 
SNCA (PARK1/4) gene, encoding -synuclein, was the first gene to be identified causally 
linked to Parkinson’s disease (Polymeropoulos et al., 1997). Originally, the investigators 
identified a point mutation – A53T – however, gene duplications (Ibanez et al., 2004) and 
triplications (Singleton et al., 2003) are much more common. Since then, several other single 
point mutations have been identified including A30P (Narhi et al., 1999), E46K (Zarranz et 
al., 2004), H50Q (Proukakis et al., 2013), and G51D (Lesage et al., 2013). The function of -
synuclein remains unknown although it has been implicated in hippocampal neurogenesis 
Table 1.1 PD Mendelian genes 
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(Winner et al., 2012). Nevertheless, the pathogenicity of mutant -synuclein forms is 
attributed to their increased propensity to aggregate into toxic oligomers, leading to 
formation of sheets (Bertoncini et al., 2005). Patients with SNCA multiplications suffer 
from earlier-onset, and more rapidly progressive PD with strong correlation to gene-dosage 
effects (Fuchs et al., 2007). 
Mutations in LRRK2 (PARK8) gene are the most common cause of autosomal dominant PD 
and are commonly found in idiopathic cases; they were first identified in 2004 in multiple 
studies carried out in different parts of the world (Cookson, 2015, Zimprich et al., 2004, 
Paisan-Ruiz et al., 2004). LRRK2 encodes a large (>250 kDa) protein and contains both a 
kinase and GTPase domain; in addition, several other domains involved in protein-protein 
interaction have been identified, however, the physiological function of the protein is still 
unknown. Multiple mutations linked to PD have been reported with the most prevalent being 
G2019S, demonstrated to significantly increase kinase activity by 2-3 fold (Jaleel et al., 2007, 
West et al., 2005). While being common, the G2019S mutation does not demonstrate full-
penetrance, suggesting that additional factors might be important for manifestation of 
symptoms (Cookson, 2015).  
VPS35 has been identified relatively recently (Vilarino-Guell et al., 2011) and suggest that 
vesicle and endosomal trafficking may be implicated in PD but further work is needed to 
understand how mutations in this gene confer pathogenicity. 
1.1.5 Autosomal recessive Parkinson’s Disease 
While multiple genes with autosomal recessive mode of inheritance have been linked to PD 
(Table 1.1), only three have been extensively studied and will be discussed here: Parkin, 
PINK1 and DJ1. 
Mutations in Parkin (PARK2) gene, first identified in 1998 (Kitada et al., 1998), are the 
leading cause of autosomal recessive Parkinson’s disease. Over 100 missense mutations and a 
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multitude of gene rearrangements have been identified leading to early onset PD (EOPD) 
(age of onset <40) and juvenile parkinsonism (age of onset <21) (Klein and Westenberger, 
2012). Parkin encodes an E3 ligase that has been implicated in monitoring mitochondrial 
quality control, further discussed below.  
The PINK1 (PARK6) gene has also been linked to EOPD (Valente et al., 2004). The PINK1 
gene encodes a mitochondrial serine/threonine kinase PINK1 (PTEN (phosphatase and 
tensin homologue)-induced kinase 1), mutations in which have been found to disrupt the 
kinase activity (Woodroof et al., 2011) and confer the second most common cause of early-
onset PD.  
The link between mutations in DJ-1 (PARK7) and EOPD was first established in 2003 
(Bonifati et al., 2003). Mutations in DJ-1 amount to only 1-2 % of the cases (Pankratz et al., 
2006) with a phenotype that resembles other EOPD syndromes linked to PINK1 and Parkin 
(Hardy et al., 2006). DJ-1 is thought to encode an oxidative chaperone that is ubiquitously 
expressed, mutation of which (L166P) renders the protein unstable and leads to its rapid 
degradation by the 20S proteasome (Anderson and Daggett, 2008). 
1.2 Post-translational modifications 
Post-translational modifications (PTMs) are amongst the most universal regulatory 
mechanisms across all living species. They are defined as (mostly) enzyme-catalysed covalent 
modifications of polypeptide chains and roughly fall into one of three classes: linkage, 
breakage or cross-linking (Farriol-Mathis et al., 2004). PTMs are highly diverse, dynamic and 
reversible with over 400 identified to date (Khoury et al., 2011). While some of the PTMs 
are stable (e.g. glycosylation, lipidation, etc.) and serve a function in protein folding, stability 
and localisation, others, such as phosphorylation, methylation, acetlylation and 
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ubiquitylation, are far more transient  and serve an important function in cellular signalling 
via regulation of protein activity, degradation and localisation.  
Post-translational modifications encompass the second level of governance in the cell after 
the gene regulation resulting in exponential increase in the cellular proteome complexity and 
creating a multi-layered fine-tuned organisational system. Despite what the name suggests, 
PTMs can occur before (deamidation), during (cleavage of signalling peptides) and after 
(phosphorylation) an amino acid has been incorporated to a polypeptide chain. They can be 
induced by extracellular or intracellular signalling events and can affect multiple different 
proteins or be directed at a highly specific pool of proteins. More than one PTM can be found 
on a protein at any one time and indeed it has been found that several different PTMs can 
serve in concert or in opposition of each other. 
1.2.1 Ubiquitylation 
1.2.1.1 Ubiquitin 
Ubiquitin is a small, 76 amino acid, modifier protein first discovered in 1975 that is 
ubiquitously expressed in eukaryotes and is highly conserved from yeast to humans 
(Schlesinger and Goldstein, 1975, Goldstein et al., 1975). It is encoded by four separate genes 
in mammals 2 of which encode a polyubiquitin precursor while the other 2 encode a 
monoubiquitin moiety fused to an essential ribosomal subunit; after expression, the 
polypeptides are cleaved by deubiquitylating enzymes (DUBs) and a monoubiquitin is 
released (Kimura and Tanaka, 2010). Ubiquitin is a part of a family of ubiquitin-like modifiers 
(UBLs) that share a structural homology – the -grasp fold - and include autophagy related 
protein-8 (ATG8) and -12 (ATG12), human leukocyte antigen F associated transcript 10 
(FAT10), Fau ubiquitin-like protein (FUB1), neural precursor cell expressed developmentally 
down-regulated protein 8 (NEDD8), small ubiquitin-like modifier (SUMO), interferon-α-
stimulated gene-15 (ISG15), ubiquitin-like protein-5 (UBL5), ubiquitin fold-modifier-1 
(UFM1) and ubiquitin-related modifier-1 (URM1) (Hochstrasser, 2009). Ubiquitin is an 
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essential constituent of ubiquitylation – a master regulatory reversible PTM that has been 
demonstrated to play a key role in regulating protein degradation, signal transduction, protein 
trafficking and others (Kimura and Tanaka, 2010). The reversal of ubiquitylation is called 
deubiquitylation and is mediated by DUBs. 
1.2.1.2 Ubiquitylation cascade 
The ubiquitylation cascade facilitates covalent ubiquitin attachment to the -amino group of 
a substrate lysine. It involves 3 relay steps, each of which is catalysed by a different class of 
enzymes. The cascade is initiated when ubiquitin is activated by E1 ubiquitin activating 
enzyme in an ATP-dependent manner, followed by ubiquitin transfer to the catalytic cysteine 
on the E2 ubiquitin conjugating enzyme and finally its ligation to the target protein carried 
out by an E3 ubiquitin ligase (Figure 1.1). During the cascade a single ubiquitin moiety can 
be attached to a single target lysine (monoubiquitylation), or to several lysines on the 
substrate protein (multi-monoubiquitylation). Alternatively, further ubiquitin moieties can 
be conjugated onto the first ubiquitin in a head to tail manner via the N-terminal methionine 
(called linear or M1 chain formation) or one of the seven native ubiquitin lysines (Lys6, 
Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) – this process is called polyubiquitylation.  
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Figure 1.1 Ubiquitylation cascade.  
Ubiquitin activating enzyme E1 activates the C-terminus of ubiquitin in an 
ATP-dependent manner. Ubiquitin is next transferred to the catalytic cysteine 
of ubiquitin conjugating enzyme E2 ensuing interaction with an E3 ubiquitin 
ligating enzyme. RING E3s bind and coordinate the E2-ub and substrate pair to 
facilitate a direct transfer of ubiquitin while HECTs have a catalytic cysteine 
that forms a thioester intermediate with the ubiquitin moiety before its transfer 
to the target protein. The ubiquitylated proteins are subjected to various fates 
including degradation and cell signalling. 
 
Polyubiquitin chains can be of varying lengths and constructed in a variety of different ways. 
The consecutive ubiquitins can be added on the same lysine repeatedly, leading to formation 
of homotypic ubiquitin chains or incorporate several different linkage types leading to 
heterotypic and/or branched chain formation (Figure 1.2). It is the chain topology, length 
and linkage type that define the interaction with ubiquitin-binding domains on a variety of 
proteins (Hicke et al., 2005) and determine the end outcome of the ubiquitin signalling event. 
Protein degradation was the first physiological outcome of ubiquitylation to be described 
(Ciehanover et al., 1978), it was only later that ubiquitin’ s role in the regulation of cell cycle, 
transcription and DNA repair were discovered. Indeed, even now ubiquitylation carries a 
strong connotation towards degradative cellular pathways, although a vast variety of 
signalling outcomes have been discovered (reviewed in (Kulathu and Komander, 2012)).  
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1.2.1.3 Catalytic triad of ubiquitin system  
The first step of the ubiquitylation cascade is catalysed by E1 activating enzymes. As its 
name suggests, E1 activates ubiquitin. It achieves this in a two-step manner, wherein it first 
acyl-adenylates the carboxy terminus of the ubiquitin sacrificing an ATP molecule. The E1 
catalytic cysteine then attacks the adenylated ubiquitin, forming an E1-ubiquitin thioester 
Figure 1.2 Ubiquitin chain topologies 
A Summary of different ways ubiquitin can be attached to a target protein. Mono 
ubiquitylation ensues when a single ubiquitin moiety is attached to the substrate 
protein. Multi-mono ubiquitylation is attachment of more than one ubiquitin that 
do not form a chain. Polyubiquitin chains can be homotypic meaning the same 
linkage type is formed between all ubiquitin molecules or heterotypic – different 
linkage types can be found in the same ubiquitin. If two or more ubiquitin moieties 
are attached to a preceding ubiquitin, branched chain formation is observed. B 
Ubiquitin structure showing N-terminal methionine and lysine residues all of 
which can act as linkage points for the formation of polyubiquitin chains. PDB 
ID: 1UB 
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bond that is accessible to E2 enzymes (Schulman and Harper, 2009). Two E1 genes have been 
identified in human genome, UBE1 (Haas et al., 1982) and UBE1L2 (Jin et al., 2007).  
The next step in the signal relay is catalysed by one of over 40 E2 conjugating enzymes. It is 
achieved by a nucleophilic attack on the E1-ubiquitin bond by the E2 catalytic cysteine and 
formation of another high-energy thioester bond between the E2 and ubiquitin. E2 enzymes 
are heterogeneous in their preference for E1 enzyme and usually interact with more than one 
E3 ligase (Ye and Rape, 2009). The pairing of the E2 and E3 is extremely important for 
determining ubiquitin chain topology – it has been demonstrated that pairing of E3 ligases 
CHIP and MuRF1 with E2 UbcH5 results in a branched, heterotypic chain formation, while 
the same E2 pairing with E6AP E3 ligase resulted in homotypic K48 chain formation, and in 
addition, when dimeric E2 UbcH13/Uev1a was tested, CHIP and MuRF1 produced 
homotypic K63 chains (Kim et al., 2007). 
Ubiquitin transfer onto the substrate protein is catalysed by an E3 ubiquitin ligating enzyme. 
It is estimated that the human genome encodes over 600 E3 ligases, the majority of which 
belong to the RING (really interesting new gene) superfamily (Li et al., 2008). RING E3s act 
as scaffold proteins, bringing the ubiquitin-bound E2 (E2-ub) and substrate together and 
orienting them in a manner that allows a direct ubiquitin transfer to occur. RING E3s are 
characterised by the presence of a RING domain that typically contains 8 cysteine or histidine 
residues (with some exceptions) that coordinate zinc ions in a cross-brace conformation and 
help maintain the globular domain folding (Deshaies and Joazeiro, 2009). The canonical 
RING domains recruit and bind an E2 ligase as well as a hydrophobic patch on the donor 
ubiquitin; some also directly interact with substrate proteins (Deshaies and Joazeiro, 2009). 
Lacking a bona-fide catalytic cysteine, RING E3s catalyse the transfer of ubiquitin to 
substrate via activation of the E2-ub conjugate by conformational rearrangement (Metzger 
et al., 2013), the mechanistic insights of which have been revealed in recent studies 
(Plechanovova et al., 2012, Branigan et al., 2015). Recent structural analysis of the RING 
E3 ligase, RNF4, in complex with the E2, UbcH5A linked to ubiquitin via an isopeptide bond 
has shed light on the mechanism and reveals alteration of the E2 active site that primes it 
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for catalysis to enable deprotonation of the incoming substrate lysine residue (Plechanovova 
et al., 2012). The majority of RING E3s exist in multimeric complexes and are found as 
homo- or hetero-dimers, e.g. cIAP (Mace et al., 2008) and BRCA1-BARD1 (Hashizume et 
al., 2001), others can oligomerise and be a part of supramolecular complexes (Kentsis et al., 
2002) although some monomeric E3s can also be found. Substrate recognition of RING E3s 
is commonly facilitated by interacting proteins that contain F-box, SOCS box, VHL box 
or BTB domains (Metzger et al., 2013). 
The other catalytic class of E3 ligases are HECT (Homologous to E6-AP C-Terminus) E3s. 
Unlike RING E3s, HECT ligases have a catalytic cysteine and catalyse the ubiquitylation 
reaction in a two-step mechanism, wherein the ubiquitin from E2-ub first forms a thioester 
bond with the E3 forming an unstable intermediate and leading to the subsequent ubiquitin 
transfer to the target protein (Kamadurai et al., 2013). HECT E3s contain a C-terminal 
HECT domain that carries the evolutionary-conserved catalytic cysteine, while their N-
termini are diverse and usually involved in substrate recognition (Berndsen and Wolberger, 
2014, Scheffner and Kumar, 2014). HECT E3s display a preference for their cognate E2, 
specifically UbcH7 and members of UbcH5 family have been shown to be preferentially 
recruited by these E3s (Schwarz et al., 1998). 
RING – In Between RING – RING (RBR) could be called the ‘ misfits’  of the E3 ligases 
since they do not fit exclusively in either of the above described categories. Traditionally 
believed to belong to RING E3 superfamily, due to presence of two RING domains, RBR 
ligases carry a catalytic cysteine that forms a thioester intermediate with ubiquitin (Wenzel 
et al., 2011) therefore displaying HECT-like properties. Indeed, RBRs have been reclassified 
as RING/HECT hybrids (Spratt et al., 2014, Smit and Sixma, 2014) and were found to have 
several unusual properties. First, they are able to overcome the requirement for E2 and are 
able to interact with E1-ub thioester directly (Smit et al., 2012, Stieglitz et al., 2012a, Chew 
et al., 2011). In addition, their ubiquitin thioester intermediate is difficult to trap/detect, 
suggesting that it might be highly unstable. Finally, all the RBRs studied so far display a 
tight regulation and auto-inhibition (Smit et al., 2012, Stieglitz et al., 2012a, Chew et al., 
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2011, Chaugule et al., 2011, Burchell et al., 2012). Parkin, the main topic of my thesis, is an 
RBR E3 ligase and will be discussed further in section 1.3. 
1.2.1.4 Ubiquitin system and human disease 
Given the diversity of ubiquitylation functions, some of which have likely not yet been 
discovered, it is no wonder that misregulation of this system at any level leads to a variety 
of human diseases, e.g. two missense mutations in E1 UBA1 enzyme have been linked to X-
linked infantile spinal muscular atrophy (Ramser et al., 2008), while mutations in Ube2H 
have been implicated in X-linked mental retardation syndrome (Nascimento et al., 2006). 
Mutations in E3 ligases and their interacting proteins have been linked to a variety of disease, 
including cancers and neurological disorders (Petroski, 2008). Mutations in E3 ligase BRCA1 
(breast cancer type 1) have been strongly linked to predisposition to breast and ovarian 
cancer (Futreal et al., 1994, Hall et al., 1990). Three different ubiquitin-related proteins are 
linked to Parkinson’s disease. Mutations in RBR E3 ligase Parkin – topic of this thesis - are 
the most common cause of early onset Parkinson’s Disease (Kitada et al., 1998). Mutations 
in Fbxo7 – F-box protein that is part of SKP1-Cullin E3 ligase complex – are linked to 
juvenile Parkinsonism (Shojaee et al., 2008). UCHL1 – a carboxy terminal ubiquitin hydrolase 
– has also been linked to PD (Wintermeyer et al., 2000). Angelman’s syndrome – a complex 
neurodevelopmental disorder – has been shown to be caused by mutations in HECT E3 ligase 
E6-AP (Kishino et al., 1997) while another E3 HUWE1 has been implicated in a mental 
retardation syndrome (Froyen et al., 2008). This is by all means not a complete list of 
disorders and illnesses caused by mutations in the ubiquitin system, but it serves to show 
how important it is and opens new avenues for discovery and progress – in particular the 
ubiquitin proteasome system has been scrutinised recently as a potential target for drug 
discovery. It is therefore paramount to gain as much information about molecular, cellular 
and physiological mechanisms governing its correct regulation and thereby ways to 
manipulate them. 
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1.2.2 Phosphorylation 
1.2.2.1 Phosphorylation – general overview 
Protein phosphorylation is a reversible formation of a phosphoester bond between a 
phosphoryl group of the donor ATP and hydroxyl group of one of three amino acids - serine, 
threonine or tyrosine (Figure 1.3). It was first discovered in 1954 when G. Burnett and E. 
Kennedy have radioactively labelled casein by incubating it with mitochondrial fractions from 
rat livers (Burnett and Kennedy, 1954). Phosphorylation plays an important role in a number 
of cellular events, including metabolism, transcription, cytoskeletal rearrangements, cell cycle 
progression and others with up to 30% of the human proteome estimated to be subject to 
phosphorylation (Kreegipuu et al., 1999). Addition of a double negative charge of the 
phosphate group on to a substrate protein, commonly on more than one residue, induces a 
large change in the local chemical environment of the protein that might lead to formation 
of new hydrophobic and/or electrostatic interactions (Johnson and Lewis, 2001). Such 
alterations can cause conformational and/or activity shifts in the substrate protein (Figure 
1.3). In fact, kinase self-activation via auto-phosphorylation is a commonly employed 
mechanism. In addition, phosphorylation might lead to changes in protein-protein 
interactions resulting in altered protein function, localisation or stability (Figure 1.3).  
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Protein phosphorylation is catalysed by a family of 518 enzymes, termed kinases, while its 
reversal is achieved via hydrolysis facilitated by the phosphatase family members. Protein 
kinases (PKs) can be classified by amino acid they phosphorylate or by sequence homology 
of their kinase domain. The first method gives rise to serine/threonine kinases and tyrosine 
kinases (TKs), which are further subdivided into receptor and non-receptor TKs. The second 
method was used in a landmark bioinformatic study that has classified all known and newly 
identified human kinases according to their sequence similarities and giving rise to the human 
kinome (Manning et al., 2002). Kinases in the eukaryotic protein kinase (ePK) superfamily 
were divided into TK; TKL (tyrosine kinase-like); STE (containing the homologues of yeast 
Sterile 7, Sterile 11 and Sterile 20 kinases); CK1 (casein kinase 1); AGC (containing PKA, 
PKG and PKC families); CAMK (calcium/calmodulin-dependent protein kinases); and 
 Figure 1.3 Protein phosphorylation 
A Proteins can be phosphorylated by kinases in an ATP-dependent manner. The 
process can be reversed by a class of proteins named phosphatases. B Protein 
phosphorylation can lead to a variety of changes, including shifts in protein 
structure and/or activity, interaction with other proteins and target protein 
localisation. 
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CMGC (containing the CDK, MAPK, GSK3 and CLK families) subfamilies (Manning et al., 
2002). A smaller kinase superfamily with an atypical protein kinase (aPK) domain comprised 
of 13 families was also reported (Manning et al., 2002).  
Protein phosphatases catalyse the removal of the phosphate group(s) from a phosphoprotein 
via hydrolysis leading to the release of a phosphate ion. Unlike PKs, phosphatases have 
evolved in separate families that have distinct structural and functional differences (Tonks, 
2006). They are therefore classified into 3 distinct families depending on their catalytic 
activity as well as sequence and structure into protein Serine-Threonine phosphatases, 
Tyrosine phosphatases, and dual (S/T-Y) phosphatases (Cohen, 2011). Representing a far 
smaller group of proteins, protein phosphatases are more promiscuous than their kinase 
counterparts, however, their activity is very finely controlled. This is achieved through a 
dynamic association and dissociation of the catalytic and regulatory subunits that is spatially 
and temporally controlled (Tonks, 2006, Shi, 2009).    
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Figure 1.4 The human kinome 
Classification ePKs by Manning et al, 2002: TK (tyrosine kinase); TKL (tyrosine 
kinase-like); STE (containing the homologues of yeast Sterile 7, Sterile 11 and 
Sterile 20 kinases); CK1 (casein kinase 1); AGC (containing PKA, PKG and PKC 
families); CAMK (calcium/calmodulin-dependent protein kinases); and CMGC 
(containing the CDK, MAPK, GSK3 and CLK families). PINK1, a kinase 
mutated in PD, is highlighted in a red oval.  
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1.2.2.2 Protein kinases and human disease 
Protein phosphorylation is a ubiquitous regulatory mechanism evolutionary conserved in all 
living organisms, including bacteria, archaea and eukaryotes. It therefore comes as no surprise 
that upon failure to preserve normal kinase functions, whether due to genetic inheritance or 
sporadic mutations, diseases can arise. Mutations in kinases have been associated with 
neurological disorders, cancers and autoimmune diseases summarised in (Lahiry et al., 2010) 
and http://www.cellsignal.com/common/content/content.jsp?id=science-tables-kinase-
disease. The ever-increasing number of kinase mutations associated with human disease has 
led to research into molecular pathways underlying pathologies and human kinases have 
become a popular drug target (Cohen and Alessi, 2013). The proof of concept was achieved 
with Imatinib (Gleevec) that was designed to inhibit a constitutively active TK Bcr-Abl that 
causes the development of chronic myeloid leukaemia (Capdeville et al., 2002). To date, 28 
small molecule kinase inhibitors have been approved by Food and Drug Administration 
(FDA), two of which were approved earlier this year (Wu et al., 2015). 
1.3 Parkin 
Autosomal-recessive mutations in Parkin were first identified in an Asian cohort of PD 
patients in 1998 (Kitada et al, 1998) and have since been established as the most common 
cause of early onset (<40 yr) PD (~20% worldwide, ~50% of familial forms, ~80% in cases 
when onset <20yr) (Hedrich et al., 2004, Periquet et al., 2003, Lucking et al., 2000). The 
PARK2 gene is the second largest in the human genome, spanning over 1.3 MB; it contains 
12 exons and encodes a 465 amino acid (52 kDa) protein that functions as an E3 ligase (Zhang 
et al., 2000, Shimura et al., 2000).  
Parkin is a complex multi-domain protein that belongs to the RBR family of E3 ligases 
(Figure 1.5). It has an N-terminal regulatory Ubl domain that shares 31% identity and 61% 
similarity with ubiquitin (Tanaka et al., 2001).  The C-terminal portion of the protein 
harbours a RING1 domain separated by an IBR domain from the catalytic IBR-like RING2 
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domain forming a catalytic core of the enzyme. The two ends of the protein are connected 
via unique Parkin domain (UPD) (Figure 1.5). Parkin was first identified as a candidate E3 
ligase due to sequence homology with other RING domains and upon testing it was shown to 
have E2-dependent ubiquitylation activity (Zhang et al., 2000, Shimura et al., 2000). While 
mutation-induced failure to regulate canonical proteasome-dependent degradative pathways 
was the first leading hypothesis as per mode of pathology, it was soon challenged by the 
discovery of non-degradative functions of Parkin – formation of Parkin-dependent K48 and 
K63 polyubiquitin chains was demonstrated on synphilin1 (Lim et al., 2005). In addition, 
Parkin was shown to possess auto-ubiquitylation, mono and multi-mono ubiquitylation 
activities (Hampe et al., 2006). In recent years the understanding of Parkin-dependent 
ubiquitylation function has become even more complicated due to reports demonstrating 
Parkin’s apparent lack of preference for a single ubiquitin type topology both in vitro and in 
cells (Kazlauskaite et al., 2014a, Ordureau et al., 2014). 
In addition to a large functional variety, Parkin displays a great range of neuroprotective 
effects. In different model systems Parkin has been shown to mediate neuroprotection against 
mitochondrial-dependent apoptosis, dopamine-mediated toxicity, kainate-induced 
excitotoxicity, the toxicity associated with overexpression of parkin substrates or other 
proteins (Pael-R, p38/JTV-1, mutant α-synuclein, CDCrel-1, mutant tau and an expanded 
polyglutamine ataxin-3 fragment), proteasomal inhibition, mitochondrial toxins (MPP+ and 
rotenone) and manganese toxicity among others (Moore, 2006). Vice versa, parkin-deficient 
cells are characterized by an increased vulnerability to stress-induced cell death (Exner et al., 
2012). It is therefore paramount to understand the molecular details underlying Parkin 
regulation and function to gain a better understanding of neuronal vulnerability.  
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Figure 1.5 Domain architecture and structure of Parkin 
Top. Representative view of Parkin domain architecture. Ubl – ubiquitin like 
domain, UPD, RING1 and RING2 – really interesting new gene domains 0, 1 
and 2, IBR – in between RING domain. Bottom. Crystal structure of full-length 
Parkin, colouring the same as above. PDB ID: 4k95 
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Parkin normally resides in the cytoplasm, but upon mitochondrial stress it translocates to 
the mitochondria via mechanisms discussed later in this chapter. Historically, Parkin was 
believed to be a constitutively active RING E3 ligase. It was work by Wenzel and colleagues 
that had revealed for the first time that Parkin contains a catalytic cysteine in the RING2 
domain, Cys431, thereby suggesting it may have RING-HECT hybrid properties (Wenzel et 
al., 2011). Further analysis revealed that Parkin exists in an auto-inhibited conformation 
mediated by its Ubl domain (Chaugule et al., 2011) and that addition of N-terminal tags 
displaces this mechanism and leads to constitutive enzyme activation (Burchell et al., 2012). 
The panoply of auto-inhibitory intramolecular interactions was greatly expanded once Parkin 
structures were solved: Ubl domain and repressor element (REP) of Parkin were shown to 
bind RING1 where the putative E2 binding site is located (Riley et al., 2013, Wauer and 
Komander, 2013, Trempe et al., 2013) (Figure 1.5). Furthermore, the interaction between the 
UPD and RING2 domains was revealed to partially occlude the catalytic site, suggesting that 
several molecular rearrangements need to occur for Parkin activation. The key upstream 
signal leading to initiation of these conformational changes – phosphorylation by PINK1 – is 
the main subject of this thesis. 
1.4 PINK1 
PINK1 gene was first described in 2001 when it was found to be up-regulated upon 
introduction of exogenous PTEN in endometrial cancer cells (Unoki and Nakamura, 2001), 
the same year that the PARK6 locus was identified in a consanguineous Sicilian family with 
EOPD (Valente et al., 2001). However, it was not until 2004 with the identification of two 
other consanguineous families (one from Italy and one from Spain) that homozygous 
autosomal recessive mutations were mapped onto PINK1 (Valente et al., 2004). 
PINK1 gene is ubiquitously expressed in humans with higher abundance detected in heart, 
skeletal muscle and testis (Unoki and Nakamura, 2001). PINK1 encodes a 581 amino acid 
Ser/Thr protein kinase that is unique amongst all other PKs. It has an N-terminal 
mitochondrial targeting sequence (MTS) and a transmembrane domain. The catalytic kinase 
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domain resides in the C-terminal portion of the protein and contains three insertions that are 
not conserved with other human kinases (Cardona et al., 2011). 
 
 
The presence of the N-terminal MTS dictates that in cells PINK1 gets imported to 
mitochondria (Figure 1.7). Translocase of the outer membrane (TOM) is a multi-subunit 
complex on the outer mitochondrial membrane that selectively recognises and successively 
imports PINK1 across the inner mitochondrial membrane via TIM40 and TIM23 (Figure 1.7) 
(Model et al., 2002, Lazarou et al., 2012). Upon mitochondrial import, PINK1 undergoes 
sequential cleavage by mitochondrial proteases MPP (mitochondrial processing peptidase) 
and PARL (presenilin-associated rhomboid-like protein) (Figure 1.7) (Deas et al., 2011, Jin 
et al., 2010, Whitworth et al., 2008, Greene et al., 2012); the C-terminal fragment of PINK1 
lacking the first 103 amino acids is then released to the cytoplasm where its N-terminal 
residue, Phe, signals it for rapid degradation via the N-end rule pathway (Yamano and Youle, 
2013) (Figure 1.7). Consequently, very low levels of PINK1 are detectable in healthy cells.     
Figure 1.6 Domain architecture of PINK1.  
MTS- mitochondrial targeting sequence, TM –transmembrane helix, Ins1, Ins2, 
Ins3 – insertions 1,2 and 3 respectively, CTD – C-terminal domain. 
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PINK1 stability was first found to be regulated by mitochondrial membrane potential in a 
seminal study wherein cellular treatment with valinomycin was found to inhibit PINK1 
cleavage and hence degradation (Lin and Kang, 2008). This in turn led to its accumulation 
on the outer mitochondrial membrane (OMM) (Lin and Kang, 2008) where its kinase domain 
is exposed to cytosol and available for substrates (Zhou et al., 2008). Further studies have 
demonstrated that a mitochondrial ionophore, carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP), also leads to PINK1 accumulation on the mitochondria (Meissner et al., 2011, 
Matsuda et al., 2010, Narendra et al., 2010) due to inhibition of PARL protease that is 
dependent on mitochondrial potential (Jin et al., 2010).  
1.5 PINK1, Parkin and mitochondrial integrity 
1.5.1 Mitochondria in Parkinson’s disease 
It was a batch of illicitly produced heroin and a group of Californian drug addicts that 
provided the first compelling link between mitochondrial dysfunction and PD (Langston et 
Figure 1.7 PINK1 import and processing.  
PINK1 gets imported to mitochondria via its N-terminal positively charged MTS 
through TOM/TIM machinery as depicted above. It then gets sequentially 
cleaved by MPP and PARL. Releasing a C-terminal fragment lacking first 103 
amino acids. This is then recognized by N-end rule pathway and degraded by 
proteasome. 
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al., 1983). The botched heroin contained a neurotoxic byproduct MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) that readily crosses brain-blood barrier and is rapidly 
incorporated into the acidic organelles of astrocytes where it is oxidised to MPP+ (1-methyl-
4-phenylpyridinium) (Brady et al., 2005). Upon release to the extracellular matrix, MPP+ is 
taken up by dopaminergic nerve terminals via dopamine transporters, where it exercises its 
effects via complex I (NADH ubiquinone oxidoreductase) inhibition leading to a severe 
dopaminergic loss and Parkinsonism (Nicklas et al., 1985).  
Mitochondrial dysfunction in PD is further supported by increased incidence of atypical 
Parkinsonism syndromes in Guadeloupe, where consumption of teas containing complex I 
inhibitor annonacin is common (Exner et al., 2012). Reduction in complex I activity levels 
has also been reported in substantia nigra pars compacta neurons and frontal cortex of post-
mortem PD brains (Parker et al., 2008, Schapira et al., 1989). In addition, complex I subunits 
isolated from the frontal cortex samples from PD patients displayed oxidative damage and 
reduction in levels attributed to decreased stability caused by oxidative damage (Keeney et 
al., 2006). Altogether, this evidence has strongly implicated mitochondrial damage in PD, 
but it was not until the discovery of PINK1 that first direct link has been established. 
1.5.2 PINK1 and Parkin - sensors of mitochondrial damage 
The very first suggestion of a mechanistic link between PINK1 and Parkin came from 
phenotypic studies of PD patients harbouring mutations in either one of these genes and their 
striking clinical resemblance (Khan et al., 2002). The decisive evidence of epistatic interaction 
between the two genes followed from studies of PINK1 -/- and Parkin -/- mutant Drosophila 
melanogaster flies. Drosophila PINK1 null flies were shown to exhibit reduced life span, 
mitochondrial abnormalities, neuronal loss, motor and morphological changes including 
altered wing posture and flight muscle degeneration – a phenotype remarkably alike Parkin 
null flies (Clark et al., 2006, Park et al., 2006, Greene et al., 2003). Furthermore, PINK1 -/- 
phenotype could be rescued by Parkin overexpression, but not vice versa, placing PINK1 
Chapter 1 Introduction 
25 
 
upstream of Parkin in a putative mitochondrial pathway (Clark et al., 2006, Park et al., 
2006).  
Parkin normally resides in mitochondria, however, ground breaking work revealed that upon 
mitochondrial damage Parkin could be selectively recruited to damaged mitochondria and 
stimulate their autophagic removal termed mitophagy (Narendra et al., 2008). Given the 
epistatic regulation of PINK1 and Parkin and knowledge that upon mitochondrial damage 
PINK1 accumulates on the OMM with its catalytic core exposed to the cytosol, it was 
plausible that the two proteins interact directly. Indeed, it was later shown that Parkin 
recruitment was PINK1 dependent and could be induced in healthy cells by exogenous 
introduction of non-cleavable forms of PINK1 (Geisler et al., 2010, Matsuda et al., 2010, 
Narendra et al., 2010, Vives-Bauza et al., 2010). 
The mechanisms underpinning Parkin recruitment to mitochondria remained elusive for a 
long time. In the last several years it has been discovered that PINK1 stabilisation was 
associated with an increase in its catalytic kinase activity and autophosphorylation at Ser228, 
Thr257 and Ser402 providing the first direct evidence that mammalian PINK1 was an active 
kinase (Kondapalli et al., 2012, Okatsu et al., 2012). Parkin recruitment was also shown to 
be directly dependent on PINK1 activity (Geisler et al., 2010, Matsuda et al., 2010, Narendra 
et al., 2010, Vives-Bauza et al., 2010). The first evidence of direct regulation of Parkin by 
PINK1 came from studies from our lab. Utilizing catalytically active PINK1 insect 
orthologues (Woodroof et al., 2011) Dr Chandana Kondapalli demonstrated that Parkin is 
directly phosphorylated by PINK1 at Serine 65 (Ser65) (Kondapalli et al., 2012) which was 
confirmed by another group (Shiba-Fukushima et al., 2012) and provided the framework for 
my project and subsequent analysis of PINK1 phosphorylation-dependent activation of 
Parkin.  
It was initially postulated that PINK1-dependent phosphorylation might serve to alter Parkin 
localisation and lead to its recruitment to OMM, however, Ser65Ala (S65A) mutant lacking 
phosphorylation site displayed only a partial defect in mitochondrial translocation, suggesting 
that additional factors or PINK1 substrates were required (Shiba-Fukushima et al., 2012). 
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Very recently work in our lab and two others have identified the missing molecular player – 
PINK1 phosphorylated ubiquitin (Kazlauskaite et al., 2014c, Kane et al., 2014, Koyano et 
al., 2014), which was later shown to be the missing link for Parkin translocation (Okatsu et 
al., 2015). It is perhaps ironic that having come to do my PhD at MRC Protein 
Phosphorylation and Ubiquitylation Unit, I have been part of a team of scientists that have 
observed and defined the interaction of the two in its most acute form.  
1.5.3 PINK1, Parkin and mitophagy 
Mitochondria serve key functions in eukaryotic cells including generation of ATP, calcium 
signalling and pre-programmed cell death as well as participation in generation and removal 
of reactive oxygen species (ROS) (Suliman and Piantadosi, 2016), it is therefore no wonder 
that health and integrity of mitochondria are closely monitored and well maintained. 
Mitochondria are formed by an expansive network of organelles undergoing constant 
dimensional and structural changes aimed at meeting the energy requirements of the cell 
(Suliman and Piantadosi, 2016). The mass, shape and function of mitochondria is largely 
regulated by its biogenesis opposed by selective degradation of damaged or senescent 
mitochondria via mitochondria-specific autophagy termed mitophagy. Interruption of these 
processes results in failure to maintain healthy mitochondria has been linked to a large 
number of pathologies (Wallace et al., 2010). Upon induction of mitophagy, the proteins on 
the OMM get ubiquitylated (further discussed below) leading to recruitment of LC3-
interacting region (LIR)-containing autophagy receptors (mitophagy receptors) that in turn 
interact with phagophore which enlarges to fully engulf the damaged organelle and form an 
autophagosome (Hamacher-Brady and Brady, 2015). The autophagosome then fuse with an 
endolysosome leading to formation of a mature autolysosome wherein the lysosomal 
hydrolases degrade its contents (Hamacher-Brady and Brady, 2015).  
There is accumulating evidence that implicates PINK1-Parkin signalling in the selective 
removal of damaged mitochondria via mitophagy (Pickrell and Youle, 2015). PINK1 levels 
in healthy cells are tightly regulated due to its mitochondrial processing and continued 
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degradation via the N-end rule pathway. However, upon dissipation of mitochondrial 
membrane potential PINK1 gets stabilised and activated making it a perfect sensor for 
mitochondrial damage. The subsequent recruitment of Parkin leads to generation of 
mitochondrial phospho-ubiquitin signal (Matsuda et al., 2010, Geisler et al., 2010). NDP52 
and optineurin have recently been proposed to be the key adaptor proteins responsible for 
coupling mitochondrial ubiquitin and recruitment of autophagic machinery (Lazarou et al., 
2015, Heo et al., 2015). 
Mitochondria are highly dynamic organelles known to undergo changes in their size, shape 
and localisation. Mitochondrial size and shape are predominantly regulated by fusion and 
fission, forming highly interconnected tubular network when fusion predominates or 
fragmented spherical structures caused by high levels of fission (Exner et al., 2012). Their 
subcellular localisation is regulated by transport on cytoskeletal tracts. Several of these 
regulatory components have been found to be ubiquitylated and/or degraded by the 
PINK1/Parkin pathway including Mitofusins 1 and 2 (Mfn1 & Mfn2) – key regulators of 
fusion of OMM, and Miro 1 and 2 – Rho-like GTPases that facilitates anterograde and 
retrograde mitochondrial transport (Sarraf et al., 2013, Liu et al., 2012, Wang et al., 2011, 
Poole et al., 2010). It is therefore possible to conceive that PINK1/Parkin pathway plays a 
key role in regulating mitochondrial remodelling. Degradation of Mfn 1&2 prevents 
mitochondrial fusion, promoting sequestering of damaged mitochondrial units, while removal 
of Miro 1 & 2 stops its transport and boosts clustering (Tanaka et al., 2010, Wang et al., 
2011, Liu et al., 2012). What role, if any, this plays in the subsequent mitophagy remains to 
be seen since studies from Mfn1 and 2 knockout fibroblasts revealed that Parkin-dependent 
mitophagy was not affected (Narendra et al., 2008). 
1.6 Project aims 
Whilst a genetic interaction between PINK1 and Parkin was discovered in 2006 (Park et al., 
2006, Clark et al., 2006) defining a linear pathway with PINK1 upstream of Parkin, little was 
known about its molecular details. Progress was greatly hampered by lack of functional kinase 
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assays due to low PINK1 activity in vitro as well as low levels of PINK1 in cells. This was 
overcome by the discovery of active insect PINK1 orthologues (Woodroof et al., 2011) which 
were used to demonstrate that Parkin is a direct substrate of PINK1 and gets phosphorylated 
at Ser65 (Kondapalli et al., 2012). At the time I started the project in 2011, the first reports 
suggesting that Parkin is an autoinhibited E3 ligase that has a catalytic cysteine were being 
published (Burchell et al., 2012, Chaugule et al., 2011, Wenzel et al., 2011). These 
groundbreaking insights provided a platform upon which I could rigorously explore the 
PINK1/Parkin interaction and the role of phosphorylation on Parkin activation. The work 
presented in this thesis therefore addresses the following questions that were unsolved at the 
time my work commenced: 
 What is the functional relationship between PINK1 and Parkin? 
 What is the consequence of Ser65 phosphorylation on the Parkin Ubl domain and 
Parkin E3 ligase activity? 
 Based on PINK1 activation of Parkin, is it possible to elaborate a specific 
substrate based assay of Parkin E3 ligase activity in vitro and assess the impact 
of disease mutations? 
 Are there any additional factors involved in Parkin regulation by PINK1? 
 How does ubiquitin phosphorylation influence Parkin’s activity in vitro? 
 What is the mechanism of activation of Parkin by phosphorylated ubiquitin and 
where does phosphorylated ubiquitin bind Parkin? 
 How does phosphorylated ubiquitin binding to Parkin confer activation in cells?   
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2 Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents 
Acetone, ethanol, formic acid, glycerol, glycine, 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (Hepes), isopropanol, methanol, 2-mercaptoethanol, orthophosphoric acid, 
potassium chloride, sodium chloride, sodium ethylenediaminetetraacetic acid (EDTA), 
magnesium acetate, sodium ethylene glycol tetraacetic acid (EGTA), sodium fluoride, sodium 
β-glycerophosphate, sodium orthovanadate, pentobarbital, puromycin, adenosine 5’-
triphosphate sodium salt (ATP), anti-HA-agarose, ammonium bicarbonate, ammonium 
persulphate (APS), ampicillin, benzamidine, bovine serum albumin (BSA), bromophenol blue 
(BPB), dexamethasone, doxorubicin, dimethyl pimelimidate (DMP), dimethyl sulphoxide 
(DMSO), hydrogen peroxide, iodoacetamide, phenylmethanesulphonylfluoride (PMSF), 
Ponceau S, sodium dodecyl sulphate (SDS), sodium tetraborate, N, N, N’, N’-
Tetramethylethylenediamine (TEMED), triethylammonium bicarbonate, Nonidet P40, 
Triton-X-100 and Tween-20 were from Sigma-Aldrich (Poole, UK).  Sucrose and 
Tris(hydroxymethyl)methylamine (Tris) were from BDH (Lutterworth, UK). Cellophane 
films and Precision Plus protein markers were from BioRad (Herts, UK). 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) was from Calbiochem 
(Merck Biosciences, Nottingham, UK). Polybrene was from SantaCruz Biotechnology 
(Heidelberg, Germany). Cell culture dishes and flasks, cryovials and Spin-X columns were 
from Corning (NY, USA). Cell scrapers were from Costar (Cambridge, USA). 40% (w/v) 29:1 
Acrylamide:Bis-Acrylamide solution was from Flowgen Bioscience (Nottingham, UK). 
Protein A-agarose, Protein G-sepharose, Glutathione-sepharose, Enhanced 
chemiluminescence (ECL) kit, Hyperfilm MP, Protran nitrocellulose membrane, P81 paper, 
3mm chromatography paper were from GE Healthcare (Piscataway, USA). [γ-32P] ATP was 
from Perkin Elmer (USA). Cell dissociation buffer, Dulbecco’s modified eagle medium 
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(DMEM), RPMI-1640 medium, Phosphate buffered saline (PBS), Trypsin/EDTA, L-
glutamine, non-essential amino acids, sodium pyruvate, antibiotic/antimycotic, NuPAGE 
Novex SDS Bis-Tris gels, NuPAGE MOPS running buffer, NuPAGE reducing agent, 
NuPAGE LDS sample buffer and primers were from Invitrogen (Paisley, UK). Photographic 
developer (LX24) and liquid fixer (FX40) were from Kodak (Liverpool, UK). X-ray films were 
from Konica (Japan). Polyethylenimine (PEI) was from Polysciences (Warrington, PA). 
Skimmed milk (Marvel) was from Premier Beverages (Stafford, UK). Plasmid Maxiprep kits 
were from Qiagen Ltd (Crawley, UK). Acetonitrile (HPLC grade) was from Rathburn 
Chemicals (Walkerburn, UK). Protease inhibitor cocktail was from Roche (Lewes, UK). 
Horseradish peroxidase (HRP)- and Alexafluor-conjugated secondary antibodies, Bradford 
reagent and Fetal Bovine Serum (FBS) were from Thermo-scientific (Essex, UK). Trypsin 
(mass spectrometry grade) were from Promega (Southampton, UK). InstantBlue protein 
staining solution was from Expedeon (Harston, UK). 
2.1.2 Instruments 
The Procise 494C Sequenator was from Applied Biosystems (Foster City, USA). Centrifuge 
tubes, rotors and centrifuges were from Beckmann (Palo Alto, USA). Trans-Blot Cells, 
automatic western blot processors and gel dryer apparatus were from BioRad (Herts, UK). 
SpeedVacs were from CHRIST (Osterode, Germany). HPLC system components were 
obtained from Dionex (Camberley, UK). Thermomixer IP shakers were purchased from 
Eppendorf (Cambridge, UK). The Biofuge microcentrifuge was from Heraeus Instruments 
(Osterode, Germany). pH meters and electrodes were from Horiba (Kyoto, Japan). X-Cell 
SureLock Mini-cell electrophoresis systems and X-Cell II Blot modules were from Invitrogen 
(Paisley, UK). X-omat autoradiography cassettes, with intensifying screens, were from Kodak 
(Liverpool, UK). The Konica automatic film processor was from Konica Corporation (Japan). 
The LiCOR odyssey infrared imaging system was from LiCOR biosciences (Cambridge, UK). 
CO2 incubators were from Mackay and Lynn (Dundee, UK). Tissue culture class II safety 
cabinets were from Medical Air Technology (Oldham, UK). The PCR thermocycler (PTC-
200) was from MJ Research. The 96-well Versamax plate reader was from Molecular Devices 
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(Wokingham, UK). The Vydac 218TP54 C18 reverse phase HPLC column was from 
Separations group. The LTQ-Orbitrap mass spectrometer and Nanodrop was from Thermo 
Scientific. Scintillation counter (Tri-Carb 2800 TR) was from Perkin-Elmer. Vibrax-VR 
platform shaker was from IKA. Vydac 218TP54 C18 reverse phase HPLC column was from 
Separations Group. Dionex HPLC system components were from Dionex GINA50 
autosampler, Dionex P580 pump, DionexUVD1705 detector, EG&G Berthold Radioflow 
Detector LB509 and Gilson FC204 fraction collector. 
2.1.3 In-house reagents 
Primers were synthesised by the University of Dundee oligonucleotide synthesis service. 
Bacterial culture medium Luria Bertani (LB) broth and LB agar plates were provided by the 
University of Dundee media kitchen facility. The Protein Production Team at Division of 
Signal Transduction and Therapy (DSTT) expressed and purified His-SUMO-Miro1 as well 
as kinases used in the ubiquitin kinase screen. His-SUMO-Protein purification of recombinant 
Parkin was carried out by the Protein Production and Assay Development (PPAD) team led 
by Dr Axel Knebel.  
2.1.4 Antibodies 
In-house antibodies (Table 2.1) were raised in sheep and affinity purified on the appropriate 
antigen by the DSTT. In-house antibodies were used at 1 g/mL in 5% (w/v) skimmed milk 
in 0.1% Tween/TBS (TBST) and the in-house phospho-specific antibodies were used at 1 
g/mL in 5% (w/v) BSA-0.1%TBST supplemented with 10 g/mL non-phospho peptide to 
increase specificity. Table 2.2 summarizes commercial antibodies used. The anti-SUMO-1 
antibody was a kind gift from Professor Ron Hay (Dundee). Epitomics raised anti-
ParkinPhosphoSer65 rabbit monoclonal antibody in collaboration with the Michael J Fox 
Foundation for Research. 
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Antibody Immunogen Sheep 
Number 
Bleed 
Number 
Parkin human 
GST-Parkin full length S966C 3rd 
Parkin human 
GST-Parkin 1-108 S229D 3rd 
Parkin phospho Ser 65 
RDLDQQS*IVHIVQR [residues 60 - 72 of 
human PARKIN] 
S210D 2nd 
 
Antibody Catalogue number Company Host 
Parkin human  
Sc-32282 SantaCruz Mouse 
PINK1 human  
BC-100-494 Novus Rabbit 
GAPDH    
2118 Cell Signaling Rabbit 
Actin 
A2066 Sigma Rabbit 
CISD1 
16006-1-AP Proteintech Europe Rabbit 
TOMM70A 
14528-1-AP Proteintech Europe Rabbit 
MBP-HRP 
E8038S New England Biolabs Mouse 
FLAG-HRP 
A8592 SIGMA Mouse 
2.1.5 DNA constructs 
Dr M. Peggie, Dr R. Toth, Dr N. Wood, Mrs M. Wightman and Mr T. Macartney performed 
the cloning, subcloning and mutagenesis of the constructs described in this thesis. Constructs 
used are shown in Table 2.3 & Table 2.4. All constructs encoded the human version of the 
gene unless otherwise indicated.  
Expressed Plasmid Vector Type DU Number 
6His SUMO Parkin  pET156P Bacterial DU40847 
6His SUMO Parkin 1-76 pET156P Bacterial DU39607 
6His SUMO Parkin 80-465 pET156P Bacterial DU39813 
6His SUMO Parkin 80-465 K151A pET156P Bacterial DU46032 
6His SUMO Parkin 80-465 H302A pET156P Bacterial DU46034 
6His SUMO Parkin K27N pET156P Bacterial DU39837 
Table 2.1 In house antibodies used in this study 
Table 2.2 Commercial antibodies used in this study 
Table 2.3 Parkin constructs used 
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6HIs SUMO Parkin R33Q pET156P Bacterial DU39824 
6HIS SUMO Parkin R42P pET156P Bacterial DU39784 
6His SUMO Parkin A46P pET156P Bacterial DU44510 
6His SUMO Parkin S65A pET156P Bacterial DU23314 
6His SUMO Parkin K151A pET156P Bacterial DU46082 
6His SUMO Parkin K161A pET156P Bacterial DU43800 
6His SUMO Parkin K161N pET156P Bacterial DU44321 
6His SUMO Parkin R163A pET156P Bacterial DU43801 
6His SUMO Parkin K211A pET156P Bacterial DU43818 
6His SUMO Parkin K211N pET156P Bacterial DU23325 
6His SUMO Parkin R275W pET156P Bacterial DU43127 
6His SUMO Parkin H302A pET156P Bacterial DU46033 
6His SUMO Parkin R305A pET156P Bacterial DU46035 
6His SUMO Parkin Q316A pET156P Bacterial DU46037 
6His SUMO Parkin G328E pET156P Bacterial DU44322 
6HIS SUMO Parkin T415N pET156P Bacterial DU39786 
6His SUMO Parkin G430D pET156P Bacterial DU43129 
6His SUMO Parkin C431F pET156P Bacterial DU46232 
6His SUMO Parkin R455A pET156P Bacterial DU46030 
6His SUMO parkin 80-465 biotin affinity peptide 
(BAP)  pET156P Bacterial DU39836 
6His SUMO parkin 80-465 BAP H302A pET156P Bacterial DU46812 
GST-Parkin  1-76 pGEX6P Bacterial DU37369 
GST-Parkin  1-108 pGEX6P Bacterial DU37370 
Parkin pcDNA5-FRT/TO Mammalian DU23307 
Parkin S65A pcDNA5-FRT/TO Mammalian DU23315 
Parkin H302A pcDNA5-FRT/TO Mammalian DU48502 
Parkin C431F pcDNA5-FRT/TO Mammalian DU23340 
 
Expressed Plasmid Vector Type DU Number 
PINK1 - FLAG   pcDNA5-FRT/TO Mammalian DU17461 
PINK1 - FLAG D384A pcDNA5-FRT/TO Mammalian DU17462 
FLAG-empty pcDNA5 FRT/TO Mammalian DU 41457 
MBP-PINK1 (Tribolium castaneum) pMal4c  Bacterial DU34701 
MBP-PINK1 (Tribolium castaneum) D359A pMal4c  Bacterial DU34832 
GST-Pediculus humanus corporis PINK1 pGEX6P1  Bacterial DU26052 
 
Table 2.4 PINK1 constructs used 
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2.1.6 Buffers and solutions 
Lysis buffer inhibits proteases, kinases, phosphatases and other divalent cation-dependent 
enzymes ensuring that the phosphorylation and expression levels of proteins are fixed at the 
levels in which they are found in vivo. Benzamidine and PMSF or complete protease inhibitor 
tablets prevent the action of metallo, aspartic, cysteine and serine proteases. EDTA chelates 
Mg2+ and EGTA chelates Ca2+. Sodium fluoride, sodium-ß-glycerophosphate and sodium 
pyrophosphate are Ser/Thr phosphatase inhibitors. Sodium orthovanadate is a Tyr 
phosphatase inhibitor. Sodium orhovanadate was prepared, as recommended by the 
manufacturer, by repeated rounds of boiling and cooling until the solution was colourless at 
pH10 at room temperature to ensure that it is in the monomeric state that favours Tyr 
phosphatase inhibition. Buffers used in this thesis are summarised in Table 2.5. 
Buffer Composition 
Mammalian cell lysis buffer
  
 
25 mM Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 50 
mM NaF, 5 mM sodiumpyrophosphate, 1 mM sodium 
orthovanadate, 10 mM sodium b-glycerophosphate, 1 mM 
benzamidine, 0.2 mM PMSF, 0.1% 2-mercaptoethanol, 0.27 M 
sucrose and one mini Complete™protease inhibitor cocktail tablet 
per 10ml of lysis buffer. 
TBS-Tween buffer 
50 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.1% (v/v) Tween-20. 
5X sodium dodecyl sulphate 
(SDS) sample buffer 
250 mM Tris-HCl (pH 6.8), 5% SDS, 5% (v/v) 2 - mercaptoethanol, 
32.5% (v/v) glycerol, 0.05% bromophenol blue. 
Tris-Glycine SDS running 
buffer 
25 mM Tris-HCl (pH 8.3), 192 mM glycine, 0.1% (w/v) SDS. 
Tris-Glycine transfer buffer 
48 mM Tris-HCl (pH 8.3), 39 mM glycine, 20% (v/v) methanol. 
Kinase assay reaction buffer 
50mM Tris-HCl (pH 7.5), 0.1 mM EGTA, 10 mM MgCl2, 2 mM DTT 
and 0.1 mM [γ-32P] ATP (approx. 500 cpm/pmol). 
Enhanced 
chemiluminescence 
Reagent (ECL) 
ECL1: 100 mM Tris-HCl pH 8, 2.5 mM Luminol, 0.4 mM p-Coumaric 
Acid. ECL2: 100 mM Tris-HCl pH 8, 5.6 mM H2O2. Stored in the dark 
at 4ºC. Equal volumes ECL1 and ECL2 are mixed immediately before 
the use. 
Table 2.5 Commonly used buffers 
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2.1.7 Inhibitors/treatments 
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was purchased from SIGMA, dissolved 
in DMSO and stored at -20 oC. 
2.2 Methods 
2.2.1 Transformation of chemically competent Escherichia coli (E.coli) 
Calcium competent E.coli DH5α (Inoue et al., 1990) cells were provided by the DSTT. 
Approximately 10-50 ng DNA was added to 50 l of competent cells and incubated on ice for 
5 min. Bacterial cells were then subjected to heat shock at 42 oC in a water bath for 90 
seconds to induce the uptake of DNA and briefly placed back on ice. Cells were streaked onto 
LB agar plates containing 200 g/mL ampicillin and plates incubated at 37 oC overnight. 
2.2.2 Purification of plasmids from E.coli 
Transformed DH5α E.coli were cultured in 250 mL LB containing 200 g/mL ampicillin at 
37 oC while shaking at 180 rpm overnight. Cells were pelleted by centrifugation at 5000 x g 
for 15 min at 4 oC. Plasmid DNA was purified using the Qiagen plasmid Maxiprep kit 
according to the manufacturer’s instructions.  
2.2.3 Measurement of DNA and RNA concentration 
DNA and RNA concentrations were measured using NanoDrop as per manufacturer’s 
instructions based on RNA and DNA absorption at 260 nM. Absorbance was also measured 
at 280 nM to enable calculation of 260/280 ratio for estimation of purity. Ratios greater than 
1.8 were indicative of high purity. Lower ratios were suggestive of the presence of phenol, 
protein or other contaminants. 
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2.2.4 DNA mutagenesis 
Site-directed mutagenesis was performed using the QuikChange kit (Stratagene) and KOD 
polymerase (Novagen). Mutation incorporation was verified by DNA sequencing. 
2.2.5 DNA sequencing 
Plasmid sequencing was performed by the DNA Sequencing service (School of Life Sciences, 
University of Dundee, www.dnaseq.co.uk) using Applied Biosystems Big-Dye v. 3.1 chemistry 
on an Applied Biosystems model 3730 automated capillary DNA sequencer.  
2.2.6 Cell culture 
All procedures were carried out in aseptic conditions meeting biological safety category 2 
regulations. Cells were maintained at 37 oC in a 5 % CO2 water saturated incubator. The 
passaging of cells was performed by washing the cells with PBS followed by incubation with 
Trypsin/EDTA to detach the cells. Detached cells were resuspended in cell culture medium 
and split at a 1:2 – 1:20 ratios for continued culture.  Human embryonic kidney 293 (HEK293) 
and HeLa cells were cultured in Dulbecco’s modified eagle medium (DMEM); neuroblastoma 
SH-SY-5Y cells were cultured in 50:50 mixture of DMEM and Ham’s F12 media. All cell lines 
were grown in the presence of 10 % (v/v) foetal bovine serum (FBS), 2 mM L-glutamine, 100 
U/mL penicillin and 0.1 mg/mL streptomycin. HeLa PINK1 CAS9 knock-out cells (Narendra 
et al., 2013b) and HeLa T-REX flp-in culture medium was additionally supplemented with 
1x non-essential amino acids. 
2.2.7 Freezing / thawing cells 
Confluent cells grown in T-75 flasks were trypsinized and collected in culture media by 
centrifuging at 500 x g for 5 min. Culture media was aspirated and cells were resuspended in 
3 ml of freezing media (50:50 mixture of DMEM and FBS supplemented with 10% DMSO). 
1 mL aliquots were placed in cryovials in Nalgene Mr Frosty Freezing Containers at -80 oC 
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for 24 hrs prior to long-term storage in liquid nitrogen. Cells were thawed in a 37 oC water 
bath, resuspended in 20 ml of growth medium and allowed to adhere overnight prior to 
medium change. 
2.2.8 Transfection of cells using polyethylenimine (PEI) 
Cells were transiently transfected using the polyethylenimine (PEI) method (Fortier et al., 
2013).  PEI stock (1 mg/mL) was prepared by dissolving PEI powder in 20 mM Hepes (pH 
7). Aliquots were filter sterilized (0.22 μm) and stored at -80 oC. 
Cells were grown to 30-40 % confluency on 15 cm dishes; 9 µg of DNA was mixed with 60 µL 
1mg/mL PEI and 2 mL serum-free DMEM, vortexed for 10 sec and incubated for 20 - 40 min 
at room temperature before being added to cells. Cells were harvested 24-72 hrs post 
transfection. 
2.2.9 Generation of stable cell lines 
To ensure low-level uniform expression of recombinant proteins, manufacturer's instructions 
(Invitrogen) were followed to generate stable cell lines that express proteins of interest (cDNA 
subcloned into pcDNA5-FRT-TO plasmid) in a doxycycline-inducible manner. Flp-In T-Rex-
293 host cells containing integrated FRT recombination site sequences and Tet repressor, 
were co-transfected with 9 μg of pOG44 plasmid (which constitutively expresses the Flp 
recombinase), and 1 μg of pcDNA5/FRT/TO vector containing a hygromycin resistance gene 
for selection of the gene of interest under the control of a tetracycline-regulated promoter. 
Cells were selected for hygromycin and blasticidin resistance three days after transfection by 
adding new medium containing hygromycin (100 μg/ml) and blasticidin (7.5 μg/ml). After 3 
– 4 weeks of selection, remaining colonies were trypsinized and expanded. Expression of the 
recombinant protein was induced with 0.1 μg/ml of doxycycline for 24 - 72 hours. 
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2.2.10 Treatment of cells with mitochondrial depolarising agents  
Cells were treated with 10 M CCCP (Sigma) dissolved in DMSO; it was added to the cell 
culture medium and incubated at 37 oC and 5% CO2 for the times indicated in the figure 
legends. The equivalent volume of DMSO was added to another dish as a vehicle control. 
2.2.11 Cell lysis and mitochondrial fractionation 
Cells were lysed using mammalian cell lysis buffer as listed in Table 2.6; 0.5 ml of lysis buffer 
per 15 cm dish was used. Lysates were clarified by centrifugation at 14,000 x g for 15 min at 
4 C and the supernatant was collected. For mitochondrial fractionation, cells were harvested 
in ice-cold PBS and later swelled in hypotonic mitochondrial fractionation buffer (Table 2.6) 
at 4 C. Cells were disrupted using a glass hand held homogeniser (40 passes) and lysates 
were clarified by sequential centrifugation: first, 10 min at 1200 x g at 4C after which the 
supernatant was collected and further centrifuged at 14,000 x g for 10 min at 4C. The 
resultant supernatant was retained as the cytosolic fraction. The pellet containing the 
mitochondrial fraction was resuspended in the lysis buffer and centrifuged at 14,000 x g for 
10 min. This final supernatant contained solubilized mitochondrial proteins. All lysates were 
snap-frozen at -80 oC until use. 
EDTA and EGTA was used to chelate divalent cations, which serve as co-factors for 
proteolytic activity. Sodium fluoride, sodium pyrophosphate, sodium β-glycerophosphate 
inhibit serine/threonine protein phosphatases; and sodium orthovanadate (Na3VO4) inhibits 
protein tyrosine phosphatases. Benzamidine and PMSF were added to inhibit serine proteases 
and metallo, aspartyl, cysteinyl, and seryl proteinases.  
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Buffer Composition 
Cell lysis buffer 
25 mM Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1 % Triton 
X-100, 50 mM NaF, 5 mM sodiumpyrophosphate, 1 mM sodium 
orthovanadate, 10 mM sodium -glycerophosphate, 1 mM 
benzamidine, 0.2 mM PMSF, 0.1% 2-mercaptoethanol, 0.27 M 
sucrose and one mini Complete™protease inhibitor cocktail 
tablet per 10ml of lysis buffer. 
Mitochondrial 
frantionation buffer 
20 mM HEPES, 3 mM EDTA, 1 % (w/v) 1 mM sodium 
orthovanadate,10 mM sodium β-glycerophosphate, 250 mM 
sucrose, 50 mM NaF, 5 mM sodium pyrophosphate, pH 7.5 and 
one mini Complete™protease inhibitor cocktail tablet per 10ml 
of buffer. 
 
2.2.12 Quantification of protein concentration with Bradford assay 
The protein concentration of lysates was estimated using the Bradford assay in a 96 well 
plate in triplicates (Bradford, 1976). 200 l of Bradford reagent, containing Coomassie 
Brilliant Blue G250, was added to 10 l of sample, diluted 5-20 times in water. The assay 
utilizes the shift of maximum absorbance of Coomassie reagent from 465 nm to 595 nm upon 
binding protein in acidic medium; it is therefore possible to generate a standard curve by 
plotting absorbance at 595 nm against BSA standards and use it to back-calculate the sample 
concentrations. 
2.2.13 Quantification of protein concentration with bicinchoninic acid (BCA) 
assay 
The protein concentration of lysates containing detergent was estimated using the BCA assay. 
The samples were prepared the same as for Bradford assay, then 200 l of working reagent 
was added to each well. The samples were incubated in the dark at 37 C for 30 min before 
reading at a plate reader. The absorbance measurements at 562 nm was made. Standard 
curve was generated and concentrations were calculated as before. The assay uses a 
Table 2.6 Buffers used for cell lysis 
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colorimetric shift that is proportional to copper(II) reduction to copper(I) by peptide bonds 
present in the sample followed by binding of copper(I) to bicinchoninic which produces purple 
colour that absorbs light at 562nm. 
2.2.14 Covalent coupling of antibodies 
Antibodies were coupled to protein G-sepharose using a dimethyl pimelimidate (DMP) cross-
linker, a homo-bifunctional imidoester that reacts with primary amine groups in the pH range 
7.0 – 10.0. Protein G, isolated from Group G Streptococci, binds to the Fc region of IgG-class 
antibodies with a high affinity for antibodies generated in various species. Protein G-beads 
were washed in PBS 4 times followed by coating with antibody - 1 g of antibody per 1 l of 
resin was incubated for 1 hr at 4 C. The unbound antibody was washed off with PBS followed 
by three washes with 10 times the bead volume of 0.1 M sodium tetraborate pH 9.3. Beads 
were then incubated with 20 mM DMP in 0.1 M sodium tetraborate (prepared fresh) twice 
for 30 min at room temperature followed by four washes with 50 mM glycine pH 2.5 to 
remove any non-covalently coupled antibody and further two washes with 0.2 M Tris-HCl 
pH 8 to neutralise the pH. Finally, the beads were incubated for 2 hrs in 0.2 M Tris-HCl pH 
8 at room temperature to quench any residual DMP, before storing in PBS at 4 C. 
2.2.15 Immunoprecipitation of proteins 
5 L of covalently coupled antibody was mixed with 1 mg of lysate for 2 hrs at 4 C on a 
rotating wheel. Beads were then washed twice with lysis buffer containing 0.5 M NaCl and 
twice with lysis buffer containing 0.15 M NaCl. Reducing agent was omitted from the washes. 
The immunoprecipitates were eluted by resuspending the beads in 1x LDS sample buffer 
lacking reducing agent for 10 min with gentle shaking followed filtering through Spin-X 
columns to remove the beads. Reducing agent was added to the eluted samples and the 
samples were heated on the heat block at 92 C for 5 min.  
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2.2.16 Ubiquitin enrichment in membrane fractions 
His-Halo-Ubiquilin1 UBA-domain tetramer (UBAUBQLN1) was expressed in E.coli BL21 cells, 
affinity purified on Ni-NTA-agarose and dialysed into 50 mM Hepes pH 7.5, 10 % glycerol, 
150 mM NaCl, 1 mM DTT.  UBAUBQLN1 was coupled to HaloLink Resin as described previously 
(Kristariyanto et al., 2015a). 1 mg of mitochondria-enriched fractions were then subjected to 
pull downs as described previously (Kristariyanto et al., 2015a). 
2.2.17 Resolution of protein samples via SDS-PAGE 
Polyacrylamide gel electrophoresis (PAGE) is commonly used to separate proteins according 
to their electrophoretic mobility. Anionic reagents, such as sodium dodecyl sulphate (SDS) 
or lithium dodecyl sulphate (LDS), bind proteins linearizing them and giving them a net 
negative charge that is proportional to the molecular mass of the protein. Consequently, the 
protein migration through a PAGE matrix represents a linear function of the logarithm of 
their molecular weight. 
Home-made isogradient and commercial 4-12% gels were used to resolve different protein 
species. The home-made gel constituents included a resolving gel (375 mM Tris-HCl (pH 8.6), 
0.1 % SDS and 8/10/12 % acrylamide) and a stacking gel (125 mM Tris HCl pH 6.8, 0.1 % 
SDS, 4 % acrylamide). TEMED and ammonium persulphate (APS) were used to initiate 
polymerisation.  
Samples for pre-cast NuPAGE 4-12% Bis-Tris gels were prepared in 1x LDS sample buffer 
with or without reducing agent as specified; the electrophoresis was carried out at 180 V for 
50 min. Samples for home-made gels were made in 1x SDS buffer and heated at 92 C for 2 
min. The electrophoresis was initiated at 80V until the dye front entered the resolving gel; 
the voltage was then increased to 160 – 180 V until the dye front reached the end of the 
resolving gel. 5-30 g of lysate or 10-30 L of immunoprecipitate were loaded per lane 
alongside protein standards 
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2.2.18 Coomassie staining of polyacrylamide gels 
Polyacrylamide gels were stained in Instant Blue staining solution for 1 hr and destained with 
MilliQ water overnight. Gels were scanned on a Li-Cor Odyssey infrared system for imaging 
and quantification. For mass spectrometry, gels were stained with Colloidal Coomassie 
(Invitrogen) according to the manufacturer’s instructions. 
2.2.19 Dessication of polyacrylamide gels and autoradiography 
Gels, carrying samples incorporating 32P were dried to enhance signal. They were incubated 
in 5 % glycerol for 10 min and sandwiched between two sheets of pre-wet cellophane. The gel 
was then dried in a GelAir Dryer for 40-100 min. Dried gels were exposed to Hyperfilm MP 
for 1-72 hrs in an X-Omat autoradiography cassette. Films were developed using a Konica 
auto-developer. 
2.2.20 Transfer of proteins onto nitrocellulose membranes 
Gels were sandwiched between nylon sponges, Whatman 3 mm filter papers and nitrocellulose 
or PVDF membrane (pre activated in 100 % methanol) all soaked in transfer buffer. The 
transfer cell was submerged in transfer buffer in Biorad Trans-Blot Cell and transfer was 
carried out at 90 V for 2 hrs. 
2.2.21 Immunoblotting 
After transfer, membranes were blocked with 5% (w/v) skimmed milk or BSA in TBST for 
1 hour at room temperature. Membranes were then incubated with primary antibodies diluted 
in either 5% (w/v) skimmed milk or BSA in TBST at 4 C for 16 hrs. Unbound antibody 
was then collected and membranes were washed four times for 15 minutes with TBST at 
room-temperature. Horseradish peroxidase (HRP)-conjugated secondary antibodies diluted 
at 1:2500 in 5% (w/v) skimmed milk in TBST were incubated with the membranes for 1 hr 
at room temperature and the membranes were washed four more times with TBST. 
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Membranes were incubated with the enhanced chemiluminescence (ECL) substrate and 
exposed to X-ray films for various lengths of time. Films were developed using a Konica 
automatic developer.  
2.2.22 Immunofluorescence 
HeLa cells stably expressing untagged Parkin WT, S65A or H302A were plated on glass 
coverslips and treated as described. Immunofluorescence was performed as previously 
described in (Allen et al., 2013). Briefly, coverslips were washed twice with phosphate‐
buffered saline (PBS), fixed with 3.7 % formaldehyde, 50 mM Hepes pH 7.0 for 10 min, washed 
twice with and then incubated for 10 min with DMEM, 10 mM HEPES pH7.4. Cells were 
permeabilized by incubation with 0.2% Triton X-100 in PBS followed by two washes and 
blocking for 15 min at RT with PBS supplemented with 1 % BSA (PBS/1 % BSA). Cells 
were stained with the primary antibodies as follows: ParkinPhospho-Ser65 (1:500) antibody for 16 
h at 4 C; total Parkin antibody (1:1000) for 1 h at 37 C; followed by anti–mouse or anti–
rabbit Alexa Fluor 405– or Alexa Fluor 488–conjugated secondary antibodies (Life 
Technologies).  Mitochondria were stained using MITO-ID Red detection kit (Enzo Life 
Sciences) for 30 min at 37 C. 
Immunofluorescently labelled cells were imaged using a Zeiss LSM 700 laser scanning confocal 
microscope with the Alpha Plan-Apochromat x100/NA 1.46 objective (optical section 
thickness 0.7 m). Parkin-Alexa 405 was excited with the 405 laser, P-Parkin-Alexa 488 was 
excited with the 488 laser and Mitochondria MITO-ID® Red was excited with the 555 laser. 
All labels were excited independently to prevent cross-channel bleed through.  
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2.2.23 Gel filtration chromatography analysis of complexes – performed by Dr. 
Axel Knebel 
A Superdex 200 Increase 10/300 GL column (GE-Healthcare Life Sciences) was equilibrated 
with 50 mM Tris pH 7.5, 150 mM NaCl. The proteins: 100 g of Dac-Ubiquitin, Dac-
UbiquitinPhosSer65, Parkin (1-465) or Parkin 1-465 H302A or mixtures thereof, were made and 
subjected to chromatography on the column at a flowrate of 0.3 ml/min. Mixtures were 
incubated for 30 minutes prior to chromatography. The elution of the proteins was monitored 
by UV-absorption at 280 nm. 
2.2.24 Alphascreen binding assay – performed by Dr. Scott Wilkie 
Serial three fold, 10-point dilution curves of inhibitor proteins ubiquitinPhosSer65 and ubiquitin 
were prepared in PBS + 0.1 % BSA + 0.1 % Triton X-100 with a maximum concentration 
of 400 nM. Similar three fold 10-point dilution curves of UblPhosSer65 and Ubl were produced 
with a maximum concentration of 24.7 mM. Biotinylated wild-type or H302A mutant Parkin 
protein and GST-Ubl were diluted to 40 nM in PBS + 0.1 % BSA +0.1 % Triton X-100. 5 
l of inhibitor, 5 l of GST-Ubl and 5 l of Parkin protein were added to a white-walled 384 
well plate (Griener Bio-one). Plates were centrifuged at 500 x g for 3 min and mixed on an 
orbital shaker at 450 rpm for 3 min prior to incubation at RT for 20 min. 5 l of a 20 g/ml 
mixture of Streptavidin donor and Glutathione acceptor beads in PBS + 0.1 % BSA +0.1 % 
Triton X-100 were added to all wells. Plates were briefly centrifuged and incubated at RT in 
the dark for 1 h prior to reading on PHERAstar (BMG LABTECH) using an AlphaLISA 
optical module (excitation wavelength = 680 nm and emission wavelength = 615 nm).  
2.2.25 Isothermal calorimetric Assay – performed by Dr. Julio R. Martinez 
ITC measurements were carried out on an ITC200 Microcalorimeter (GE Healthcare). Wild-
type, H302A, and K151A mutant Parkin and ubiquitinPhosSer65 were dialyzed in buffer 
containing 50 mM HEPES (pH 8.0), 150 mM NaCl and 500 μM of TCEP. The sample cell 
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contained 50 μM of wild-type or mutant Parkin and sufficient amount of ubiquitinPhosSer65 was 
titrated in the injection syringe to achieve a complete binding isotherm. All binding 
experiments were undertaken in duplicate at constant temperature of 20 C. A total of 20 
injections of 2.0 μl were dispensed with a 5 second addition time and spacing of 120 seconds. 
Data was analysed and titration curves fitted using MicroCal Origin software assuming a 
single binding site mode. 
2.2.26 Thermal shift assay - performed by Dr. Julio R. Martinez 
Thermal denaturation experiments were performed using Differential Scanning Fluorimetry 
(DSF). 5 μg of wild-type, His302Ala or Lys151Ala mutant Parkin protein was added to 45 μl 
reaction buffer (50 mM Hepes pH 8.0, 150 mM NaCl, 500 μM TCEP), and 2.5 μl of 100 × 
Sypro Orange (Invitrogen) fluorescent dye to yield a final reaction volume of 50 μl. Each 
experiment was repeated three times in a 96‐well plate in a Bio‐Rad iQ5 thermal cycler, with 
a temperature gradient set from 10 C to 95 C at steps of 0.5 C per minute.  
2.2.27 Mass spectrometry 
2.2.27.1 Processing protein bands for analysis by mass spectrometry 
To minimise contamination with proteins such as keratin, samples were handled in a laminar 
flow hood. Protein bands were excised from the gel and washed sequentially with 0.5 ml of 
water, 50 % acetonitrile (v/v), 0.1 M NH4HCO3 and 50 % acetonitrile (v/v)/ 50 mM 
NH4HCO3 until the gel pieces were colourless. All washes were performed for 10 min on a 
Vibrax shaking platform. Proteins were then reduced with 10 mM DTT/ 0.1 M NH4HCO3 at 
65 C for 45 min and alkylated with 50 mM Chloroacetamide/0.1 M NH4HCO3 for 20 min at 
room temperature. They were then washed with 0.5 ml 50 mM NH4HCO3 and 50 mM 
NH4HCO3 / 50 % acetonitrile (as before). Gel pieces were shrunk with 0.3 ml acetonitrile for 
15 min. Acetonitrile was aspirated and trace amounts removed by drying sample in a Speed-
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Vac at 45 C. Gel pieces were then rehydrated and proteins were digested in 25 mM 
triethylammonium bicarbonate containing 5 g/ml trypsin at 30 C for 16 hrs on a shaker. 
An equivalent volume of acetonitrile (same as trypsin) was added to each sample and further 
incubated on a shaking platform for 15 min. The supernatants were dried by Speed-Vac. 
Another extraction was performed by adding 100 l 50 % (v/v) acetonitrile/2.5 % (v/v) 
formic acid for 15 min. This supernatant was combined with the first extract and dried by 
Speed-Vac at 45 C. Peptides were purified on C18 MicroSpin Columns (The Nest Group) 
and stored at -20 C before MS analysis as described below. 
2.2.27.2 In-solution protein digestion for Miro1 ubiquitylation site 
identification 
In-vitro ubiquitylation assays were terminated with 1 % Rapigest™ and reduced in 5 mM 
TCEP (Tris-(2-carboxyethyl)phosphine) at 50 C for 30 min. Additional Tris-HCl was added 
to 10 mM to ensure buffering at pH 7.5 followed by cysteine alkylation in 10 mM 
chloroacetamide at 20 C in the dark for 30 min. Samples were diluted to 0.1% Rapigest™ 
and digested with 1:50 (w/w) trypsin overnight at 37 C. Peptides were acidified with 1 % 
TFA (trifluoroacetic acid) and incubated at 37 C for 1 hr before precipitating acid-cleaved 
Rapigest™ by centrifugation at 17,000 x g for 10 min. Peptides were purified on C18 
MicroSpin Columns (The Nest Group) before MS analysis.  
2.2.27.3 Mass Spectrometry 
Approximately 30 ng of peptide was analysed by C18 LC–MS/MS over a 60 min gradient 
from 1-37 % acetonitrile/0.1 % formic acid. Mass spectrometric analysis was conducted by 
data-dependent acquisition with spectra acquired by collision-induced dissociation on an LTQ 
Orbitrap Velos (Thermo Fisher Scientific). Data were analysed using Mascot 
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(www.matrixscience.com) and ion signals were extracted using Skyline (MacLean et al., 
2010). 
2.2.28 Mapping the site on ubiquitin phosphorylated by TcPINK1 - performed 
by Robert Gourlay 
Flag-ubiquitin (10 g) (Boston Biochem) was incubated with 10 g of either wild-type MBP-
TcPINK1 (1–570) or kinase-inactive MBP TcPINK1 (D359A) for 80 min at 30 C in 50 mM 
Tris-HCl (pH 7.5), 0.1 mM EGTA, 10 mM MgCl2, 0.15 -Mercaptoethanol and 0.1 mM [γ-
32P] ATP (approx. 20 000 cpm/pmol) in a total reaction volume of 50 l. The reaction was 
terminated by addition of LDS sample buffer with 10 mM DTT, boiled and subsequently 
alkylated with 50 mM iodoacetamide before samples were subjected to electrophoresis on a 
Bis–Tris 4 – 12 % polyacrylamide gel, which was then stained with Colloidal Coomassie blue 
(Invitrogen). Phosphorylated ubiquitin was digested with trypsin and 78 % of the 32P 
radioactivity incorporated into ubiquitin was recovered from the gel bands. Peptides were 
chromatographed on a reverse phase HPLC Vydac C18 column (Cat no. 218TP5215, 
Separations Group, Hesperia, CA) equilibrated in 0.1 % (v/v) trifluoroacetic acid and the 
column developed with a linear acetonitrile gradient at a flow rate of 0.2 ml/min and fractions 
(0.1 ml each) were collected and analysed for 32P radioactivity by Cerenkov counting. Isolated 
phosphopeptides were analysed by LC-MS/MS on a Thermo U3000 RSLC nano liquid 
chromatography system coupled to a Thermo LTQ-Orbitrap Velos mass spectrometer. The 
resultant data files were searched using Mascot (www.matrixscience.com) run on an in-house 
system against a database containing the ubiquitin sequence, with a 10 ppm mass accuracy 
for precursor ions, a 0.6 Da tolerance for fragment ions, and allowing for Phospho (ST), 
Phospho (Y), Oxidation (M) and Dioxidation (M) as variable modifications. Individual 
MS/MS spectra were inspected using Xcalibur v. 2.2 software (Thermo, Bremen, Germany). 
The site of phosphorylation of these 32P-labelled peptides was determined by solid-phase 
Edman degradation on a Shimadzu PPSQ33A sequencer (Hyoto, Japan) of the peptide 
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coupled to Sequelon-AA membrane (Applied Biosystems) as described previously (Campbell 
and Morrice, 2002). 
2.2.29 MALDI analysis - - performed by Dr. Maria S. Ritorto and Alba 
Gonzalez 
MALDI-TOF was used to confirm and establish the ratios of phosphorylated versus non-
phosphorylated protein species. An aliquot of the reaction (2 μl, 400-600 fmols) was added to 
2 μl of the matrix (2,5-dihydroxyacetophenone, 15 mg/ml in 80% ethanol, 20 % of 12 mg/ml 
ammonium citrate bibasic) and 2 μl of 2 % (v/v) trifluoroacetic acid was added before 
spotting 0.5 μl of the sample on to an AnchorChip target (Bruker Daltonics). The analysis 
was performed manually in linear positive mode using an UltrafleXtreme (Bruker Daltonics) 
MALDI–TOF mass spectrometer. For external calibration, six average masses were used: 
insulin [M+H]+avg (m/z 5734.520), cytochrome c [M+2H]2+avg (m/z 6181.050), myoglobin 
[M+2H]2+avg (m/z 8476.660), ubiquitin I [M+H]+avg (m/z 8565.760) and cytochrome C 
[M+H]+avg (m/z 12360.970). 
2.2.30 Analysis of Ser65 phosphorylation of Parkin by aquapeptides and mass 
spectrometry - performed by Dr. Julien Peltier 
In order to quantify phosphorylation stoichiometry, 2 ng of Parkin or Phospho-Parkin were 
digested with trypsin and analysed by absolute quantitation selected reaction monitoring 
(SRM) LC mass spectrometry (Surinova et al., 2013). Samples were separated by a 60 min 
gradient on a 50 cm Acclaim PepMap 100 analytical column (75 μm ID, 3 μm C18) in 
conjunction with a PepMap trapping column (100 μm x 2 cm, 5 μm C18) (Thermo-Fisher 
Scientific) in a Dionex Ultimate 3000 Nano LC system (Dionex/Thermo Fisher) coupled to 
a QTRAP 5500 (ABSCIEX) mass spectrometer. Synthetic peptides were used to define 
retention time and the optimal 10 transitions per peptide, based on optimal intensity of 
precursor charge state and fragment ions. One pmol of heavy labelled peptides of Parkin 
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NDWTVQN[C(CAM)]DLDQQSIVHIVQRPW[R(13C6; 15N4)], 
R.NDWTVQN[C(CAM)]DLDQQ[S(PO3H2)]IVHIVQRPWR(13C6; 15N4)] (AQUA 
QuantPro, Thermo Scientific) was mixed with the trypsin digest of phosphoParkin and the 
ratio of peak intensities of ten distinct transitions for light (endogenous) and heavy peptides 
was used to calculate the amount of endogenous proteins. Data were analysed with Skyline 
software (MacLean et al., 2010). 
2.2.31 In-vitro assays 
2.2.31.1 Kinase assays 
Reactions were set up in a volume of 25 μl, using 1 μg of the indicated kinase (or as stated 
in figure legend) and varied amounts of substrate protein in 50 mM Tris-HCl (pH 7.5), 0.1 
mM EGTA, 10 mM MgCl2, 2 mM DTT and 0.1 mM [γ-32P] ATP (approx. 500 cpm/pmol). 
Assays were incubated at 30 C with shaking at 1050 r.p.m. and terminated after 60 min or 
times indicated in figure legends by addition of LDS sample loading buffer. The reaction 
mixtures were then resolved by SDS-PAGE. Proteins were detected by Coomassie staining 
and gels were imaged using an Epson scanner and dried completely using a gel dryer (Bio-
Rad). Incorporation of [γ-32P] ATP into substrates was analysed by autoradiography using 
Amersham Hyper-Film. 
2.2.31.2 In-vitro ubiquitylation assays 
Wild-type or indicated mutant Parkin (2 μg) was initially incubated with 1μg (or indicated 
amounts) of E. coli-expressed wild-type or kinase-inactive (D359A) MBP-TcPINK1 in a 
reaction volume of 25 μl (50 mM Tris-HCl (pH 7.5), 0.1 mM EGTA, 10 mM Magnesium 
acetate, 1 % -mercaptoethanol and 0.1 mM ATP. Kinase assays were incubated at 30 C 
for 60 min followed by addition of ubiquitylation assay components and Mastermix to a final 
volume of 50 μl (50 mM Tris-HCl (pH 7.5), 0.05 mM EGTA, 10 mM MgCl2, 0.5% -
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mercaptoethanol, 0.12 μM human recombinant E1 purified from Sf21 insect cell line, 1 μM 
human recombinant UbcH7 and 2μg 6xHis-Sumo-Miro1 (WT or point mutants) both purified 
from E. coli, 0.05 mM Flag-Ubiquitin (Boston Biochem) and 2 mM ATP). Ubiquitylation 
reactions were incubated at 30 C for 60 min and terminated by addition of LDS sample 
buffer. For all assays, reaction mixtures were resolved by SDS-PAGE. Ubiquitylation 
reactions were subjected to analysis by immunoblotting. 
During experiments investigating the effect of ubiquitinPhospho-Ser65 and UblPhospho-Ser65 on Parkin 
activity, ubiquitylation reactions were performed in the absence of PINK1 in a final volume 
of 50 μl (50 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 0.12 μM UbE1, 1 μM UbcH7 and 2 μg 
6xHis-Sumo-Miro, 2 mM ATP). When effects of ubiquitinPhospho-Ser65 were investigated, the 
total amount of ubiquitin used per assay was 25 μg: increasing concentrations of 
ubiquitinPhospho-Ser65 or non-phosphorylated ubiquitin were added as indicated and the final 
amount of ubiquitin was reached by addition of Flag-ubiquitin (Boston Biochem). When 
effects of UblPhospho-Ser65 were investigated, 0.05 mM Flag-Ubiquitin was used and the UblPhospho-
Ser65 or non-phosphorylated-Ubl were added as indicated. Ubiquitylation reactions were 
incubated at 30 C for 60 min; terminated by addition of LDS sample buffer and subjected 
to immunoblotting as described. 
For the E2 scan, a version of the E2scanTM kit was obtained from Ubiquigent and 1 μg of each 
E2 enzyme was used per reaction. 
2.2.31.3 In-vitro E2 discharge assays 
Wild-type or indicated mutant Parkin (2 μg) was incubated with 1 μg of E. coli expressed 
wild-type or kinase-inactive (D359A) MBP-TcPINK1 in a reaction volume of 15 μl (50 mM 
HEPES (pH 7.5), 0.1 mM EGTA, 10 mM Magnesium acetate and 0.1 mM ATP). Kinase 
assays were incubated at 30 C for 60 min. E2-charging reaction was assembled in parallel in 
5 μl containing Ube1 (0.5 μg), an E2 (2μg), 50 mM HEPES pH 7.5 and 10 μM ubiquitin in 
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the presence of 2 mM magnesium acetate and 0.2 mM ATP. After initial incubation of 60 
min at 30 C, the reactions were combined and allowed to continue for a further 15 min or 
indicated times at 30 C. Reactions were terminated by the addition of 5 μl of LDS loading 
buffer and subjected to SDS-PAGE analysis in the absence of any reducing agent. Gels were 
stained using InstantBlue. 
During experiments investigating the effect of ubiquitinPhospho-Ser65 and UblPhospho-Ser65 on the 
Parkin mediated E2 discharge, 1 g of the indicated ubiquitin and Ubl species were combined 
with the E2 discharge reaction.  
2.2.32 Protein purification 
2.2.32.1 MBP-tagged protein purification from E. coli 
Full-length wild-type and kinase-inactive TcPINK1 was expressed in E. coli as maltose 
binding protein (MBP) fusion protein and purified as described. BL21 Codon+ transformed 
cells were grown at 37 C to an OD600 of 0.3, then shifted to 16 C and induced with 250 μM 
IPTG (isopropyl β-D-thiogalactoside) at OD600 of 0.5. Cells were induced with 250 μM IPTG 
at OD 0.6 and were further grown at 16 C for 16 h. Cells were pelleted at 4000 r.p.m., and 
then lysed by sonication in lysis buffer (Table 2.7). Lysates were clarified by centrifugation 
at 30 000g for 30 min at 4 C followed by incubation with 1 ml per litre of culture of amylose 
resin for 1.5 h at 4 C. The resin was washed thoroughly in wash buffer (Table 2.7), then 
equilibration buffer (Table 2.7), and proteins were then eluted. Proteins were dialysed 
overnight at 4 C into storage buffer (Table 2.7), snap-frozen and stored at −80 C until use. 
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Buffer Composition 
Lysis buffer 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 5 % (v/v) glycerol, 1 % (v/v) Triton X-100, 0.1 % (v/v) 
2-mercaptoethanol, 1 mM benzamidine and 0.1 mM PMSF 
Wash buffer 
50 mM Tris-HCl (pH 7.5), 500 mM NaCl, 0.1 mM EGTA, 5 % 
(v/v) glycerol, 0.03 % (v/v) Brij-35, 0.1% (v/v) 2-
mercaptoethanol, 1 mM benzamidine and 0.1 mM PMSF 
Equilibration buffer 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1 mM EGTA, 5 % 
(v/v) glycerol, 0.03 % (v/v) Brij-35, 0.1 % (v/v) 2-
mercaptoethanol, 1 mM benzamidine and 0.1 mM PMSF 
Elution buffer Same as equilibration buffer with the addition of 12 mM 
maltose. 
Storage buffer 
Same as equilibration buffer with the addition of 0.27 M sucrose 
and glycerol—PMSF and benzamidine were omitted. 
2.2.32.2 Purification of Parkin constructs – performed by Clare 
Johnson 
Wild-type and indicated mutant untagged Parkin (His-SUMO cleaved) was expressed and 
purified using a modified protocol (Chaugule et al., 2011). No significant difference in 
solubility or expression between the mutants and wild-type Parkin protein was observed. 
BL21 cells were transformed with His-SUMO-tagged Parkin constructs, overnight cultures 
were prepared and used to inoculate 12 × 1 l LB medium, 50 μg/ml carbenicillin, 0.25 mM 
ZnCl2. The cells were grown at 37 C until the OD600was 0.4 and the temperature was dropped 
to 16 C. At OD600 = 0.8 expression was induced with 25 μM IPTG. After overnight 
incubation the cells were collected and lysed in lysis buffer (Table 2.8). After sonication and 
removal of insoluble material, His-SUMO-Parkin was purified via Ni2+-NTA-Sepharose 
chromatography. The protein was collected in elution buffer (Table 2.8). This was dialysed 
twice against cleavage buffer (Table 2.8) in the presence of His-SENP1 415–643 at a ratio of 
1 mg His-SENP1 per 5 mg His-SUMO-Parkin. The protease, the His-SUMO tag and any 
uncleaved protein was removed by two subsequent incubations with Ni2+–NTA–Sepharose. 
Table 2.7 Buffers used in MBP-tagged protein purification 
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The cleaved Parkin was further purified in wash buffer (Table 2.8) over a Superdex 200 
column. 
Buffer Composition 
Lysis buffer 
75 mM Tris pH 7.5, 500 mM NaCl, 0.2 % Triton X-100, 25 mM 
imidazole, 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP), 1 
mM Pefablok, 10 μg ml−1 Leupeptin 
Equilibration buffer 
50 mM Tris, pH 8.2, 200 mM NaCl, 10 % glycerol, 0.03 % Brij-
35, 0.5 mM TCEP 
Elution buffer 
Same as equilibration buffer with the addition of 400 mM 
imidazole. 
Cleavage buffer 
50 mM Tris pH 8.2, 200 mM NaCl, 10 % glycerol, 0.5 mM 
TCEP 
Wash buffer 
50 mM Tris, pH 8.2, 200 mM NaCl, 20 % glycerol, 0.03 % (v/v) 
Brij-35, 0.5 mM TCEP 
2.2.32.3 Purification of His-SUMO-Miro1 – performed by DSTT 
Wild-type 6xHis-Sumo-Miro1 (1 – 592) and K572R and K567R mutants were expressed in 
E. coli. Briefly, BL21 CodonPlus (DES)-RIL transformed cells were grown at 37 C to an 
OD600 of 0.4, then induced at 15 C with 10 M IPTG at an OD600 of 0.6. Cells were then 
grown at 15 C for a further 20 hours. Cells were pelleted at 4200 x g and then lysed by 
sonication in lysis buffer (Table 2.9). Lysates were clarified by centrifugation at 30 000 g for 
30 min at 4 C followed by incubation with Cobalt resin at 4 C for 45 min. The resin was 
washed thoroughly in high salt buffer (Table 2.9), then equilibrated in low salt buffer, and 
the proteins were then eluted (Table 2.9). The eluted Miro1 proteins were further purified by 
anion exchange chromatography. Proteins were applied to a Mono-Q HR 5/5 column and 
chromatographed with a linear gradient of NaCl from 0 M to 0.5 M. Fractions containing the 
purified Miro1 protein were then dialysed (Table 2.9), snap frozen in liquid nitrogen and 
stored at -80 C. 
 
Table 2.8 Buffers used for Parkin purification 
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Buffer Composition 
Lysis buffer 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 % Triton, 1 mM 
Pefabloc, 20 ug/ml Leupeptin, 1 mM Benzamidine and 0.5 mM 
TCEP 
High salt buffer 
50 mM Tris-HCl pH 7.5, 500 mM NaCl, 20 mM imidazole 1 mM 
Pefabloc, 20 ug/ml Leupeptin, 1 mM Benzamidine and 0.5 mM 
TCEP 
Low salt buffer 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM imidazole 1 mM 
Pefabloc, 20 ug/ml Leupeptin, 1 mM Benzamidine and 0.5 mM 
TCEP 
Elution buffer 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 300 mM imidazole 1 
mM Pefabloc, 20 ug/ml Leupeptin, 1 mM Benzamidine and 0.5 
mM TCEP 
Dialysis buffer 
50 mM Tris-HCl, 150 mM NaCl, 0.1 mM EGTA, 270 mM 
Sucrose, 0.1 % B-mercaptethanol 
2.2.33 Purification of phospho-proteins – performed by Dr. Axel Knebel 
2.2.33.1 Purification of Ser65-phosphorylated ubiquitin and Ser65-
phosphorylated Parkin Ubl domain (residues 1-76) 
23 μM bovine ubiquitin (SIGMA) was phosphorylated for 24 h with 3.7 μM MBP-PINK1 at 
22 C in the presence of 100 μM ATP and 10 mM MgCl2. To replace ADP with ATP, the 
reaction was dialysed against Mg-ATP solution. Ubiquitin was filtered through a 30 kDa 
Vivaspin filter to remove MBP-PINK1, concentrated in a 3 kDa MWCO filter device, washed 
extensively with water and loaded onto a Mono Q-column, which bound phospho-ubiquitin 
but not bind ubiquitin, . The former was recovered by washing the column with 50 mM Tris 
pH 7.5, which was sufficient to elute stoichiometrically phosphorylated ubiquitin. Similarly, 
Parkin Ubl domain (residues 1-76) was expressed as previously described (Kondapalli et al., 
2012) and was phosphorylated with MBP-TcPINK1, recovered by filtration and applied to a 
Mono-Q column. Phospho Parkin Ubl bound to the column and eluted with about 100 mM 
NaCl. At least 60 % purity was achieved.  
Table 2.9 Buffers used for Miro1 purification - performed by DSTT 
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2.2.33.2 Purification of Ser65-phosphorylated Parkin 
Ser65-phosphorylated Parkin was produced by expression of His-SUMO-tagged Parkin then 
captured by Ni2+-NTA-Sepharose as described above. After extensive washes, captured His-
SUMO-Parkin was incubated with MBP-PINK (Parkin : PINK1 ratio of 2:1) twice 
consecutively for 3 h in the presence of 0.5 mM ATP and 10 mM Mg-acetate at 27 C. PINK1 
was removed and Parkin was eluted with 0.4 M imidazole and further incubated for 16 h 
with MBP-PINK1 in solution. The proteins were concentrated using VivaSpin filters and 
then diluted again to reduce the imidazole concentration to 20 mM to recapture His-SUMO-
Parkin on Ni-agarose. Residual MBP-PINK1 was removed by extensive washes, before His-
SUMO-Parkin was eluted with 0.4 M imidazole and further purified as described above.  
2.2.33.3 Purification of Dac-ubiquitin and Ser65-phosphorylated Dac-
ubiquitin 
The Dac-tag is a fragment of E.coli Penicillin Binding Protein 5, comprising residues 37-297, 
where the N-terminus was modified to MSAIPG to allow efficient mRNA translation (Lee et 
al., 2012b). pET28-Dac-Ubiquitin was transformed into BL21 cells. Protein expression was 
induced with 250 μM IPTG for 16 h at 26 C. Cells were sedimented and lysed in 50 mM 
Tris pH 7.5, 0.5 % Triton X-100, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM Pefabloc®, 10 μg/ml 
Leupeptin. After sonication insoluble material was removed by centrifugation. Dac-ubiquitin 
fusion protein was captured by incubation for 45 min at 22 C with ampicillin-Sepharose. 
The ampicillin-Sepharose was thoroughly washed and the protein was eluted with 50 mM 
Tris pH 7.5, 150 mM NaCl, 5 % glycerol, 10 mM ampicillin, 0.03 % Brij35. The protein was 
dialysed into 40 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT. 
Ser65-phosphorylated Dac-ubiquitin (Dac-UbiquitinPhosSer65) was prepared by phosphorylation 
of Dac-Ubiquitin with GST-Pediculus humanus PINK1 126-end (ratio Dac-Ub: GST PhPINK 
of 6.25:1) for 3 h in the presence of 20 mM Mg-acetate and 2 mM ATP. Dac-Ubiquitin was 
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repurified over Ampicillin Sepharose and concentrated to match the concentration of Dac-
ubiquitin. 
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3 Chapter 3: PINK1 and Parkin - a molecular interaction  
3.1 Introduction 
Whilst familial Parkinson’s disease (PD) patients with mutations in the ubiquitin E3 ligase 
Parkin and the serine/threonine protein kinase PINK1 (PTEN (phosphatase and tensin 
homologue)-induced kinase 1) exhibit a similar phenotype (Khan et al., 2002), it was initially 
difficult to reconcile a molecular link between these two proteins since Parkin is localised to 
the cytosol, whereas PINK1 is localised to the mitochondria.  
A decisive functional genetic link between Parkin and PINK1 was first established in 2006, 
when it was shown in a Drosophila melanogaster model that Parkin null flies have a 
mitochondrial phenotype that is near-identical to that of PINK1 null flies – namely defects 
in mitochondrial morphology, flight muscle degeneration and motor deficits (Clark et al., 
2006, Park et al., 2006, Yang et al., 2006). Moreover, epistatic analysis revealed that over-
expression of Parkin rescued the PINK1 null phenotype but that the effect was not reciprocal, 
suggesting that PINK1 acts upstream of Parkin (Clark et al., 2006, Park et al., 2006, Yang 
et al., 2006).  
In mammalian cell studies, a major breakthrough came from the discovery that Parkin is 
recruited to damaged mitochondria upon induction of mitochondrial depolarisation, and 
furthermore that Parkin promotes autophagic degradation of mitochondria via a process 
termed mitophagy (Narendra et al., 2008). Subsequent studies described the requirement of 
mammalian PINK1 for Parkin recruitment to mitochondria following depolarisation (Geisler 
et al., 2010, Matsuda et al., 2010, Narendra et al., 2010, Vives-Bauza et al., 2010) and 
provided a second line of evidence for linear regulation within the signalling pathway, placing 
Parkin firmly downstream of PINK1. However, the mechanism by which Parkin is recruited 
and activated by PINK1 remains a major point of enquiry.  
Elucidation of the molecular basis of the pathway was largely hindered by difficulties in 
detecting mammalian PINK1 activity in vitro. This was overcome by the discovery in our 
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laboratory of active insect orthologues of PINK1, specifically Tribolium castaneum 
(TcPINK1) and Pediculus humanus corporis (PhcPINK1),  which could be purified from E. 
coli (Woodroof et al., 2011). These insect orthologues of PINK1 are active against generic 
substrates including myelin basic protein, and enabled elaboration of a peptide substrate 
termed PINKtide (Woodroof et al., 2011). Furthermore, this discovery facilitated direct 
assessment of the effects of ~20 PINK1 human pathogenic mutations that were conserved in 
the insect PINK1 orthologues, which revealed that the majority of PINK1 mutations lead to 
a disruption of catalytic activity (Woodroof et al., 2011). Following this finding, a member 
of our laboratory, Dr. Chandana Kondapalli, deployed TcPINK1 to screen a panel of proteins 
linked to forms of PD with Mendelian inheritance in order to identify potential PINK1 
substrates, and found Parkin to be phosphorylated (Kondapalli et al., 2012). She subsequently 
mapped the site of phosphorylation to a single residue at serine 65 (Ser65) (Kondapalli et al., 
2012), later validated by other groups (Shiba-Fukushima et al., 2012, Iguchi et al., 2013, 
Koyano et al., 2013), providing the first evidence of a direct regulatory link between these 
enzymes.  
Ser65 lies within the N-terminal Ubl domain of Parkin. Historically, Parkin was thought to be 
a constitutively active RING E3 ligase, but in 2011, ground-breaking work revealed that 
Parkin exhibits HECT-like properties (Wenzel et al., 2011) and furthermore that it exists in 
an auto-inhibited conformation, mediated by the interactions of the N-terminal ubiquitin-like 
domain (Ubl) domain with the rest of the protein (Burchell et al., 2012, Chaugule et al., 
2011).  Since then, multiple high resolution structures of Parkin lacking the Ubl domain 
(Riley et al., 2013, Trempe et al., 2013, Wauer and Komander, 2013) and one low resolution 
structure of the full-length protein (Trempe et al., 2013) have been determined, revealing a 
complex auto-inhibited state mediated by multiple intramolecular interactions. However, the 
molecular mechanism of inhibition mediated via the N-terminal Ubl domain, within which 
Ser65 is found, remained obscure.  
I have set out to establish the importance of PINK1-mediated Ser65 phosphorylation and to 
determine the impact of PINK1 phosphorylation on Parkin function and activity. In order to 
Chapter 3: PINK1 and Parkin - a molecular interaction 
59 
 
address this goal, I have sought to investigate and confirm the phosphorylation of Parkin in 
mammalian cells, as well as to establish a robust E3 ligase assay in vitro. To date, the 
majority of Parkin assays had been based on measuring Parkin autoubiquitylation activity 
in vitro and in cells and there were no robust substrate-based assays of Parkin E3 ligase 
activity available. To address this, I have tested whether Miro1, an atypical mitochondrial 
GTPase, which has emerged as a candidate Parkin substrate (Sarraf et al., 2013, Liu et al., 
2012, Wang et al., 2011), could be deployed as a substrate to enable in vitro measurement of 
Parkin activity. 
3.2 Tool development and validation 
3.2.1 Generation and characterisation of novel Parkin antibodies 
In order to establish effective tools to detect Parkin in cells, I designed and raised two 
antibodies against different human Parkin epitopes in conjunction with the Division of Signal 
Transduction Therapy (DSTT) and compared these to two commercially available antibodies 
raised against the full length protein (Figure 3.1). In addition, a phospho-Ser65 specific 
antibody was raised using a peptide epitope (Figure 3.1). The antibodies were compared by 
assessing their ability to immunoblot and immunoprecipitate overexpressed Parkin in cell 
extracts.   
Lysates of HEK293 cells, both those transiently overexpressing full-length untagged Parkin, 
and untransfected controls, were analysed. Both in-house antibodies were able to selectively 
recognise Parkin in whole cell lysates as judged by the detection of two bands, representing 
the full-length and an N-terminally truncated version of the E3 ligase (Henn et al., 2005) 
(Figure 3.2 A, B). The antibodies were also able to successfully immunoprecipitate 
overexpressed Parkin (Figure 3.2 E).  
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Two commercial antibodies were tested – the Santa Cruz biotechnologies PRK8 was 
previously successfully used in biochemical studies (Berger et al., 2009, Yamauchi et al., 2008) 
and could immunoblot and immunoprecipitate Parkin (Figure 3.2 C, F top panel); the Cell 
signalling 2132 antibody, which has also been used in previous studies (Cesari et al., 2003), 
was able to immunoblot Parkin in lysates (Figure 3.2 D) but failed to immunoprecipitate 
Parkin (Figure 3.2 F bottom panel) and was therefore not used in future experiments in 
HEK293 cells. The DSTT 210D antibody was raised against a peptide encompassing Parkin 
phospho-Ser65 (ParkinPhospho-Ser65) (Figure 3.1 B) and was tested on 200 g immunoprecipitates 
from Flp-in T-Rex PINK1 HEK293 cell lines transiently overexpressing either wild-type (WT) 
 
Figure 3.1 Schematic representation of Parkin antibody epitopes generated. 
(A) Schematic representation of Parkin protein domains and epitope regions 
against which in-house (DSTT) and commercial antibodies were raised. (B) 
Table summarizing antibodies tested.  
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or a non-phosphorylatable Ser65Ala (S65A) mutant Parkin and stimulated with 10 M CCCP 
(a mitochondrial depolarising agent) or DMSO for 3 h.  Both the first and second bleeds 
detected ParkinPhospho-Ser65 following CCCP treatment (Figure 3.2 G). Only the second bleed 
did not detect any phosphorylation under unstimulated conditions, and was therefore used 
for subsequent experiments.  
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Figure 3.2 Characterisation of Parkin antibodies in overexpressed system 
(A) HEK293 transfected with untagged Parkin and untransfected cells were 
lysed and 30g of lysates were analysed by immunoblotting with indicated 
bleeds of DSTT 966C antibody. (B) As in (A) except DSTT 229D antibody 
was used. (C) As in (A) except PRK8 antibody was used. (D) As in (A) except 
2132 antibody was used. (E, F) as in (A) except 0.5mg of lysates were 
immunoprecipitated (IP) with the indicated antibodies and the IPs were 
analysed by immunoblotting with PRK8antibody. (G) as in E except the IP 
was done from Flp-in T-Rex wild-type PINK1-FLAG HEK293 cells 
overexpressing indicated Parkin constructs using the 2nd bleed of DSTT 966C 
antibody and analysis was done by immunoblotting using the indicated bleeds 
of DSTT 210D antibody.  
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3.2.2 Evidence that PINK1 phosphorylates Parkin in cells 
To examine whether Parkin becomes phosphorylated following the activation of PINK1, Flp-
In T-Rex HEK293 cells stably expressing wild-type PINK1-FLAG were transiently 
transfected with WT or S65A Parkin and stimulated with 10 M CCCP or DMSO for the 
indicated amount of time (Figure 3.3). Parkin was immunoprecipitated from 250 g of lysate 
followed by immunoblotting with the anti-Parkin Ser65 (ParkinPhospho-Ser65) antibody. Parkin 
phosphorylation could be first observed 5 minutes after the addition of CCCP (Figure 3.3) 
and reached maximum levels at 40 minutes. The peak in Parkin phosphorylation coincided 
with the appearance of a PINK1 bandshift, suggesting that the bandshift is related to, but 
does not correlate as well with PINK1 activity as Parkin phosphorylation (Figure 3.3). When 
Parkin S65A was overexpressed, no Ser65 phosphorylation was detected 3 hours after addition 
of CCCP, confirming the specificity of the antibody (Figure 3.3).  
 
Figure 3.3 Time course analysis of Parkin phosphorylation in cells 
Flp-In T-Rex PINK1 HEK293 cells were transfected with untagged wild-type 
(WT) or Ser65Ala (S65A) Parkin mutant, induced with doxycycline and 
stimulated with CCCP for the indicated amount of time. 0.25 mg of the whole-
cell lysate was immunoprecipitated using the 2nd bleed of DSTT 966C antibody 
and analysed by immunoblotting with the 2nd bleed of DSTT 210D antibody 
in the presence of dephosphorylated peptide. 1% of the immunoprecipitate was 
blotted with PRK8 antibody to determine the total Parkin levels. 1.5 mg of the 
lysates were immunoprecipitated using anti-FLAG agarose beads and 
immunoblotted with total PINK1 antibody. 
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3.2.3 Parkin is phosphorylated by TcPINK1 in vitro  
Previous work in our lab has identified active insect orthologues of PINK1 (Woodroof et al., 
2011), including Tribolium castaneum (TcPINK1), that are capable of phosphorylating 
human Parkin at Ser65 in vitro (Kondapalli et al., 2012). To determine the stoichiometry of 
Parkin phosphorylation by TcPINK1, a kinase assay using three different amounts of the 
kinase was carried out (Figure 3.4). The stoichiometry of phosphorylation at Ser65 was 
determined to be approximately 0.07 moles of phosphate incorporated per mole of Parkin 
after 60 min reaction irrespective of the quantity of TcPINK1 present in the reaction. Since 
this low stoichiometry of phosphorylation precluded facile production of phosphorylated 
Parkin, I chose to study the effects of Parkin phosphorylation via a 2-step assay combining 
an initial kinase assay followed by a ubiquitylation assay.   
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Figure 3.4 Stoichiometry of Parkin phosphorylation by PINK1.  
0.5, 1 and 2 g of wild-type (WT) or kinase-inactive (KI) PINK1 were 
incubated in the presence or absence of 1g of Parkin in a kinase assay as 
described in Section 2.2.28.1. Reactions were then analysed by SDS-PAGE. 
Proteins were detected by Coomassie staining. Incorporation of [γ-32P] ATP 
into substrates was analysed by autoradiography. Stoichiometry of 
incorporation was determined by scintillation counting. The bar chart displays 
mol of ATP incorporated per mol of Parkin. 
3.2.4 Phosphorylation of Parkin at Ser65 stimulates its E3 ligase activity 
Ser65 is a highly conserved residue that lies in the core of the N-terminal Parkin Ubiquitin-
like (Ubl) domain, which has been previously shown to be required for the regulation and 
auto-inhibition of Parkin E3 ligase activity (Burchell et al., 2012, Chaugule et al., 2011). I 
therefore hypothesised that PINK1 phosphorylation of Ser65 might act to relieve this Ubl-
mediated autoinhibition by causing electrostatic repulsion at the interface of the inhibitory 
intramolecular interaction, thus leading to structural rearrangements and activation.  
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To test this, I established a Parkin auto-ubiquitylation E3 ligase assay. In order  to generate 
highly pure full-length recombinant Parkin purified from E.coli with no epitope tags that 
might interfere with Ubl-mediated Parkin autoinhibition (Burchell et al., 2012), I adapted a 
purification protocol first reported by Helen Walden’s laboratory (Chaugule et al, 2011). As 
an initial step, Parkin was phosphorylated by TcPINK1. Reactions were initiated by 
incubating wild-type or Ser65Ala Parkin with the indicated amounts of kinase (Figure 3.5) 
in the presence of [-32P] ATP; after 60 min, half of the reaction volume was used to determine 
Parkin phosphorylation levels (Figure 3.5 middle panel). The autoubiquitylation activity of 
phosphorylated Parkin was then tested by adding the E3 ligase assay components (E1 
ubiquitin-activating ligase, UbcH7 ubiquitin conjugating ligase, Flag-ubiquitin and Mg-ATP) 
to the kinase assays and incubating the reaction for a further 60 min at 30 °C. The reactions 
were terminated using SDS sample buffer containing -mercaptoethanol (-Me) and E3 ligase 
activity was assessed by blotting for ubiquitin, Parkin and TcPINK1 using anti-Flag, anti-
Parkin and anti-MBP antibodies respectively.  
In agreement with previous reports (Burchell et al., 2012, Chaugule et al., 2011), Parkin 
displayed no significant E3 ligase activity in the absence of PINK1 (Figure 3.5 A, lane 1). 
Upon addition of increasing levels of TcPINK1 and the resultant increased levels of Parkin 
phosphorylation (Figure 3.5 A, middle panel), I excitingly observed appearance of non-
reducible polyubiquitin species migrating between 30 kDa and 50 kDa that increased 
corresponding to PINK1 concentration (Figure 3.5, top panel). Consistent with this effect 
being Ser65 phosphorylation dependent, the appearance of polyubiquitin chains was inhibited 
by introducing an Asp359Ala (D359A) point mutation in PINK1 that ablates catalytic 
activity (Figure 3.5 B) or by mutating Ser65 in Parkin to a non-phosphorylatable Ala residue 
(S65A) (Figure 3.5 C).  
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3.2.5 Analysis of the effects of Parkin phosphorylation via elaboration of a 
substrate-based Parkin E3 ligase assay 
To validate the discovery that phosphorylation by PINK1 activates Parkin, I chose to develop 
an in vitro substrate-based Parkin activity assay. Miro1 was chosen as a candidate substrate 
since it had been previously reported to be targeted by Parkin in multiple cellular and genetic 
studies (Sarraf et al., 2013, Liu et al., 2012, Wang et al., 2011). Since full-length recombinant 
His-SUMO-Miro1 (residues 1- 618) expressed in E.coli was insoluble (data not shown), a C-
terminal truncation removing the transmembrane domain (residues 1-592) (subsequently 
referred to as Miro1) was expressed and purified to homogeneity and used in subsequent 
assays.  
Reactions were carried out as described in Section 3.2.4 with the addition of 0.5 M Miro1. 
Consistent with previous findings, in the absence of phosphorylation, Parkin was inactive 
(Figure 3.6 A, lane 1). However, when wild-type TcPINK1 was added, free polyubiquitin 
chain formation was observed, together with Miro1 multi-monoubiquitylation (a major mono- 
and minor multi-ubiquitylated species) (Figure 3.6) providing the first evidence that Miro1 
is a direct substrate of Parkin. No significant Miro1 ubiquitylation or polyubiquitin chain 
formation was observed in the presence of the kinase-inactive TcPINK1 (Figure 3.6 B) or 
using the Ser65Ala (S65A) Parkin point mutant (Figure 3.6 C) indicating that Parkin activity 
as judged by Miro1 ubiquitylation is critically dependent on Ser65 phosphorylation. 
Figure 3.5 PINK1 phosphorylation of Parkin at Ser65 mediates activation of 
Parkin E3 ligase activity. 
Wild-type (WT) (A) but not kinase-inactive (KI) (D359A) (B) TcPINK1 
activates wild-type (WT) Parkin, but does not alter the activity of Ser65Ala 
(S65A) mutant Parkin (C). Two micrograms of WT or S65A Parkin were 
incubated with indicated amounts of WT or KI TcPINK in a kinase reaction 
for 60 min. Half of reaction was terminated and incorporation of [-32P] ATP 
was detected by autoradiography (middle panel). The ubiquitylation reaction 
was then initiated and allowed to run for a further 60 min, then terminated by 
addition of loading buffer and resolved by SDS-PAGE. Ubiquitin (anti-Flag), 
Parkin (anti-Parkin) and PINK1 (anti-MBP) were detected by 
immunoblotting. E1-ubiquitin (Ub-Ube1) and ubiquitin dimer (Ub2) formation 
occurred in all conditions (A-C). Ubiquitylation of PINK1 (Ub-PINK1) is 
indicated (A). Formation of polyubiquitin chains (poly-Ub) upon Parkin 
activation (A) is indicated. Representative of five independent experiments. 
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3.2.6 Phosphorylation of Parkin at Ser65 promotes discharge of ubiquitin from 
loaded UbcH7 E2 ligase 
To obtain further evidence that PINK1-dependent phosphorylation of Parkin leads to Parkin 
activation, I assessed whether phosphorylation might influence other readouts of Parkin 
activity, including binding of ubiquitin-loaded E2 to the RING1 domain and/or E2-mediated 
ubiquitin transfer. In order to address these questions, I set up an E2 discharge assay. Several 
E2s were initially tested (data not shown), however UbcH7 was chosen for future experiments 
due to its consistent loading and discharge. UbcH7 was loaded with ubiquitin by incubation 
with the E1 (Ube1) and ubiquitin in the presence of Mg-ATP for 60 min at 30 °C. Various 
Parkin species were then added to the reaction mixture and incubated for a further 15 min. 
In all experiments, a control reaction without E3 ligase was included to enable assessment of 
the efficiency of UbcH7 loading. Reactions were terminated using LDS loading buffer without 
any reducing agent and immediately analysed by SDS-PAGE, followed by Coomassie 
staining. The electrophoretic separation of the proteins enabled the facile discrimination of 
ubiquitin conjugated UbcH7 (UbcH7-ub) from free UbcH7.  
To determine the effect of phosphorylation of Ser65 on Parkin’s ability to discharge ubiquitin, 
Parkin pre-phosphorylated by wild-type TcPINK1, and non-phosphorylated Parkin (either 
incubated in the presence of kinase-inactive TcPINK1 or in the absence of TcPINK1) was 
added to the loaded UbcH7. Non-phosphorylated Parkin species failed to induce a significant 
discharge of ubiquitin from UbcH7, however, ParkinPhospho-Ser65 mediated robust ubiquitin 
Figure 3.6 PINK1-dependent phosphorylation of Parkin Ser65 leads to 
activation of Parkin E3 ligase activity and multi-monoubiquitylation of Miro1.  
(A) Wild-type (WT), but not kinase-inactive (KI) (D359A) (B) TcPINK1 
activates wild-type (WT) Parkin leading to Miro1 ubiquitylation; activation is 
blocked by Parkin Ser65Ala (S65A) mutation (C). Two micrograms of wild-
type or Ser65Ala Parkin were incubated with indicated amounts of WT or KI 
TcPINK in a kinase reaction for 60 min. The ubiquitylation reaction was 
initiated as described in Section 2.2.28.2 in the presence of 0.5 M His-Sumo-
Miro1. Reactions were terminated after 60 min by addition of loading buffer 
and resolved by SDS-PAGE. Miro1, Ubiquitin, Parkin and PINK1 were 
detected using anti-SUMO, anti-FLAG, anti-Parkin and anti-MBP antibodies, 
respectively. Representative of 3 independent experiments. 
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discharge, as demonstrated by a reduction of the UbcH7-ub thioester band (Figure 3.7 A). A 
Parkin-ubiquitin thioester was not observed in this experiment, consistent with a previous 
analysis of full length Parkin (Sarraf et al., 2013, Spratt et al., 2013, Wenzel et al., 2011).  
I next undertook a time course analysis to gain further insights into Parkin phosphorylation-
dependent stimulation of UbcH7 discharge. Parkin pre-phosphorylated by TcPINK1 was 
added to the loaded UbcH7 and reactions were allowed to continue for the indicated times 
(Figure 3.7 B) before being stopped with LDS loading buffer. Under the conditions used, 
maximal ubiquitin discharge induced by ParkinPhospho-Ser65 occurred within 4-5 min (Figure 3.7 
B). To ensure that the discharge is indeed mediated by phosphorylation at Ser65,  the Parkin 
Ser65Ala mutant was included in this analysis, and I observed that the mutation prevented 
ubiquitin discharge from UbcH7 even in the presence of wild-type TcPINK1 (Figure 3.7 C).  
 
Figure 3.7 PINK1-dependent phosphorylation of Parkin Ser65 stimulates 
discharge of ubiquitin from loaded E2, UbcH7.  
(A) Parkin alone or pre-phosphorylated with wild-type (WT) or kinase-inactive 
(KI) TcPINK1 was incubated with two micrograms of UbcH7 loaded with 
ubiquitin (UbcH7-ub). Reactions were allowed to continue for 15 min, stopped 
using LDS loading buffer in absence of reducing agent. Samples were resolved 
by SDS-PAGE; proteins were detected by Coomassie staining. Ubiquitin 
discharge was monitored by qualitatively assessing reduction in UbcH7-ub 
band. (B) As in (A), but only Parkin with WT TcPINK1 was used. Reactions 
were allowed to continue for indicated times.  (C) Parkin Ser65Ala (S65A) was 
compared with wild-type Parkin for its ability to discharge UbcH7-ub.  
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3.3 Parkin phosphorylated at Ser65 catalyses multi-
monoubiquitylation of Miro1 
3.3.1 Parkin Ubl domain is required for efficient Miro1 ubiquitylation 
Full-length Parkin is maintained in an auto-inhibited conformation and is catalytically 
inactive, however multiple reports have revealed that deletion of the Ubl domain is sufficient 
to activate Parkin (Chaugule et al., 2011, Wenzel et al., 2011). To probe the potential role 
of the Ubl domain in substrate ubiquitylation, I chose to investigate the effect of deletion of 
the said domain on Miro 1 ubiquitylation. A Parkin fragment lacking this domain (Ubl-
Parkin, residues 80-465) was expressed and tested (Figure 3.8). Ubl-Parkin alone was 
assayed in parallel with full-length Parkin pre-incubated with 0.8 M of either wild-type or 
kinase-inactive TcPINK1. This optimal concentration, equivalent to 1 g of TcPINK1 in the 
final assay, was chosen based on the results displayed in Figure 3.5.  
Whilst Ubl-Parkin exhibited autoubiquitylation activity comparable to phosphorylated full-
length Parkin, it could not efficiently catalyse Miro1 ubiquitylation or stimulate the formation 
of low molecular weight polyubiquitin chains (Figure 3.8). These data suggest that the Ubl 
domain is required for the full spectrum of Parkin activity and that the Ubl domain 
phosphorylated at Ser65 might have additional roles in enabling substrate ubiquitylation 
beyond potentially mediating relief of Parkin autoinhibition. 
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3.3.2 Identification of Parkin-mediated Miro1 ubiquitylation sites  
Post-translational protein modification with ubiquitin constitutes a major cell regulatory 
system (Finley et al., 2004). One of the key outstanding questions in the field remains 
identification of ubiquitylation sites. Commonly, a mass spectrometry approach utilizing a 
tryptic Gly-Gly (GG) remnant of ubiquitin on the substrate lysine  (Goldknopf and Busch, 
1977) is used to determine sites of ubiquitylation. I have utilized this approach to determine 
the major site(s) of Miro1 ubiquitylation by TcPINK1-activated Parkin. To achieve this, an 
 
Figure 3.8 Ubl domain of Parkin is required for optimal substrate 
ubiquitylation.  
Full length (lanes 1, 2), but not Ubl-Parkin (lanes 5, 6) ubiquitylates Miro1. 
Ubl-Parkin alone was tested in parallel with full-length (WT) Parkin pre-
phosphorylated by wild-type (WT) or kinase-inactive (KI) TcPINK1 in an in 
vitro ubiquitylation assay. Reactions were analysed by SDS-PAGE; Miro1, 
Ubiquitin and Parkin were detected using anti-SUMO, anti-FLAG and anti-
Parkin antibodies, respectively. 
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in vitro Miro1 ubiquitylation assay using Parkin pre-incubated with wild-type or kinase-
inactive TcPINK1 was performed; the reaction was then subjected to SDS-PAGE followed 
by staining and in-gel tryptic digestion (Figure 3.9). Mass spectrometric analysis was 
conducted by Dr. Van Kelly (laboratory of Dr. Patrick Pedrioli).  
Five unique peptides carrying a K-GG tryptic remnant were identified in samples incubated 
with Parkin and wild-type TcPINK1, but were absent in the presence of Parkin and kinase-
inactive TcPINK1 (Figure 3.10 B). Lysine 153 (Lys153) was found in a tryptic peptide located 
within the first GTPase domain; lysine 230 (Lys230) and lysine 235 (Lys235) were found carrying 
K-GG remnants in two independent peptides found within the central linker region and Lys330 
was identified in fourth peptide located within the second EF-hand domain of Miro1 (Figure 
3.10 A,B). A fifth peptide containing a K-GG remnant at Lys572 was located within the C-
terminal non-catalytic region of Miro1, between the second GTPase domain and the 
transmembrane domain (Figure 3.10 A, B).  
 
Figure 3.9 Sample preparation for Mass spectrometry analysis 
In vitro ubiquitylation assay using wild-type (WT) or kinase-inactive (KI) 
PINK1 was carried out as described in Section 3.2.5. 80% of the sample was 
subjected to analysis by SDS-PAGE. Miro1 and ubiquitylated Miro1 (Miro1-
ub) gel bands were excised and analysed by LTQ-Orbitrap mass spectrometry. 
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In parallel, an in-solution tryptic digest was set up and yielded a miscleaved peptide, 
MPPPQAFTCNTADAPSKDIFVK(GG)LTTMAMYPHVTQADLK, spanning lysine 572 
(Lys572) and another highly conserved lysine residue, lysine 567 (Lys567) (data not shown). 
Peptide fragmentation pattern analysis supported the modification occurring at Lys572. To 
validate the finding, two point mutants – Lys567Arg (K567R) and Lys572Arg (K572R) – of 
Miro1 were generated and ubiquitylation assays were undertaken. Lys572Arg Miro1 displayed 
a significant reduction in monoubiquitylated as well as multi-monoubiquitylated species 
(Figure 3.11), whereas the Lys567Arg mutant behaved like the wild-type Miro1 under the 
assay conditions used (Figure 3.11). This mutagenesis analysis is consistent with the mass 
spectrometry data and indicates that Lys572 is a major site of Miro1 ubiquitylation.  
These analyses indicate that Miro1 undergoes multi-monoubiquitylation and that Lys153, 
Lys230, Lys235, Lys330, and Lys572 are the major sites of Miro1 ubiquitylation targeted by 
activated Parkin. All the sites identified are highly conserved (Figure 3.10 C), and several of 
these residues in Miro1 (Lys153, Lys235, and Lys572) have also recently been reported to be 
ubiquitylated in cells over-expressing tagged Parkin (Sarraf et al., 2013). 
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Figure 3.10 Miro1 ubiquitylation sites 
(A) Schematic representation of Miro1 domain architecture showing the 
identified ubiquitylation sites and truncation site (red dotted line). (B) Table 
summarizing peptide sequences used to identify Lys153, Lys230, Lys235, Lys330 and 
Lys572 as ubiquitylation sites on Miro1. Ubiquitin isopeptides were identified by 
Mascot (www.matrixscience.com) and spectra were manually validated to 
ensure peptide fragmentation gave good sequence coverage (* 417 ppm error 
equates to a -1.81 ppm error around the C13 isotope). (C) Sequence alignment 
showing high degree of conservation of residues surrounding Lys153, Lys230 and 
Lys235 (left), Lys330 and Lys572 (right) in human Miro1 and a variety of lower 
organisms.  
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Figure 3.11 Miro1 Lys572 is a major site of ubiquitylation catalysed by 
activated Parkin. 
Mutation of Lys572Arg (K572R) but not Lys567Arg (K567R) substantially 
reduces ubiquitylation by activated Parkin. Wild-type Miro1 (WT) and two 
point mutants (K567R, K572R) were used in a ubiquitylation assay with WT 
Parkin pre-incubated with WT or KI TcPINK1 as described in Section 2.2.28.2. 
Proteins were detected by Coomassie blue staining or immunoblotting using 
anti-Sumo, anti-FLAG, anti-Parkin and anti-MBP antibodies to detect Miro1, 
ubiquitin, Parkin and TcPINK1 respectively. Multi-monoubiquitylated Miro1 
(Miro1-ub) is denoted by black dots.  
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3.3.3 Analysis of Parkin-generated ubiquitin isopeptide linkages 
Ubiquitin signalling cascade outcomes rely heavily on the topology of the polyubiquitin 
chain(s) synthesised (Komander and Rape, 2012). I next attempted to determine the chain 
topology or topologies present following Parkin ubiquitylation in my assay. A similar mass 
spectrometry approach, as described in the previous section, identifying K-GG remnants on 
ubiquitin backbone was utilised. In order to rigorously determine the critical role of Parkin 
activation by PINK1 phosphorylation at Ser65 a number of different conditions, summarised 
in Table 3.1, were analysed. 
PINK1 
Parkin 
UbcH7 
WT 
WT 
+ 
KI 
WT 
+ 
- 
WT 
+ 
WT 
T415N 
+ 
WT 
S65A 
+ 
WT 
- 
+ 
WT 
WT 
- 
Expected 
phosphorylation 
at Ser65 
       
Expected 
Parkin activity 
       
Wild-type (WT) Parkin was phosphorylated by wild-type (WT) TcPINK1 and ubiquitylation 
assays with and without UbcH7 were carried out. Samples lacking the E2 ubiquitin 
conjugating ligase were used in order to identify any ubiquitin bonds that might be present 
in the Flag-ubiquitin source. WT TcPINK1 with Ser65Ala (S65A) Parkin as well as kinase-
inactive (KI) PINK1 with WT Parkin were used as controls to validate the critical role of 
Parkin phosphorylation at Ser65 for chain formation. A sample lacking TcPINK1 was included 
as a control for potential peptide carry-over from the TcPINK1 samples. Two conditions 
reflecting lack of Parkin activity – one omitting the E3 ligase and one with a Parkin 
Thr415Asn (T415N) catalytically inactive point mutant - were included to ensure that 
ubiquitin chains generated were dependent on Parkin E3 ligase activity.  
The ubiquitylation assays were carried out as previously described and subjected to in-
solution digestion followed by LTQ-Orbitrap mass spectrometry performed by Dr. Van Kelly 
Table 3.1 Summary outline of experimental conditions for identification of Parkin-
generated ubiquitin chain topologies 
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(laboratory of Patrick Pedrioli). The methods used to determine the relative quantities of 
peptides carrying K-GG remnants in different conditions enabled determination of Parkin-
catalysed formation of polyubiquitin linkage types. The formation of both canonical (K48 and 
K63) and non-canonical (K6, K11, K33) ubiquitin chain linkages in a ParkinPhospho-Ser65-
dependent manner was detected (Figure 3.12). K27 isopeptides were also detected, but were 
independent of Parkin (Figure 3.12).  
Unfortunately, due to limitations of the mass spectrometry methodology employed, it was 
not possible to determine if Parkin was responsible for the formation of branched ubiquitin 
chain topologies or if distinct homogenous chains of each linkage type were being formed. 
Consistent with my analysis, a recent study has confirmed the Parkin-dependent formation 
of most of these chain types on the mitochondria of cells stimulated with CCCP (Ordureau 
et al., 2014).  
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Figure 3.12 Identification and relative quantification of ubiquitin-ubiquitin 
chain linkage isopeptides generated by Parkin.  
Ubiquitylation assays were carried out as described in Section 2.2.28.2, followed 
by in-solution tryptic digestion and analysis by LTQ-Orbitrap mass 
spectrometry. Ubiquitin isopeptides were identified by Mascot 
(www.matrixscience.com) on six lysines in the wild-type PINK1/wild-type 
Parkin/+UbcH7 sample (top).  Note that the FLAG-tag on ubiquitin 
prohibited analysis of linear M1 conjugation and additional amino acids (arising 
from the FLAG tag) were observed on the K6 peptide.  The most abundant 
charge state identified was selected for relative quantification of each ubiquitin 
isopeptides across all samples (bottom).  Chromatographic peak areas were 
extracted for the theoretical m/z of MS1 precursor ion signals and two isotopes 
using Skyline (MacLean et al., 2010).  With the exception of K27, all observed 
linkages were depended on wild-type parkin and PINK1. K29 was not detected. 
Chain composition differences between free and substrate bound ubiquitin 
chains could not be determined in the present analysis without prior 
fractionation of substrates. 
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3.3.4 Analysis of the influence of Parkin Ser65 phosphorylation on Parkin-E2 
interactions 
Parkin was first designated as an E3 ligase due to its similarity to another E3 ligase HHARI 
and the subsequent demonstration of its E2-dependent autoubiquitylation activity (Zhang et 
al., 2000). Multiple studies have since identified UbcH7 (UBE2L3), UbcH8 (UBE2L6), UBC6 
(UBE2J1), UBC7 (UBE2G1, UBE2G2), and the Ubc13/Uev1a heterodimer 
(UBE2N/UBE2V1) (Lazarou et al., 2013, Walden and Martinez-Torres, 2012, Wenzel and 
Klevit, 2012, Dawson and Dawson, 2010) as partnering E2s for tagged Parkin in 
autoubiuqitylation assays. Furthermore, Parkin was unexpectedly found to be capable of E2-
independent monoubiquitylation in vitro (Chew et al., 2011). However, evidence to support 
the identity of the physiological E2(s) that Parkin interacts with has remained elusive. Since 
Parkin was historically thought to behave as a RING E3 ligase, determining the partnering 
E2(s) was regarded as crucial since the RING E3 - E2 interaction plays an important role in 
specifying the diversity and specificity of ubiquitin conjugates (Metzger et al., 2013, Deshaies 
and Joazeiro, 2009).  
I therefore set out to test how a panel of 25 E2 ligases influenced the ability of Parkin to 
catalyse free chain formation and monoubiquitylation of Miro1 by assessing Parkin free chain 
formation and Miro1 ubiquitylation in the presence of each of these E2s, using E2 Ube2L3 
(UbcH7) as a control to provide a reference level for Parkin activity. This experiment was 
repeated three times in duplicate and each E2 was tested under three conditions: firstly, 
without any PINK1 or Parkin to enable visualisation of E3-independent activity; or in the 
presence of Parkin with wild-type; or kinase-inactive, TcPINK1. Results were analysed by 
immunoblotting for ubiquitin, Miro1 and PINK1.  
Strikingly, activated Parkin exhibited a similar pattern of free chain formation and Miro1 
ubiquitylation in the presence of 18 out of 25 E2s, UBE2L3 included (Figure 3.13) with 
varying levels of free chain formation and Miro1 ubiquitylation observed when pre-
phosphorylated Parkin was added (Figure 3.13). The other 7 E2s tested, e.g. Ube2T, did not 
permit activated Parkin to catalyse the formation of free ubiquitin chains but still enabled 
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Miro1 to become ubiquitylated by Parkin in the presence of wild-type TcPINK1 in all cases 
(Figure 3.13). 
Since the ubiquitin signal strength as well as the band pattern differed slightly depending on 
the E2 ligase used, this suggests that free chain formation, in addition to the resultant chain 
topology, may be critically dependent on the E2-E3 interaction, akin to canonical RING E3 
ligases. At the time that these experiments were conducted, the first evidence of Parkin acting 
as a RING-HECT hybrid was revealed (Wenzel et al., 2011). In contrast to RING E3 ligases, 
the specification of substrate/ubiquitin chain topology by HECT E3 ligases is largely 
independent of the identity of the E2, and instead the topology and pattern of ubiquitin 
conjugates is conferred primarily by the E3 - substrate interaction. The results from this E2 
scanning experiment are consistent with the observation that Parkin exhibits mainly HECT-
like properties, wherein ubiquitylation of Miro1 is governed principally by its interaction with 
Parkin itself.  
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Figure 3.13 Parkin can interact with multiple different E2 conjugating enzymes 
to catalyse Miro1 ubiquitylation with or without free ubiquitin chain formation.  
An E2 scan of 25 different E2 conjugating enzymes was undertaken. Two 
micrograms of wild-type Parkin were incubated with one microgram of wild-
type (WT) or kinase-inactive (KI) (D359A) TcPINK in a kinase reaction for 
60 min, as described in Section 2.2.282. Activated Parkin was then added into 
pre-assembled ubiquitylation reactions containing one microgram of the E2 
ubiquitin conjugating enzyme, as indicated. Reactions were terminated after 60 
min by addition of SDS loading buffer and resolved by SDS-PAGE. Miro1, 
Ubiquitin and PINK1 were detected by immunoblotting using anti-SUMO, 
anti-FLAG and anti-MBP antibodies, respectively.  
3.4 Analysis of Parkin disease mutants on Parkin E3 ligase activity 
Mutations in Parkin were first associated with autosomal recessive juvenile Parkinsonism in 
a Japanese patient cohort in 1998 (Kitada et al., 1998). They have since been linked with 
familial cases of early-onset Parkinson’s disease (PD) in a wide range of studies (Lucking et 
al., 2000, Abbas et al., 1999). To date, over 200 mutations in the PARK2 gene have been 
mapped (http://www.molgen.vib-ua.be/). Whilst the impact of mutations on Parkin function 
has been previously reported, the majority of studies have used either N-terminally tagged or 
N-terminally truncated versions of Parkin (Trempe et al., 2013, Wauer and Komander, 2013, 
Hampe et al., 2006, Matsuda et al., 2006, Sriram et al., 2005, Ren et al., 2003, Shimura et 
al., 2001, Shimura et al., 2000). Consequently, several conflicting lines of evidence regarding 
the changes in activity mediated by disease mutations exist. Shimura and colleagues reported 
the Arg42Pro (R42P) mutant to be ligase-inactive (Shimura et al., 2001, Shimura et al., 2000) 
whereas others have reported no effect on activity (Matsuda et al., 2006, Hampe et al., 2006); 
the Lys161Asn (K161N) mutation was reported to be ligase-inactive (Trempe et al., 2013, 
Ren et al., 2003), whilst other groups reported no effect on ligase activity (Wauer and 
Komander, 2013, Matsuda et al., 2006, Hampe et al., 2006).  
In order to shed light on this controversial issue, I chose to utilise my novel substrate-based 
assay for Parkin activity to assess the effect of disease-assocated Parkin mutations on Miro 1 
ubiquitylation. In order to avoid any artefactual effects on Ubl-mediated inhibition that might 
be caused by tagging the N-terminus of Parkin, a range of disease-associated mutations were 
introduced into full-length untagged Parkin. The selected variants of Parkin encompassed 
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mutations affecting every functional domain of Parkin and are as follows: Lys27Asn (K27N), 
Arg33Gln (R33Q), R42P, and Ala46Pro (A46P) (Ubl domain); K161N, Lys211Asn (K211N) 
(UPD domain); Arg275Trp (R275W) (RING1 domain); Gly328Glu (G328E) (IBR domain); 
Thr415Asn (T415N); Gly430Asp (G430D); and Cys431Phe (C431F) (RING2 domain). These 
mutations were chosen since they have been reported as homozygous or compound 
heterozygous mutations that co-segregate with the disease in early-onset PD cases (Figure 
3.14). 
 
Figure 3.14 Location of Parkinson’s disease-associated mutations in Parkin 
A schematic representation of Parkin domain architecture showing the location 
of disease-associated Parkin mutants. 
3.4.1 Parkin disease-associated mutants exhibit differential effects on Parkin-
mediated ubiquitylation following Ser65 phosphorylation 
The above mentioned Parkin mutants, together with wild-type and Ser65Ala controls, were 
tested for their ability to catalyse Miro1 ubiquitylation and/or formation of free ubiquitin 
chains after activation by TcPINK1 (Figure 3.15 top). To determine if their phosphorylation 
by TcPINK1 is affected, a kinase assay with [γ-32P] ATP was set up in parallel (Figure 3.15 
bottom). Diverse effects on Parkin E3 ligase activity were observed, enabling mutations to 
be classified into several distinct groups. In Group 1, two mutations, C431F, which disrupts 
the catalytic cysteine, and the RING1 mutant R275W, completely abolished Parkin activity 
(Figure 3.15). In Group 2, three mutations caused a marked reduction in both free ubiquitin 
chain formation and Miro1 ubiquitylation; the G430D mutation that lies adjacent to the 
catalytic cysteine, the UPD mutant K161N and the RING2 mutant T415N (Figure 3.15). In 
Group 4, two mutations abolished free ubiquitin chain formation while promoting Miro1 
monoubiquitylation rather than multi-monoubiquitylation (Figure 3.15), these were the Ubl 
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mutant A46P and the UPD mutant K211N. Furthermore, in Group 5, two mutants exhibited 
a differential increase in Parkin E3 ligase activity: both the Ubl mutant R33Q and the IBR 
mutant G328E led to increased Miro1 ubiquitylation, while increased free chain formation 
was only observed with R33Q. This effect might be explained by the observation that the 
phosphorylation of the R33Q and G328E mutants was significantly higher than that of wild-
type Parkin (Figure 3.15 bottom panel). Finally, mutations in Group 6, which comprise the 
Ubl domain mutations K27N and R42P, had no effect on Parkin mediated ubiquitylation. No 
mutations led to a decrease/abolition of Miro1 ubiquitylation with free ubiquitin chain 
formation remaining unaffected. 
Following activation of Parkin, TcPINK1 undergoes monoubiquitylation observed in a 
bandshift detectable by ubiquitin immunoblotting that is absent when kinase-inactive 
TcPINK1 or Ser65Ala Parkin is used (Figure 3.5). During the mass-spectrometry analysis, 
the site of ubiquitylation was mapped to a lysine residue located within the N-terminal MBP 
tag (Lys306 lying in the SYEEELVKDPR sequence motif; data not shown). MBP-TcPINK1 
ubiquitylation was lost in mutants associated with a decrease in either Miro1 ubiquitylation 
or free chain formation (A46P, K211N) or both (S65A, R275W, C431F, G430D, K161N, 
T415N) (Groups 1-3) (Figure 3.15), and was unaltered in mutants that had no effect or 
increased Parkin activity (WT, K27N, R33Q, R42P, G328E) (Groups 4-6) (Figure 3.15).  
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Figure 3.15 Heterogeneity of the impact of Parkinson’s disease associated point 
mutations on Parkin E3 ligase activity. 
Parkin mutations exhibit diverse effects on E3 ligase activity. Assays using 
wild-type (WT) and kinase inactive (KI) PINK1 (D359A) in combination with 
WT and indicated mutants of Parkin and the substrate Miro1 were undertaken 
as described in Section 2.2.28.2. A kinase reaction including 0.1 mM [γ-32P] 
ATP (approx. 500 cpm/pmol) was carried out in parallel for 60 min to confirm 
the phosphorylation as described in Section 2.2.28.1. Reactions were terminated 
after 60 min by addition of SDS loading buffer and resolved by SDS-PAGE. 
Miro1, Ubiquitin, Parkin and PINK1 were detected using anti-SUMO, anti-
FLAG, anti-Parkin and anti-MBP antibodies, respectively. Representative of 3 
independent experiments. 
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3.4.2 Impact of disease-associated point mutations on ubiquitin discharge 
from loaded UbcH7 following Ser65 phosphorylation 
Subsequently, I sought to further my investigation into the effect of disease-associated 
mutations on Parkin activity by analysing their impact on ubiquitin discharge from UbcH7. 
E2 discharge reactions were set up as previously described (Section 2.2.28.3). Each of the 
disease mutants, as well as the wild-type and Ser65Ala Parkin, was incubated with charged 
UbcH7, both without kinase as well as with wild-type and kinase-inactive TcPINK1 (Figure 
3.16). Reactions were subjected to SDS-PAGE, followed by Coomassie staining and LICOR 
quantification of the stained bands. Since ubiquitin discharge generates free E2, the ratio of 
UbcH7:UbcH7-ub was used as a measure of ubiquitin discharge (Figure 3.16, upper panel). 
All active mutants displayed maximal unloading of ubiquitin from the E2 when incubated 
with wild-type TcPINK1. Samples containing kinase-inactive TcPINK1 or no kinase showed 
none to minimal discharge, comparable to the Parkin empty control.  
Parkin mutants that exhibited normal or increased ubiquitylation of Miro1, namely K27N, 
R33Q, R42P, and G328E, showed no significant changes in their ability to stimulate ubiquitin 
discharge (Figure 3.16). However, a possible Parkin-ubiquitin thioester was observed for the 
R33Q mutant, suggesting that this point mutation may lead to conformational changes that 
increase the stability of the thioester bond (Figure 3.16). Further experiments examining the 
nature of the bond will be necessary to clarify this. 
The Parkin mutants A46P, R275W and T415N displayed a considerably reduced level of E2-
ubiquitin discharge, similar to that of the S65A mutant and the active site mutant C431F, 
suggesting that these residues might impact E2 binding or ubiquitin discharge upon Parkin 
Ser65 phosphorylation. The remaining mutants, comprising the UPD mutants K161N, K211N 
and the RING2 mutant G430D, exhibited intact or modestly reduced (K211N) Ser65 
phosphorylation-dependent E2 discharge. 
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Figure 3.16 Analysis of the effect of Parkin disease-associated mutations on 
ubiquitin discharge from UbcH7 following Ser65 Parkin phosphorylation. 
Parkinson’s disease associated mutants of Parkin were phosphorylated by wild-
type (WT) or kinase-inactive (KI) TcPINK1 alongside a control reaction 
lacking kinase carried out in parallel. E2 discharge reactions were performed by 
incubation of Parkin after the kinase assay with ubiquitin loaded UbcH7 
(UbcH7-ub) for 15 min at 30 °C.  Discharge was estimated by quantifying 
UbcH7-ub and UbcH7 bands by LICOR and calculating the ratio of 
UbcH7:UbcH7-ub. Mean values ± standard deviation of 3 independent 
experiments are presented. Red dotted line indicates the WT activity. * 
indicates the R33Q Parkin–ubiquitin thioester.  
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3.5 Discussion  
3.5.1 Phosphorylation of Parkin at Ser65 by PINK1 stimulates its E3 ligase 
activity 
Whilst genetic studies (Clark et al., 2006, Park et al., 2006, Yang et al., 2006) and cell 
biological studies (Geisler et al., 2010, Matsuda et al., 2010, Narendra et al., 2010, Vives-
Bauza et al., 2010) have linked PINK1 and Parkin in a linear signalling pathway, the 
molecular details of how these proteins interact have remained obscure. The discovery that 
PINK1 phosphorylates Parkin at Ser65 and the demonstration that phosphorylation stimulates 
the activation of Parkin E3 ligase activity represents a fundamental advance in our 
understanding of how these proteins interact although a further regulatory mechanism will 
be revealed in Chapter 4. Furthermore, the elaboration of both a novel E3 ligase assay 
(monitoring free-poly-ubiquitin chain formation as well as substrate ubiquitylation) (Figure 
3.5 & Figure 3.6 respectively) and UbcH7 ubiquitin discharge assay (Figure 3.7) has enabled 
demonstration of the dependence of Parkin activity on Ser65 phosphorylation, and provides 
powerful new tools for the field to probe Parkin biology and activity. 
3.5.2 Miro1 is a direct Parkin substrate 
Miro1 plays a crucial role in mitochondrial trafficking by tethering mitochondria to KIF5 
motor proteins, enabling mitochondria to be transported along microtubules (Macaskill et al., 
2009). Its levels were shown to be regulated by PINK1 and Parkin in two previous studies 
(Wang et al., 2011, Liu et al., 2012). Wang and colleagues reported that over-expression of 
PINK1 and/or Parkin resulted in decreased Miro1 levels in HEK 293T cells, mediated by 
PINK1-dependent phosphorylation of Miro1 at Ser156 (Wang et al., 2011). In contrast, Liu 
and colleagues found no evidence of Miro1 phosphorylation at Ser156 and reported a decrease 
in Miro1 levels upon PINK1 knockdown by siRNA in HeLa cells, as well as in PINK1 knock-
out MEFs when compared to levels in wild type MEFs (Liu et al., 2012). A global Parkin 
ubiquitylome analysis reported Miro1 Lys153, Lys194, Lys235 and Lys572 sites in cells over-
expressing tagged Parkin stimulated with CCCP (Sarraf et al., 2013). Unfortunately, due to 
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the limitations of global mass spectrometry analysis, this study failed to address if Miro1, 
amongst other ubiquitin-modified proteins, was ubiquitylated directly by Parkin. The in vitro 
results presented in this chapter are the first to demonstrate that Miro1 is a direct substrate 
of Parkin.  
Furthermore, I have demonstrated that the Miro1 Lys572Arg mutation causes a drastic 
reduction of ubiquitylation (Figure 3.11), suggesting that Lys572 is a major Parkin-targeted 
site. I also identified Lys230, and Lys330 as direct sites of Parkin ubiquitylation, neither of 
which have previously been reported (Figure 3.10). Whilst I did not identify a K-GG remnant 
on Miro1 Lys194, as has been previously reported from a mass spectrometry analysis (Sarraf 
et al., 2013), I cannot rule it out as a direct Parkin-mediated ubiquitylation site, since it may 
be of lower stoichiometry and therefore undetectable in the present analysis (Figure 3.10). 
Alternatively, the inherent lack of selectivity in global mass-spectrometry approaches raises 
the possibility of this site being modified by an alternative E3 ligase which in itself is regulated 
by the PINK1 pathway.  
 Several of the identified sites lie within or near functional domains of Miro1, including Lys153, 
which is located within the N-terminal GTPase domain, Lys330, which lies within the second 
EF hand domain, and Lys572, which lies in a C-terminal linker region, near the transmembrane 
domain that localises Miro1 to the outer mitochondrial membrane.  In a recently solved 
structure of D. melanogaster orthologue of Miro1, Glu354 was shown to be involved in Ca2+ 
coordination (Klosowiak et al., 2013). This residue lies one amino acid away from Lys356, 
which is homologous to Lys330 in human Miro1 and which we identified as a Parkin 
ubiquitylation site. Given that Parkin induces multi-monoubiquitylation of Miro1, as opposed 
to attachment of a polyubiquitin chain, it is tempting to speculate that ubiquitylation of 
Lys330 could impact Ca2+ binding of Miro1. In addition, Miro1 was shown to be rapidly 
ubiquitylated after activation of the PINK1-Parkin pathway with CCCP, however its 
degradation by the proteasome was delayed (Birsa et al., 2014), suggesting a dual regulation 
by ubiquitin. It is possible that an initial ubiquitylation event acts to change the function of 
Miro1, leading perhaps to segregation of damaged mitochondria. Recruitment of additional 
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adaptor proteins via this ubiquitylation event might be required before its subsequent 
degradation by the proteasome. In future studies it would therefore be exciting to test whether 
Parkin-mediated ubiquitylation of Miro1 leads to direct alteration of its function, for example 
its GTPase activity, localisation, calcium binding, or role in mitochondrial transport. 
Previous studies employing N-terminally tagged Parkin have also observed 
monoubiquitylation activity. The Tanaka laboratory first reported that MBP-Parkin could 
catalyse in vitro MBP monoubiquitylation in cis (Matsuda et al., 2006), and  
multimonoubiquitylation activity has also been reported in an autoubiquitylation assay 
employing GST-Parkin (Hampe et al., 2006). Monoubiquitylation and 
multimonoubiquitylation have been shown to play a role in a range of cellular functions 
including histone regulation, DNA repair, viral budding and endocytosis (Sadowski et al., 
2012, Hicke, 2001). The consequences of mono/multimonoubiquitylation of outer 
mitochondrial membrane proteins such as Miro1 are as yet unknown. This modification could 
be critical for intermolecular signalling at the mitochondria - in endocytosis, many proteins, 
such as Eps15, contain ubiquitin interaction motifs (UIMs) that bind monoubiquitin (Husnjak 
and Dikic, 2012). Alternatively, monoubiquitylated Miro1 and other Parkin substrates may 
be targeted by other E3 ligases. This has been demonstrated for the ubiquitylation of 
proliferating cell nuclear antigen (PCNA), which binds DNA during DNA replication 
(Bergink and Jentsch, 2009). However, the possibility that Parkin itself can catalyse the 
formation of polyubiquitylated Miro1 under specific cellular conditions or in the presence of 
a regulatory protein missing from our assay cannot be excluded.  The E4 CHIP has previously 
been shown to enhance Parkin-mediated polyubiquitylation of the substrate Pael-R (Imai et 
al., 2002), providing prior evidence for this phenomena.  
3.5.3 Parkin-E2 interactions  
Given that Parkin possesses both RING and HECT-like properties it was not obvious how 
the nature of the ubiquitin conjugates might be influenced by the partnering E2. I therefore 
tested the activity of Parkin in conjunction with a panel of 25 different E2s, and observed 
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that the ubiquitylation of the substrate Miro1 by Parkin was not influenced by the vast 
majority of the E2s tested when compared to the control E2 Ube2L3 (UbcH7) (Figure 3.13).  
This observation suggests that Parkin exhibits mainly HECT-like properties, such that the 
interaction between Parkin and Miro1 is the critical feature governing the ubiquitylation of 
Miro 1. Differential effects in the ability of the tested E2s to enable Parkin to catalyse the 
formation of free ubiquitin chains were nevertheless observed. For example, UBE2L3 enabled 
both Miro1 ubiquitylation and free chain formation, whereas UBE2T restricted Parkin to 
Miro1 ubiquitylation. This does suggest that the formation of free chains may be dependent 
on the E2-E3 interaction. The molecular mechanisms underpinning E2-mediated ubiquitin 
chain formation remain poorly understood, with a few exceptions. In yeast, the Anaphase 
promoting complex/cyclosome (APC) has been shown to promote multi-monoubiquitylation 
of cyclin B in the presence of Ubc4 in vitro, whereas Ubc1 enabled it to catalyse polyubiquitin 
chain formation (Rodrigo-Brenni and Morgan, 2007). Moreover, APC has been shown to 
exploit the differential selectivity of both E2s in targeting substrates for ubiquitylation in 
vivo (Rodrigo-Brenni and Morgan, 2007). It would be interesting to uncouple substrate 
ubiquitylation and polyubiquitin chain formation by Parkin and repeat the E2 screen to 
better understand how the E2-RING1 interaction influences the outcome. Unfortunately, the 
data presented in this chapter suggests that in vitro analysis is unlikely to be helpful in 
pinpointing the E2 ligases that act with Parkin under physiological conditions. To address 
this question in future, in vivo approaches could be utilised, such as selective ablation of E2s 
using CRISPR/Cas9 technologies and monitoring of downstream effects on substrate 
ubiquitylation, mitochondrial segregation and mitophagy initiation.  
3.5.4 Differential effects of Parkin disease mutants  
A major breakthrough in understanding Parkin molecular biology came in 2013, when several 
high-resolution structures of Parkin were solved and published (Trempe et al., 2013, Riley et 
al., 2013, Wauer and Komander, 2013). Inspection and analysis of these structures can 
potentially shed light on the structural effects of Parkin disease-associated mutations and 
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suggest an explanation for the molecular mechanisms by which these mutations exert their 
myriad effects on Parkin activity summarised in Table 3.2. 
  
Table 3.2 Summary of Parkinson’s disease mutation effects on Parkin activity 
Parkin 
mutation 
Location 
E3 activity 
E2 discharge 
Miro1-ub Free-chains 
WT N/A ↔ ↔ ↔ 
K27N Ubl ↔ ↔ ↔ 
R33Q Ubl ↑ ↑ ↔ 
R42P Ubl ↔ ↔ ↔ 
A46P Ubl ↔ No ↓ 
S65A Ubl No No ↓ 
K161N UPD ↓ ↓ ↔ 
K211N UPD ↔ No ↔ 
R275W RING1 No No ↓ 
G328E IBR ↑ ↔ ↔ 
T415N RING2 ↓ ↓ ↓ 
G430D RING2 ↓ ↓ ↔ 
C431F RING2 No No ↓ 
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Residue Cys431 lies within the RING2 domain and acts as the active site cysteine of Parkin. 
The Parkin crystal structures reveal that this residue is obscured by an autoinhibitory 
interface between the RING2 and UPD domains, suggesting that this is a major mechanism 
through which Parkin autoinhibition is maintained.  
The finding that the C431F disease mutation abolishes human Parkin E3 ligase activity in 
an in vitro substrate assay (Figure 3.15) lends further support to the essential catalytic role 
of Cys431 and is consistent with previous analyses (Matsuda et al., 2006, Sriram et al., 2005, 
Ren et al., 2003). In addition, the demonstration of C431F mutation abrogating ubiquitin 
discharge from UbcH7 (Figure 3.16) correlates well with reports showing that mutation of 
the catalytic cysteine to alanine in other RBR family enzymes, such as  Cys357Ala mutation 
in HHARI and the Cys885Ala mutation in HOIP prevents E2-ubiquitin discharge (Duda et 
al., 2013, Stieglitz et al., 2012b). 
The R275W mutation is located in RING1 and leads to complete abolition of Parkin E3 ligase 
activity (Figure 3.15). Furthermore, the R275W mutant displayed significantly reduced 
ubiquitin discharge from the E2 (Figure 3.16). This mutation has been the subject of intense 
investigation since it was identified as a compound heterozygote mutation in a family with 
evidence of Lewy body pathology at post-mortem (Farrer et al., 2001). The nature of its 
pathogenicity was unknown, since all prior studies of the R275W mutant had found no effect 
on E3 ligase activity (Hampe et al., 2006, Matsuda et al., 2006, Sriram et al., 2005). As 
mentioned, Arg275 lies within the core of the RING1 helical domain, therefore, its mutation 
might disrupt the proper fold of the protein, altering or disrupting E2 binding to the RING1 
domain and/or transfer of ubiquitin from the loaded E2 onto the ubiquitin acceptor Cys431 in 
the RING2 domain.  
Lys161 lies within the UPD domain, and structural analysis suggests that it forms a salt bridge 
with the RING2 domain as well as a putative phospho-peptide binding pocket that may be 
important for Parkin activation (Wauer and Komander, 2013). The K161N mutation leads 
to a significant decrease in the E3 ligase activity of Parkin; both Miro1 ubiquitylation and 
free chain formation are reduced (Figure 3.15). Previous reports on the K161N mutation have 
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been conflicting - most studies employing autoubiquitylation assays have found no effect on 
Parkin activity (Wauer and Komander, 2013, Hampe et al., 2006, Matsuda et al., 2006, Gu 
et al., 2003), whilst a few studies found that the mutation dampened it down (Trempe et al., 
2013, Ren et al., 2003). This mutation did not affect E2-ubquitin discharge, suggesting an 
alternative mechanism for ubiquitylation disruption. Structural analysis of Parkin has 
revealed a sulphate-binding pocket, which Lys161 contributes to (Wauer and Komander 2013). 
In future work, it will be important to determine whether Lys161 indeed forms part of a 
phospho-peptide binding pocket and whether the Ser65 phosphorylated Ubl might dock there.  
The K211N and A46P mutations are located in RING1 and Ubl domains respectively and 
displayed differential effect on Parkin E3 ligase activity; while Miro1 ubiquitylation ability 
was preserved, free chain formation was reduced (Figure 3.15). Such differential effects 
imparted by disease-associated mutations or artificial mutations have not been previously 
reported for either Parkin or other members of the RBR E3 ligase family of enzymes. As 
mentioned, Lys211 lies within the UPD domain and has also been suggested to form part of 
the previously mentioned putative phospho-peptide binding pocket (Wauer and Komander, 
2013), whilst Ala46 lies within the Ubl domain. Previous autoubiquitylation assays have failed 
to show any changes in K211N mutant activity compared to wild-type Parkin (Hampe et al., 
2006, Matsuda et al., 2006),  whereas the A46P mutant was reported to be hyperactive in an 
autoubiquitylation assay (Chaugule et al., 2011). Interestingly, both the A46P and K211N 
mutants led to a decrease in E2-ubiquitin discharge (Figure 3.16), suggesting that E2 binding 
and ubiquitin discharge may be essential for the formation of  free ubiquitin chains but 
dispensable for the catalytic activity of Parkin directed towards Miro1 ubiquitylation.  
Two mutants, R33Q and G328E, found within the Ubl domain and IBR respectively, 
exhibited increased Parkin E3 ligase activity upon phosphorylation by PINK1. A previous 
report has demonstrated the Ubl domain mutants R33Q, K27N and R42P to be constitutively 
hyperactive (Chaugule et al., 2011). In contrast with this finding, I have observed low basal 
autoubiquitylation activity for R33Q when compared to wild-type Parkin in the absence of 
PINK1 (data not shown). Furthermore, upon phosphorylation by PINK1, the activity of the 
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R33Q mutant increased (Figure 3.15). This was associated with a striking increase in the 
phosphorylation of R33Q when compared to that of wild-type Parkin (Figure 3.15). Residue 
Arg33 is located within the α1 helix of the Ubl domain, which forms extensive interactions 
with a beta-sheet comprising strands 2, 1 and 5 and contributes to the integrity of the Ubl 
domain (Sakata et al., 2003, Tashiro et al., 2003, Tomoo et al., 2008). Mutation of Arg33 to 
glutamine might disrupt a stabilising hydrogen bond between Arg33 and the adjacent residue, 
glutamine 34 (Figure 3.17). Molecular dynamics simulations of the R33Q mutation in the 
murine Ubl domain (Tomoo et al., 2008) predicted that loss of this hydrogen bond would 
lead to decreased stability of the α1 helix, and as a result, increased structural fluctuations 
in the β2, 1, 5 sheet. Ser65 is located at the N-terminus of β5 and in all structures of the Ubl 
domain is partially buried, however it is plausible that fluctuations in the structure of this 
strand induced by the R33Q mutation might lead to greater surface exposure of Ser65. This 
would then lead to increased accessibility and phosphorylation of this residue by TcPINK1, 
potentially explaining the increase in E3 ligase activity observed in this mutant (Figure 3.17 
& Figure 3.15). However, enhanced phosphorylation of the R33Q mutant was not associated 
with an increase in UbcH7 ubiquitin discharge (Figure 3.16) suggesting that an alternative 
mechanism might be responsible for the increased activity of this mutant.  
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Figure 3.17 An overview of Parkin Ubl domain structure.  
(A) Cartoon representation of Ubl domain with secondary structure elements 
labelled and coloured from blue through to red (N- to C-terminus) and the 
location of Ser65 (purple sticks) and Arg33 (pink sticks) shown (PDB code: 
4K95). (B) Close up of interactions formed by residue Arg33. Arg33 is shown as 
pink sticks and the adjacent interacting residue Gln34 is shown as white sticks. 
The stabilizing hydrogen bond between the residues is shown in red (PDB code: 
4K95). 
Previous reports on the effect of the G328E mutation on E3 ligase activity have also been 
controversial, with several groups reporting no change in E3 ligase activity (Hampe et al., 
2006, Matsuda et al., 2006, Sriram et al., 2005) and one report suggesting a decreased 
autoubiquitylation activity (Trempe et al., 2013). The G328E mutation stimulated Miro1 
ubiquitylation without any effect on the formation of free ubiquitin chains. Similar to R33Q, 
change in ubiquitylation activity was not associated with any significant change in E2 
discharge of ubiquitin (Figure 3.16). A possible explanation for the lack of effect the G328E 
mutation has on the free chain formation relies on the positioning of this residue - Gly328 is 
located in the RING1:IBR interface and therefore may directly interact with the substrate, 
Miro1, rendering G328E mutation stabilising and leading to enhanced Miro1 ubiquitylation.  
Biochemical and structural studies of the other RBR E3 ligases HOIP and HHARI have 
provided strong evidence that these RBR ligases form an intermediate ubiquitin-thioester 
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bond with the catalytic cysteine (Duda et al., 2013, Stieglitz et al., 2013, Stieglitz et al., 
2012b, Wenzel et al., 2011). An intermediate oxyester of Parkin has been demonstrated in 
mammalian cells after two groups successfully trapped ubiquitin on a Cys431Ser mutant of 
Parkin after stimulation with the mitochondrial uncoupler CCCP (Lazarou et al., 2013, Zheng 
and Hunter, 2013). In contrast, direct experimental observation of a thioester intermediate 
state for full-length human Parkin has been elusive (Spratt et al., 2013, Wenzel et al., 2011). 
The strongest evidence for its existence to date comes from a study that utilised the isolated 
Drosophila Parkin IBR-RING2 domain.  The homologous residue, Cys449, was demonstrated 
to form a thioester, and this was prevented by the introduction of a Cys449Ala mutation 
(Spratt et al., 2013). I have not observed an intermediate ubiquitin-thioester state for 
activated full length wild-type Parkin (Figure 3.16), in accordance with other groups who 
have studied full-length Parkin (Spratt et al., 2013, Wenzel et al., 2011). However, Parkin 
R33Q displayed the ability to form a ubiquitin-thioester bond (Figure 3.16) representing the 
first experimental demonstration of the existence of a thioester-intermediate state for 
recombinant full-length Parkin (Figure 3.16).  
3.5.5 Conclusions 
Overall this work shed light into regulation of Parkin activity by PINK1 and firmly placed 
the two enzymes in a direct pathway. Phosphorylation of Ser65 in the Ubl domain was shown 
to play a critical part in Parkin activation although the mechanism underlying this effect 
remain unknown. This work utilized a novel substrate-based assay of untagged full-length 
Parkin that has provided further evidence that Miro1 is a bona fide target of Parkin.  
  
Chapter 4: PINK1 phosphorylation of ubiquitin at Ser65 activates Parkin 
100 
 
4 Chapter 4: PINK1 phosphorylation of ubiquitin at Ser65 
activates Parkin  
4.1 Introduction 
Post-translational modifications (PTMs) represent a master regulatory mechanism that exists 
in organisms spanning from bacteria, fungi, and unicellular eukaryotes to complex 
mammalian systems, as well as all life in between. According to Prabakaran and colleagues, 
PTMs represent ‘nature’s escape from genetic imprisonment’ (Prabakaran et al., 2012). 
Protein ubiquitylation and phosphorylation represent two major components of this system, 
and in recent years have been found to work together, for example in the epidermal growth 
factor (EGF) receptor and NF-B signalling pathways (Karin and Ben-Neriah, 2000, Nguyen 
et al., 2013). It is therefore not surprising that mutations in enzymes regulating such events 
lie at the heart of many human diseases, including cancer and Parkinson’s Disease (Bras et 
al., 2015, Richardson et al., 2009). 
In previously reported cases, protein phosphorylation has been shown to regulate 
ubiquitylation by modulating E3 ligase activity, either indirectly by creating or  blocking a 
docking site for the E3 ligase, or directly, by inducing phosphorylation-dependent 
conformational change in the E3 (Lin et al., 2002, Gallagher et al., 2006, Dou et al., 2012). 
The discovery that PINK1 directly phosphorylates and activates Parkin at Ser65 (Kondapalli 
et al., 2012) (Chapter 3) represents another example of the close interplay between 
phosphorylation and ubiquitylation. In parallel with my analysis, additional lines of evidence 
have emerged linking these two enzymes, including the observation that PINK1 is required 
for Parkin translocation to the mitochondria upon mitochondrial outer membrane 
depolarisation in mammalian cell lines (Matsuda et al., 2010, Narendra et al., 2010, Vives-
Bauza et al., 2010, Geisler et al., 2010). Moreover, it was reported that a Ser65Ala mutant 
of Parkin only showed partially disrupted recruitment to the mitochondria, suggesting that 
PINK1 may target additional, as yet undetermined substrates to mediate Parkin recruitment 
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(Shiba-Fukushima et al., 2012). Whilst studying the effects of PINK1-mediated Parkin 
phosphorylation, I made an unexpected finding - Ubl Parkin, lacking the Ser65 PINK1 
phosphorylation site, nonetheless displayed enhanced activity upon incubation with 
TcPINK1. In a series of follow-up experiments I validated this finding, ultimately leading to 
the discovery that ubiquitin itself is a novel PINK1 substrate, and subsequently that PINK1-
phosphorylated ubiquitin regulates Parkin activity.  
Ubiquitin phosphorylation has previously been detected in global mass spectrometry screens 
at various sites including: Thr7 and Thr12 (Lee et al., 2009); Ser20 (Manes et al., 2011); 
Ser57 (Malik et al., 2009, Bennetzen et al., 2010); Tyr59 (Gu et al., 2011); and Ser65 (Zhou 
et al., 2013).  However, its functional significance had been largely overlooked; no in-depth 
analysis has been undertaken and the identity of the upstream kinases responsible for 
phosphorylation of these sites remained unknown. In this chapter, I present my data, which 
unequivocally identifies ubiquitin phosphorylation at Ser65 as a second regulatory mechanism 
for Parkin activity.  
4.2 The unexpected result 
4.2.1 PINK1-dependent phosphorylation of ubiquitin activates Ubl Parkin 
E3 ligase activity 
In the previous chapter (Chapter 3) I provided robust evidence of PINK1-mediated 
stimulation of Parkin activity via direct phosphorylation at Ser65 (Kondapalli et al., 2012, 
Kazlauskaite et al., 2014a). In order to better characterise the mechanism of activation and 
gain further insights into the importance of phosphorylation of the Parkin Ubl domain, E2 
ubiquitin discharge assays were set up using a constitutively active fragment of Parkin lacking 
the N-terminal Ubl domain (Ubl Parkin; residues 80-465) (Burchell et al., 2012, Chaugule 
et al., 2011, Kazlauskaite et al., 2014a). I had previously found that ubiquitin discharge from 
UbcH7 could be catalysed by full-length Parkin only upon TcPINK1 phosphorylation of Ser65 
(Figure 3.7, Chapter 3). Therefore, as a control experiment, I tested whether TcPINK1 had 
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any effect on ubiquitin discharge from UbcH7 mediated by Ubl Parkin. E2 discharge 
reactions were established using Ubl Parkin both alone and in the presence of wild-type or 
kinase-inactive TcPINK1, as described before (Figure 4.1). As expected, Ubl Parkin alone 
caused mild ubiquitin discharge from UbcH7, consistent with its previously reported moderate 
constitutive activity (Figure 4.1, lanes 3-4). Surprisingly, upon addition of wild-type but not 
kinase-inactive TcPINK1, I observed a striking increase in ubiquitin discharge from UbcH7 
(Figure 4.1, lanes 5-6). Since Ubl Parkin lacks Ser65, I therefore chose to determine if another 
site on Parkin within the C-terminal region was becoming phosphorylated by PINK1. To 
address this, I repeated the E2-discharge assay using 0.1 mM [-32P]-ATP and monitored 
phosphorylation events using autoradiography. Although I did not observe any Parkin 
phosphorylation, the experiment clearly revealed strong ubiquitin phosphorylation in a 
manner dependent on TcPINK1 kinase activity, in addition to low levels of TcPINK1 
autophosphorylation (Figure 4.1, lower panel). 
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Figure 4.1 TcPINK1 enhances Ubl-Parkin mediated ubiquitin discharge from 
ubiquitin loaded UBcH7 
Ubl Parkin activity was assessed in an E2 discharge assay. Ubl Parkin was 
tested alone as well as in the presence of wild-type (WT) or kinase-inactive 
(KI) TcPINK1 with ubiquitin loaded UbcH7 (UbcH7-ub). [-32P]-ATP was used 
to detect phosphorylation activity. Reactions were allowed to continue for 15 
min and stopped using LDS loading buffer in absence of reducing agent. 
Samples were analysed as before by SDS-PAGE. Protein phosphorylation was 
monitored by autoradiography (lower panel). 
4.2.2 PINK1 phosphorylates ubiquitin at Ser65 in vitro 
To determine the site of ubiquitin phosphorylation, I carried out a radioactive kinase assay 
with wild-type TcPINK1 that was subsequently analysed by SDS-PAGE and Coomassie 
staining. The phosphorylated ubiquitin band was cut out and a tryptic digest was performed, 
as described in Section 2.2.27.4. Together with Robert Gourlay, 32P-labelled ubiquitin was 
analysed by chromatography on a C18 column, and one major 32P-labelled phosphopeptide 
was observed whilst no peaks were identified following incubation with kinase-inactive 
TcPINK1 (not shown) (Figure 4.2 A). A combination of solid-phase Edman sequencing and 
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mass spectrometry revealed a peptide in which Ser65 was phosphorylated (Figure 4.2 B). A 
multiple sequence alignment of this region revealed a high degree of conservation of Ser65 
across all aligned species (Figure 4.4). Furthermore, this peptide bears strong homology to 
the Parkin Ser65 peptide, with a hydrophobic residue at the -4 position and a His and Val at 
the +3 and +5 positions respectively (Figure 4.4). 
 
 
 
Figure 4.2 Mapping of phosphopeptides in ubiquitin after phosphorylation by 
TcPINK1 in vitro.  
(A) Ubiquitin (10 g) was incubated with 10 g of either wild-type TcPINK1 
or kinase-inactive TcPINK1 (D359A) in the presence of Mg2+[-32P]-ATP for 80 
mins. Assays were terminated by addition of LDS loading buffer and separated 
by SDS-PAGE. Proteins were detected by Colloidal Coomassie blue staining 
and phosphorylated ubiquitin was digested with trypsin. Peptides were 
chromatographed on a reverse phase HPLC Vydac C18 column (Cat no. 
218TP5215, Separations Group, Hesperia, CA) equilibrated in 0.1% (v/v) 
trifluoroacetic acid and the column developed with a linear acetonitrile gradient 
at a flow rate of 0.2 ml/min. Fractions (0.1 ml each) were collected and analysed 
for 32P radioactivity by Cerenkov counting  (B) The Phosphopeptide identified 
in (A) was analysed by solid-phase Edman sequencing and mass spectrometry.  
The amino-acid sequence deduced from the single phosphopeptide seen in the 
LC-MS/MS analysis is shown using the amino acid single-letter code. 
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4.2.3 Time course of ubiquitin phosphorylation 
To further validate ubiquitin phosphorylation by TcPINK1, a time course analysis was 
undertaken. To confirm the site mapping data showing that PINK1 targets Ser65, a Ser65Ala 
mutant of ubiquitin was included as a negative control. Kinase assays were set up using wild-
type or kinase-inactive PINK1 as described in Section 2.2.28.1 and the reactions were allowed 
to continue for times indicated at the top of the Figure 4.3. The stoichiometry of 
phosphorylation was also determined at each time point (Figure 4.3). 
A robust time-dependent phosphorylation of ubiquitin was observed only when wild-type 
TcPINK1 was used, and was absent with kinase-inactive TcPINK1 (Figure 4.3 A). The 
maximal stoichiometry of ubiquitin phosphorylation by TcPINK1 under these conditions was 
~0.11 moles of phosphate per mole of ubiquitin (Figure 4.3 A). Notably, mutation of Ser65 to 
alanine (Ser65Ala) abolished ubiquitin phosphorylation by wild-type TcPINK1, confirming 
this residue as the major site of PINK1 phosphorylation (Figure 4.3 B).  
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Figure 4.3 Mutation of Ser65Ala (S65A) abolishes ubiquitin phosphorylation 
by TcPINK1.  
Wild-type (WT) or Ser65Ala (S65A) ubiquitin (1 g) was incubated in the 
presence of wild-type or kinase inactive TcPINK1 (1 g) and Mg2+[-32P]-ATP 
for the indicated times; assays were terminated by addition of SDS loading 
buffer. Samples were subjected to SDS-PAGE, proteins were detected by 
Colloidal Coomassie blue staining (lower panels) and incorporation of [-32P]-
ATP was detected by autoradiography (upper panels). Cerenkov counting was 
used to calculate the stoichiometry of ubiquitin phosphorylation indicated 
above autoradiographs as moles of [-32P]-ATP incorporated per mole of 
ubiquitin.  
4.3 Specificity of ubiquitin phosphorylation by PINK1 
4.3.1 PINK1 displays selectivity in phosphorylating ubiquitin-like domains 
and proteins 
The PINK1-dependent phosphorylation sites in ubiquitin and Parkin Ubl domain are two 
homologous Ser65 residues, with a degree of sequence conservation surrounding the site of 
phosphorylation (Figure 4.4). I therefore speculated that PINK1 might be a master regulatory 
kinase of all (or a subset of) proteins containing a Ubl domain, and possibly other ubiquitin-
like modifiers in which a homologous Ser residue was present. In order to address this, a 
multiple sequence alignment aiming to identify other proteins carrying a homologous Ser 
residue was carried out by Professor Kay Hofmann. Multiple hits were identified (Figure 4.5) 
including the ubiquitin-like modifiers, Nedd8 and ISG15 (both domains), as well as Ubl 
Chapter 4: PINK1 phosphorylation of ubiquitin at Ser65 activates Parkin 
107 
 
domain containing proteins including Midnolin (MIDN), UBL4A, UBL7, USP48, USP9X, 
and USP9Y (Figure 4.5). 
 
  
 
Figure 4.4 Ubiquitin Ser65 residue is highly conserved 
Sequence alignment of residues around Ser65 in human Parkin and Ubiquitin 
in a variety of organisms showing high degree of conservation.  
 
Figure 4.5 Multiple sequence alignment analysis of Parkin and ubiquitin Ser65  
Sequence alignment of residues around Ser65 in human ubiquitin and a range of 
ubiquitin-like-modifiers and UBL-domain containing human proteins. 
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To test whether the identified hits could be phosphorylated by PINK1, a subset of the 
identified proteins, including the ubiquitin-like modifiers ubiquitin, ISG15, and Nedd8, and 
the Ubl domain containing proteins Parkin and the Parkin Ubl domain were expressed in E. 
coli.  In addition, other proteins lacking the homologous Ser65 phosphorylation site (OTU1, 
HOIL, Ubiquilin2, SUMO1) were included as a negative control. I then performed kinase 
assays using the aforementioned proteins as substrates with catalytically active recombinant 
wild-type or kinase-inactive TcPINK1 (D359A) in the presence of 0.1 mM [-32P]-ATP (Figure 
4.6). Phosphorylation of the putative substrates was monitored by autoradiography. 
 The phosphorylation levels of ubiquitin and the isolated Parkin Ubl domain (residues 1-76) 
were comparable and greater than full-length Parkin (Figure 4.6) in agreement with previous 
findings from the lab (Kondapalli et al., 2012). The only other protein that exhibited 
TcPINK1-dependent phosphorylation in this assay was NEDD8, a ubiquitin-like modifier, 
however the levels of ATP incorporation into NEDD8 were significantly lower than that of 
ubiquitin or the Ubl domain, suggesting that the phosphorylation might be non-specific, or 
alternatively that other co-factors are necessary for efficient catalysis. The low level of 
phosphorylation precluded mapping of the phosphorylation site(s) in NEDD8. All 
phosphorylation events observed in the assays were dependent on TcPINK1 kinase activity, 
since no signal was observed when the kinase-inactive mutant was used (Figure 4.6).  
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Figure 4.6 Ubiquitin and Parkin are specific substrates of TcPINK1.  
The indicated ubiquitin-like modifiers and UBL-domain containing proteins (1 
g) were incubated with wild-type (WT) or kinase-inactive (KI) TcPINK1 and 
Mg2+[-32P]-ATP for 60 min. Assays were terminated by addition of SDS 
loading buffer and analysed by SDS-PAGE. Proteins were detected by Colloidal 
Coomassie blue staining (upper panel) and incorporation of [-32P]-ATP was 
detected by autoradiography (lower panel). All substrates were human proteins  
expressed in E. coli. Tags on the substrates used for this experiment were as 
follows: glutathione S-transferase (GST)-OTU1; untagged-Nedd8; untagged-
ISG15; His-SUMO1 (1-97); Ubiquilin2 (His-SUMO tag cleaved off); His-HOIL1; 
and His-USP4. Asterisks denote the correct substrate band. 
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4.3.2 PINK1 is a specific ubiquitin kinase  
Multiple ubiquitin phosphorylation sites have been identified and reported over the last few 
years in global phosphoproteomic screens (http://www.phosphosite.org/), however the 
upstream kinases have not been determined or studied. To investigate if ubiquitin 
phosphorylation by PINK1 was a PINK1-specific event or a common phenomenon among 
protein kinases, I determined the ability of 8 other randomly selected protein kinases 
representative of the human kinome (MLK, CDK2, IKK epsilon, IKK beta, Aurora kinase A, 
NUAK1, GSK3 beta and PLK1) to phosphorylate ubiquitin, using equimolar quantities of 
ubiquitin and 0.1 mM [-32P]-ATP, as described in Section 2.2.28.1. Since kinase-inactive 
versions of the majority of these kinases were unavailable, a control with no substrate was 
included for each enzyme tested. A robust phosphorylation of ubiquitin by TcPINK1 but no 
other kinase was observed, indicating that ubiquitin phosphorylation is a property that is 
specific to PINK1 (Figure 4.7).  
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Figure 4.7 TcPINK1 is a specific upstream kinase of ubiquitin. 
The indicated kinases (1 g) were incubated with ubiquitin and Mg2+[-32P]-
ATP for 60 min. Assays were terminated by addition of SDS loading buffer and 
analysed by SDS-PAGE. Proteins were detected by Colloidal Coomassie blue 
staining (upper panel) and incorporation of [-32P]-ATP was detected by 
autoradiography (lower panel). 
4.4 Evidence of Ubiquitin Ser65 phosphorylation in cells 
4.4.1 Mitochondrial depolarisation in HEK293 cells stably overexpressing 
PINK1 leads to ubiquitin phosphorylation at Ser65 
In healthy cells, PINK1 is imported to mitochondria, where it undergoes sequential cleavage 
by the mitochondrial processing peptidase and the PARL protease, followed by rapid 
degradation via the N-end rule pathway (Greene et al., 2012, Yamano and Youle, 2013, 
Meissner et al., 2011) (Figure 1.7). Upon mitochondrial depolarisation, PINK1 is stabilised 
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and autophosphorylates at residue Thr257 (Thr257) (Kondapalli et al., 2012). In parallel 
studies in our lab, Dr. Chandana Kondapalli had undertaken a SILAC-based quantitative 
phospho-proteomic screen in order to identify novel PINK1 substrates phosphorylated in 
response to mitochondrial depolarisation. FlpIn TRex HEK293 cells stably expressing either 
FLAG empty, wild-type or kinase-inactive human PINK1-FLAG were grown in light, heavy 
or medium media, respectively, and cells were subsequently stimulated with 10 M CCCP 
for 3 hours to activate PINK1. Mitochondria-containing membrane-enriched fractions were 
made and solubilised in 1 % Rapigest, and lysates were mixed from each condition in a 1:1:1 
ratio before being subjected to tryptic digestion. Digested peptides were subjected to phospho-
peptide enrichment and analysis by mass spectrometry. Strikingly, a Ubiquitin 
phosphopeptide (TLSDYNIQKEpSTLHLVLR; pS corresponding to Ser65) was found to be 
enriched 14-fold in stimulated mitochondrial extracts of wild-type PINK1 when compared to 
kinase-inactive PINK1 across all 4 biological replicates, providing compelling evidence that 
PINK1-mediated phosphorylation of ubiquitin is not only observable in vitro, but also occurs 
in cells (Figure 4.8, Figure 4.9; manuscript in preparation).  
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Figure 4.8 Ubiquitin phospho Serine 65 peptide is upregulated in cells after PINK1 
activation by CCCP.  
FlpIn TRex HEK293 cells stably expressing FLAG empty, wild-type PINK1-
FLAG or kinase-inactive PINK1-FLAG were grown in light, heavy, and medium 
SILAC media respectively. Cells in each condition were stimulated with 10 M 
CCCP for 3 hours. Subsequently, membrane fractions were enriched by 
ultracentrifugation and solubilized in 1% Rapigest. Lysates from each of the three 
conditions were mixed in a 1:1:1 ratio and digested with trypsin prior to phospho-
peptide enrichment by HILIC and TiO2 and analysis by mass spectrometry. Data 
analysis was performed using MaxQuant. (A-D) Extracted ion chromatograms 
(XIC) representing the ubiquitin Serine 65 (Ser65) phosphopeptide 
TLSDYNIQKEpSTLHLVLR in the three SILAC labelled conditions over all four 
biological replicates.  
 
 
 
Figure 4.9 Tandem mass spectrometry fragmentation spectra of the Ser65 
phosphorylated ubiquitin peptide TLSDYNIQKEpSTLHLVLR.  
(A) Tandem mass spectrometry (MS/MS) spectrum of the heavy (R10K8)-
labelled peptide TLSDYNIQKEpSTLHLVLR identified in wild-type PINK1-
FLAG transfected cells. (B) Virtually identical MS/MS spectrum of 
TLSDYNIQKEpSTLHLVLR from a digest of ubiquitin in vitro phosphorylated 
by TcPINK1. Please note, the doubly-charged ion [1105.5650]2+ of the same 
peptide was also positively identified in both experiments with Andromeda and 
Mascot Score of 202 and 54, respectively. 
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4.5 Elaboration of phospho ubiquitin effects on Parkin activity 
4.5.1 PINK1-mediated activation of Ubl Parkin  
Since I had previously observed that wild-type PINK1 enhanced the ability of Ubl Parkin 
to discharge ubiquitin from UbcH7, I next chose to determine whether PINK 1 also exerted 
a direct effect on Ubl Parkin-mediated ubiquitylation activity. I therefore performed a 
ubiquitylation assay with Ubl Parkin, in parallel with full-length Parkin, as described in 
Section 2.2.28.2. In agreement with previous data (Figure 3.5 & Figure 3.6), a marked 
activation of full-length Parkin E3 ligase activity was observed when incubated with wild-
type but not kinase-inactive PINK1, as judged by the formation of free polyubiquitin chains 
and Miro1 multi-monoubiquitylation (Figure 4.10, lanes 1-2). Consistent with previous work 
(Burchell et al., 2012, Chaugule et al., 2011, Kazlauskaite et al., 2014a), Ubl Parkin 
appeared constitutively active and displayed detectable basal polyubiquitylation activity in 
the absence of PINK1 (Figure 4.10, lanes 9-10). However, in agreement with the UbcH7 
discharge data (Figure 4.1), upon incubation with wild-type but not kinase-inactive 
TcPINK1, I observed a substantial further activation of Ubl Parkin, as judged by high 
molecular weight polyubiquitin chain formation and autoubiquitylation of Parkin (Figure 
4.10 lanes 5-6,). Consistent with previous data (Figure 3.8), Ubl Parkin was unable to 
efficiently catalyse Miro1 multi-monoubiquitylation under any condition tested (Figure 4.10), 
suggesting that an intact Ubl domain might be necessary for substrate ubiquitylation.  
In order to confirm that Ubl Parkin activation was mediated by ubiquitin phosphorylated 
at Ser65, the Ubl Parkin ubiquitylation assays described above were repeated with wild-type 
and S65A mutant ubiquitin. Whilst normal activity levels in the presence of TcPINK1 were 
detected when wild-type ubiquitin was used (Figure 4.11, lanes 1-2), a dramatic reduction in 
Ubl Parkin activity in the presence of wild-type PINK1 was observed when using S65A 
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ubiquitin (Figure 4.11, lanes 3-4), suggesting that PINK1-mediated activation of Ubl Parkin 
is dependent on ubiquitin Ser65 phosphorylation.  
 
Figure 4.10 Ubl Parkin ubiquitylation activity is increased by WT TcPINK1.  
2 g of full-length (WT) or Ubl-Parkin were incubated with 1 g of wild-type 
(WT), kinase-inactive (KI) or no TcPINK1 in a kinase reaction for 60 min. 
Ubiquitylation reactions were then initiated by addition of ubiquitylation assay 
components (E1, UbcH7 and Flag-ubiquitin) and 2 g of His-Sumo-Miro1. 
Reactions were terminated after 60 min by addition of LDS loading buffer and 
analysed by SDS-PAGE. Miro1, ubiquitin and Parkin were detected using anti-
SUMO, anti-FLAG and anti-Parkin antibodies, respectively. 
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Figure 4.11 Enhanced activation of Ubl-Parkin by Tc-PINK1 is abrogated by 
Ser65Ala ubiquitin.  
Ubl-Parkin was incubated in presence or absence of wild-type (WT) or kinase-
inactive (KI) PINK1 in a kinase reaction. Ubiquitylation reactions were then 
initiated by addition of ubiquitylation assay components. Reactions were 
terminated after 60 min by addition of LDS loading buffer and analysed by 
SDS-PAGE. Miro1, ubiquitin and Parkin were detected using anti-SUMO, anti-
FLAG and anti-Parkin antibodies, respectively. 
4.5.2 Dual requirement of PINK1-dependent phosphorylation of Parkin and 
ubiquitin at Ser65 in mediating optimal activation of full-length Parkin  
I next chose to investigate the role of PINK1-dependent phosphorylation of ubiquitin at Ser65 
in the activation of full-length Parkin. I had previously found that the E3 ligase activity of 
full-length Parkin is dependent on PINK1 kinase activity, and that PINK1 phosphorylates 
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Parkin directly at residue Ser65 in the Ubl domain (Sections 3.2 & 3.3). Consolidating this 
finding, I showed that the Parkin S65A mutant largely abolished E3 ligase activity even in 
the presence of PINK1 (Sections 3.2.4 & 3.2.5 ), suggesting that phosphorylation of Parkin 
at Ser65 is a major driver of Parkin E3 ligase activity.  
To further validate these results, as well as to test the effects of phosphorylated ubiquitin on 
full-length Parkin activity, I assessed whether full-length, S65A Parkin, which cannot be 
phosphorylated directly by TcPINK1, can be further activated by TcPINK1 in a manner 
dependent on ubiquitin phosphorylation. Wild-type and S65A Parkin was incubated with 
wild-type or kinase-inactive TcPINK1. After the initial kinase assay, a ubiquitylation reaction 
was performed with either wild-type or S65A ubiquitin.  
The combination of full-length Parkin with wild-type TcPINK1 and wild-type ubiquitin 
resulted in maximal Parkin ubiquitylation activity, as judged by the generation of free 
polyubiquitin chains and multi-monoubiquitylation of Miro1 (Figure 4.12, lanes 1-2). The 
absolute dependence of Parkin on wild-type PINK1 for activation was confirmed by the 
absence of activity when kinase-inactive PINK1 was used (Figure 4.12, lanes 5-6). In the 
presence of S65A ubiquitin, a substantial decrease in Parkin E3 ligase activity was observed, 
however, activity was not completely abolished as Miro1 ubiquitylation was still detectable 
(Figure 4.12, lanes 3-4). In agreement with previous data, the Parkin S65A mutation led to 
a near complete loss of Parkin activity; Miro1 substrate ubiquitylation was completely lost, 
although low levels of high molecular weight polyubiquitylation could still be observed (Figure 
4.12, lanes 9-10), indicating residual E3 ligase activity. As a whole, I found that a S65A 
mutation in either ubiquitin or Parkin alone can substantially reduce but not completely 
abolish Parkin E3 ligase activity, suggesting that both PINK1-dependent phosphorylation 
events are required for mediating maximal activation of Parkin. Conversely, a complete loss 
of Parkin activity was only observed upon incubation of both Ser65Ala ubiquitin with 
Ser65Ala Parkin with wild-type TcPINK1 (Figure 4.12, lanes 11-12). 
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Figure 4.12 Phosphorylation of Parkin and ubiquitin at Serine65 are necessary 
for complete activation by PINK1.  
Full-length (WT) and Ser65Ala (S65A) Parkin was incubated in presence or 
absence of wild-type (WT) or kinase-inactive (KI) PINK1 in a kinase reaction. 
Ubiquitylation reactions were then initiated by addition of ubiquitylation assay 
components, including 0.04 mM of wild-type (WT) or Ser65Ala (S65A) His-
Flag-ubiquitin. Reactions were analysed by immunoblotting. Miro1, ubiquitin 
and Parkin were detected using anti-SUMO, anti-FLAG and anti-Parkin 
antibodies, respectively. Miro1-Ub indicates ubiquitylated Miro1. 
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4.6 Purification of Ser65–phosphorylated ubiquitin and Ser65–
phosphorylated Ubl domain  
In order to uncouple the separate roles played by ubiquitin and Parkin phosphorylation in 
mediating Parkin activation, it was necessary to conduct ubiquitylation assays utilising 
stoichiometrically phosphorylated and highly pure Ser65-phosphorylated ubiquitin 
(ubiquitinPhospho-Ser65), and additionally to compare the effect of the Ser65-phosphorylated Ubl 
domain of Parkin (residues 1-76) (UblPhospho-Ser65) to that of ubiquitinPhospho-Ser65 on the 
activation of Parkin. In order to achieve this, both ubiquitinPhospho-Ser65 and UblPhospho-Ser65 were 
generated by TcPINK1 phosphorylation and subsequent purification (performed by Dr. Axel 
Knebel). Milligram amounts of ubiquitin and the Ubl domain of Parkin (residues 1-76) were 
phosphorylated by wild-type TcPINK1. TcPINK1 was then removed using a centricon 
centrifugal high molecular weight filter and the reaction mixture subjected to ion-exchange 
chromatography. UbiquitinPhospho-Ser65 was purified to homogeneity, yielding a highly pure 
protein with 100% stoichiometry of phosphorylation, as judged by SDS-PAGE and MALDI 
mass spectrometry (performed by Dr. Maria Ritorto) (Figure 4.13 A). UblPhospho-Ser65 was 
incompletely separated from the nonphosphorylated form, resulting in a phospho-protein of 
around 60 % purity (Figure 4.13 B). Both preparations were free from contaminating 
TcPINK1. 
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Figure 4.13 Quality control of Ser65-phosphorylated Ubl (Parkin 1-76) and 
Ser65-phosphorylated ubiquitin.  
(A) MALDI-TOF spectra of non-phospho-ubiquitin (top panel) and 
ubiquitinPhospho-Ser65 (bottom panel) after incubation with MBP-PINK1 and 
separation by Mono Q column. (B) MALDI-TOF spectra of non-
phosphorylated Ubl (Parkin 1-76) (top panel) and mixed Ubl species (~60% 
phosphorylated and ~40% non-phosphorylated) (bottom panel). (A,B) Two 
micrograms of the non-phospho-ubiquitin and ubiquitinPhospho-Ser65 (A) or non-
phospho-Ubl and UblPhospho-Ser65 (B) were resolved by SDS-PAGE, followed by 
staining with Colloidal Coomassie blue for quality control. 
4.7 UbiquitinPhospho-Ser65 mediated effects on Parkin activity 
4.7.1 UbiquitinPhospho-Ser65 and UblPhospho-Ser65 can directly and differentially 
stimulate Parkin activity 
My previous data has suggested that Parkin activity is regulated by a dual PINK1-dependent 
phosphorylation mechanism. However, the individual details of how each separate 
phosphorylation event affects Parkin remained unclear. To address, this I deployed purified 
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UbiquitinPhospho-Ser65 and UblPhospho-Ser65 in Parkin activation assays, initially monitoring Miro1 
ubiquitylation. In contrast to previous assays described in this thesis so far, TcPINK1 was 
omitted from the reactions and instead the activity of full-length or Ubl Parkin (~0.8 M) 
was analysed upon addition of increasing amounts (0.04, 0.2, 1 and 5 g) of ubiquitinPhospho-
Ser65 or non-phosphorylated ubiquitin to a normal ubiquitylation assay mixture containing 
0.05mM FLAG-ubiquitin as well as other components. Full-length Parkin remained inactive 
in the absence of ubiquitinPhospho-Ser65 (Figure 4.14, lanes 1 and 6), whilst a moderate level of 
constitutive basal activity of Ubl-Parkin (Figure 4.14, lanes 11 and 16) could be observed 
as, previously described (Section 3.3). Upon addition of increasing amounts of ubiquitinPhospho-
Ser65, a striking activation of both full-length Parkin (Figure 4.14, lanes 7-10) and Ubl-Parkin 
(Figure 4.14, lanes 17-20) was detected, as evaluated by the formation of polyubiquitin chains, 
increased autoubiquitylation and increased Miro1 ubiquitylation. Importantly, no activation 
of full-length Parkin (Figure 4.14, lanes 2-5) or Ubl-Parkin (Figure 4.14, lanes 12-15) could 
be detected following the addition of an equivalent amount of non-phosphorylated ubiquitin.  
A striking difference in the sensitivity of full-length Parkin and Ubl Parkin to ubiquitinPhospho-
Ser65 was determined. Addition of 0.04 g (~0.1 M) of ubiquitinPhospho-Ser65 led to activation of 
Ubl Parkin (Figure 4.14, lane 17) but at this concentration, no significant effect on full-
length Parkin activation was observed (Figure 4.14, lane 7). Furthermore, a dose-dependent 
ubiquitylation profile catalysed by Ubl Parkin was revealed upon addition of increasing 
quantities of ubiquitinPhospho-Ser65: intermediate-sized autoubiquitylation chains were formed 
upon addition 0.04 g or 0.2 g of ubiquitinPhospho-Ser65 (Figure 4.14, lanes 17 and 18); and high 
molecular weight chains were formed on addition of 1 g (~2.5 M) or 5 g (~12 M) of 
ubiquitinPhospho-Ser65 (Figure 4.14, lanes 19 and 20). Surprisingly, the addition of molar excess 
amounts of ubiquitinPhospho-Ser65 enabled Ubl Parkin to catalyse monoubiquitylation of Miro1 
(Figure 4.14, lanes 19 and 20), which is in contrast not observed upon the addition of 
TcPINK1 to Ubl Parkin (Section 3.3).  
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Figure 4.14 Full-length wild-type and Ubl Parkin are activated by 
ubiquitinPhospho-Ser65. 
2 g of full-length (WT), and Ubl-Parkin were incubated with the 
ubiquitylation assay components (E1, UbcH7) in the presence of 0.05 mM 
FLAG-ubiquitin. Assays were spiked with indicated amounts of phospho 
(ubiquitinPhospho-Ser65) or non-phospho ubiquitin as indicated. Reactions were 
terminated after 60 min by addition of SDS-PAGE loading buffer and analysed 
by SDS-PAGE. Miro1, ubiquitin and Parkin were detected using anti-SUMO, 
anti-FLAG and anti-Parkin antibodies, respectively. Formation of short, 
intermediate and long poly-ubiquitylated species is indicated by brackets. 
I next determined the role of UblPhospho-Ser65 in the activation of Parkin. In contrast to 
phosphorylated ubiquitin species, addition of increasing amounts of UblPhospho-Ser65 (0.04, 0.2, 
1 and 5 g) had no significant effect on the activation of full length Parkin (Figure 4.15, 7-
10). However, a striking increase in the activity of Ubl Parkin was observed upon addition 
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of UblPhospho-Ser65, as judged by the formation of polyubiquitin chains, increased 
autoubiquitylation and the presence of Miro1 monoubiquitylation (Figure 4.15, lanes 17-20), 
similar to the effects induced by ubiquitinPhospho-Ser65.  
 
Figure 4.15 UblPhospho-Ser65 activates Ubl, but not full-length Parkin.  
2 g of full-length (WT), and Ubl-Parkin were incubated with the 
ubiquitylation assay components (E1, UbcH7) in the presence of 0.05 mM 
FLAG-ubiquitin. Assays were spiked with indicated amounts of phospho 
(UblPhospho-Ser65) or non-phospho Ubl as indicated. Reactions were terminated 
after 60 min by addition of SDS-PAGE loading buffer and analysed by SDS-
PAGE. Miro1, ubiquitin and Parkin were detected using anti-SUMO, anti-
FLAG and anti-Parkin antibodies, respectively. Formation of short, 
intermediate and long poly-ubiquitylated species is indicated by brackets.  
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4.7.2 UbiquitinPhospho-Ser65 and UblPhospho-Ser65 can directly and differentially 
stimulate Parkin to discharge ubiquitin from UbcH7-loaded E2 ligase  
To further probe the effect of UbiquitinPhospho-Ser65- and UblPhospho-Ser65-mediated Parkin 
activation, I next assessed their ability to induce Parkin-dependent ubiquitin discharge from 
UbcH7-loaded E2 ligase. A fixed amount of ubiquitinPhospho-Ser65 or non-phosphorylated 
ubiquitin (1 g) was added to full-length wild-type or S65A Parkin, as well as to Ubl Parkin. 
UbcH7 loaded with ubiquitin was then added to the reaction mixture. The discharge was 
measured using LICOR and quantified by calculating the ratio of UbcH7-ub:UbcH7 (Figure 
4.16, top panel). Consistent with previous results, full-length Parkin alone could not promote 
E2-ubiquitin discharge (Figure 4.16, lanes 2 and 3). However, the addition of ubiquitinPhospho-
Ser65 led to maximal observed ubiquitin discharge from UbcH7 (Figure 4.16, lanes 4 and 5) 
that was absent following addition of non-phosphorylated ubiquitin (Figure 4.16, lanes 6 and 
7). Ubl Parkin alone caused slight ubiquitin discharge from UbcH7 (Figure 4.16, lanes 8 and 
9), but addition of ubiquitinPhospho-Ser65 enhanced the reaction, leading to higher levels of free 
ubiquitin being generated (Figure 4.16, lanes 10 and 11), which was not observed upon 
addition of non-phosphorylated ubiquitin (Figure 4.16, lanes 12 and 13).  
S65A Parkin behaved like the wild-type enzyme; I observed maximal ubiquitin discharge from 
UbcH7 by S65A Parkin on addition of ubiquitinPhospho-Ser65 (Figure 4.16, lanes 16-17) but not 
non-phosphorylated ubiquitin (Figure 4.16, lanes 18-19), indicating that under the assay 
conditions used, ubiquitinPhospho-Ser65 alone is sufficient to activate Parkin-mediated ubiquitin 
discharge from UbcH7. 
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Figure 4.16 UbiquitinPhospho-Ser65 leads to increased ubiquitin discharge by full-
length wild-type, Ser65A and Ubl-Parkin.   
E2 discharge assay was established by incubation of full-length (WT), S65A or 
Ubl-Parkin in presence or absence of phospho (ubiquitinPhospho-Ser65) or non-
phospho ubiquitin (1 g) as indicated with 2 g of loaded UbcH7 loaded with 
FLAG-ubiquitin. Reactions were allowed to continue for 15 min and stopped 
using LDS loading buffer in absence of reducing agent. Reactions were resolved 
using SDS-PAGE and proteins were visualised by Colloidal Coomassie blue 
staining.  
Subsequently, I tested the ability of UblPhospho-Ser65 to stimulate Parkin-mediated ubiquitin 
discharge from UbcH7. Consistent with my ubiquitylation assay analysis (Figure 4.15), 
UblPhospho-Ser65 (~5 M) failed to stimulate full-length Parkin-mediated ubiquitin discharge 
(Figure 4.17, lanes 4-5). In contrast, Ubl Parkin-mediated E2-ubiquitin discharge was 
markedly stimulated by UblPhospho-Ser65 (Figure 4.17, lanes 10-11) when compared to Ubl-
Parkin alone (Figure 4.17, lanes 8-9) or Ubl Parkin in combination with non-phosphorylated 
Ubl (Figure 4.17, lanes 12-13). Similar to the result observed with full length wild-type 
Parkin, UblPhospho-Ser65 could not stimulate S65A Parkin to discharge ubiquitin from UbcH7 
(Figure 4.17, lanes 16-17). 
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Figure 4.17 UblPhospho-Ser65 leads to activation and increased ubiquitin discharge 
by Ubl-Parkin, but does not affect the full-length wild-type and Ser65A 
Parkin.  
E2 discharge assay was established by incubation of full-length (WT), S65A or 
Ubl-Parkin in presence or absence of phospho (UblPhospho-Ser65) or non-phospho 
Ubl (1 g) as indicated with 2 g of loaded UbcH7 loaded with FLAG-
ubiquitin. Reactions were allowed to continue for 15 min and stopped using 
LDS loading buffer in absence of reducing agent. Reactions were resolved using 
SDS-PAGE and proteins were visualised by Colloidal Coomassie blue staining.   
4.8 Discussion 
The first reports of the post-translational modifications phosphorylation and ubiquitylation 
date back to the 1950s and 1980s respectively. Whilst cross-talk of these PTMs has been 
extensively demonstrated (Clark et al., 2013, Swaminathan and Tsygankov, 2006), the work 
discussed in this chapter unveils this interplay in its most stark form; ubiquitin itself becoming  
phosphorylated. The significance of this finding is by turns small yet fundamental. It sheds 
light only on a small aspect of the complex mechanisms underlying the regulation of Parkin 
E3 ligase activity, however, it also reveals a previously undiscovered class of interaction; that 
between modified ubiquitin and an E3 ligase, which raises many unanswered questions. Is 
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interaction with phosphorylated ubiquitin a widespread E3 ligase regulatory mechanism, or 
is it specific to Parkin? What is the identity of the other ubiquitin kinases? Can 
phosphorylated ubiquitin be assembled into ubiquitin chains in a similar fashion to non-
phosphorylated ubiquitin, and if so, does the presence of phospho-ubiquitin in the different 
ubiquitin chain types affect recognition by the proteasome and deubiquitylases? Ser65 lies 
close to lysine 63 (K63), which is involved in the formation of one of the most common 
ubiquitin linkages. It is therefore possible to postulate that K63-specific deubiquitinases such 
as AMSH-like protease (Bedford et al., 2011) might exhibit altered sensitivity to K63 chains 
composed fully or partially of ubiquitinPhospho-Ser65.  
4.8.1 Dual activation of Parkin E3 ligase 
In pursuit of understanding of the molecular basis underlying cellular dysfunction in PD, a 
number of PD-linked genetic mutations, including those in PINK1 and Parkin, have been 
identified (Bras et al., 2015). In order to uncover how these mutations lead to the 
development of the disease, an in-depth knowledge of the signalling pathways affected by 
these mutations is required. One of the outstanding questions in the field is the nature and 
mechanism of the molecular triggers leading to Parkin activation. In Chapter 3, I 
demonstrated that PINK1-dependent phosphorylation of Parkin Ser65, which lies within the 
Ubl domain (Kondapalli et al., 2012), stimulates Parkin E3 ligase activity. The data presented 
in this chapter describe the discovery that PINK1-dependent phosphorylation of ubiquitin at 
Ser65 also plays a critical role in mediating Parkin activation. This discovery potentially 
explains why previously published high-resolution crystal structures of N-terminally 
truncated Parkin and one lower-resolution structure of the full-length protein were unable to 
fully explain how Parkin could be activated on the basis of  Ubl Ser65 phosphorylation alone 
(Riley et al., 2013, Trempe et al., 2013, Wauer and Komander, 2013). The validity of my 
findings has been underpinned by results published by four other groups who have reached 
similar conclusions (Koyano et al., 2014, Kane et al., 2014, Ordureau et al., 2014, Wauer et 
al., 2015b). 
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These data indicate that ubiquitinPhospho-Ser65 is a direct and potent activator of Parkin (Figure 
4.14 & Figure 4.16). The results also demonstrate differential sensitivity of full-length and 
Ubl Parkin to ubiquitinPhospho-Ser65-mediated activation, with the latter requiring smaller 
quantities of ubiquitinPhospho-Ser65 for activation to occur (Figure 4.14). Whilst the exact 
mechanistic details of Parkin activation by ubiquitinPhospho-Ser65 remain to be uncovered, these 
discoveries are consistent with a two-step activation mechanism of Parkin; either 
phosphorylation of Parkin at Ser65 by PINK1 leads to conformational changes that facilitate 
further activation by ubiquitinPhospho-Ser65, or alternatively the opposite may be true and 
binding of ubiquitinPhospho-Ser65 to Parkin facilitates Ubl phosphorylation by PINK1. 
My results demonstrate that UblPhospho-Ser65 is able to activate Parkin; more specifically, in 
contrast to ubiquitinPhospho-Ser65, UblPhospho-Ser65 enhanced the activity of Ubl Parkin but failed 
to influence the activity of full-length Parkin (Figure 4.15 & Figure 4.17). It is possible that 
this can be explained by the fact that the UblPhospho-Ser65 protein utilised in these experiments 
was only 60% phosphorylated, whereas the ubiquitinPhospho-Ser65 used was stoichiometrically 
phosphorylated (Figure 4.13). However, this is unlikely, since the activation of Ubl Parkin 
by ubiquitinPhospho-Ser65 and UblPhospho-Ser65was comparable. An alternative explanation may be 
that the binding site on Parkin for UblPhospho-Ser65 overlaps with (but is still distinct from) that 
of ubiquitinPhospho-Ser65.  In full-length Parkin, this site would not be accessible due to steric 
hindrance imposed by the non-phosphorylated Ubl domain, whereas the binding pocket for 
ubiquitinPhospho-Ser65 might still be partially accessible in the full-length conformation. In 
addition, it is plausible that the interaction between the Ubl domain and the C-terminal 
region of Parkin is of higher affinity when the Ubl domain is not phosphorylated, hence the 
inability of UblPhospho-Ser65 to mediate activation of full-length E3 ligase in trans.  
It is therefore possible to hypothesise that phosphorylation of the intrinsic full-length Parkin 
Ser65 is necessary, and could lead to release of Ubl-mediated autoinhibition and/or expose a 
binding site for UblPhospho-Ser65, supported by the observation that PINK1-induced 
phosphorylation of Parkin can still activate E3 ligase activity in the presence of S65A 
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ubiquitin, as evidenced by Miro1 ubiquitylation (Figure 4.12). It would be illuminating to 
map and compare the region of interaction between UblPhospho-Ser65 and Parkin with that of the 
interaction between Parkin and ubiquitinPhospho-Ser65, as well as to determine the structural 
rearrangements in Parkin caused by their binding.  
Overall, this chapter provides data identifying PINK1 as an upstream kinase of ubiquitin 
Ser65 and revealing a critical requirement of ubiquitinPhospho-Ser65 for mediating the activation 
of Parkin E3 ligase activity. It provides further mechanistic detail on the regulation of Parkin 
and suggests a dual mechanism in which both the Ser65-phosphorylated Ubl domain and 
ubiquitinPhospho-Ser65 are required for optimal Parkin activation. More details of this regulation 
will be presented in the next chapter. 
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5 Chapter 5: Elaboration of molecular interaction of 
phosphorylated ubiquitin and Parkin 
5.1 Introduction 
Following the publication of my results, ubiquitin phosphorylation at Ser65 was additionally 
reported by two different groups  (Koyano et al., 2014, Kane et al., 2014, Kazlauskaite et al., 
2014c) (Chapter 4).  Since then, PINK1-mediated ubiquitin phosphorylation at Ser65 has been 
shown to be required for optimal Parkin activation (Koyano et al., 2014, Kane et al., 2014, 
Kazlauskaite et al., 2014c) and has been demonstrated to facilitate Parkin recruitment to 
mitochondria (Okatsu et al., 2015, Shiba-Fukushima et al., 2014, Ordureau et al., 2014). In 
addition, phosphorylation on Ser65 was reported to induce secondary ubiquitin conformation 
as well as alter the rate of ubiquitin discharge from a range of E2 enzymes (Wauer et al., 
2015b, Han et al., 2015). However, the mechanism of how ubiquitinPhospho-Ser65 contributes to 
Parkin activation remained elusive.  
Parkin exists in an autoinhibited conformation, mediated by multiple intramolecular 
interactions. The catalytic cysteine, Cys431, is obscured by interaction between the UPD and 
RING2 domains (Riley et al., 2013, Spratt et al., 2013, Trempe et al., 2013, Wauer and 
Komander, 2013), and the predicted E2 binding site is blocked by an interaction between the 
Ubl domain, RING1 domain and the regulatory element of Parkin (REP) helix (Trempe et 
al., 2013). In addition, molecular modelling of a Parkin:UbcH5B complex revealed the E2 
(UbcH5B) and Parkin active sites were 50 Å apart, with the UbcH5B active site pointing 
away from the Parkin active site (Wauer and Komander, 2013). Taken together, these data 
suggest that large structural rearrangements need to occur for Parkin to reach a catalytically 
active ‘open’ conformation.  
Upon closer inspection of the truncated human Parkin crystal structure (Wauer and 
Komander, 2013), three positively charged regions on the surface of the protein that were 
bound to negatively charged sulphate ions were revealed, termed Pockets 1, 2 and 3 (Figure 
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5.1). The first Pocket, formed by Lys161, Arg163 and Lys211, was initially proposed to be 
responsible for Parkin recruitment to mitochondria via direct binding of PINK1 
autophosphorylation sites (Wauer and Komander, 2013). Pocket 2, formed by Lys151, His302, 
Arg305 and Gln316, resides in an interface between the UPD and RING1 domains, which makes 
it an attractive site for a regulatory binding event. Pocket 3 is unusual, since it is made up 
of only a single amino acid, Arg455, and is therefore unlikely to have a significant regulatory 
binding role. Parkin has been convincingly demonstrated to be activated both by 
phosphorylation of the Ubl domain and by binding of ubiquitinPhospho-Ser65 (Kondapalli et al., 
2012, Ordureau et al., 2014). Both Ubl-phosphorylated Parkin and ubiquitinPhospho-Ser65 carry 
a negatively charged phosphate group. It was therefore important to investigate whether any 
of the identified surface pockets on Parkin bound to these phosphorylated ligands, and if so, 
whether such a binding event influences Parkin activation.   
 
Figure 5.1 Parkin structure and putative phosphate-binding pockets. 
Structure of human Parkin 141-465 displaying location of sulphate containing 
pockets surrounded by the following residues: Pocket 1 (K161/R163/K211); 
Pocket 2 (K151/H302/R305/Q316) and Pocket 3 (R455). PDB ID: 4bm9. 
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In this chapter, I report that ubiquitinPhospho-Ser65 primes Parkin for efficient phosphorylation 
by PINK1 at Ser65 of its Ubl domain, which in turn leads to maximal activation of Parkin E3 
ligase activity. The interaction between Parkin and ubiquitinPhospho-Ser65 was investigated 
through biophysical and mutational analysis, and two residues forming Pocket 2, His302 and 
Lys151, which play a critical role in ubiquitinPhospho-Ser65 binding to Parkin and Ubl Ser65 
phosphorylation by PINK1, were identified.  
5.2 UbiquitinPhospho-Ser65 primes Parkin Ser65 for phosphorylation by 
PINK1 
5.2.1 UbiquitinPhospho-Ser65-mediated enhancement of Parkin Ser65 
phosphorylation by PINK1 
My previous work demonstrated dual phosphorylation of the Parkin Ubl domain and 
ubiquitin by PINK1. To address whether these two phosphorylation events might influence 
each other, I performed a kinase assay involving a constant amount of wild-type or kinase-
inactive TcPINK1, wild-type Parkin and increasing amounts of wild-type, Ser65Ala or 
phosphorylated ubiquitin. A marked increase in the rate as well as the stoichiometry of Parkin 
phosphorylation was observed upon addition of increasing amounts of ubiquitinPhospho-Ser65, 
reaching a stoichiometry of ~0.9 in the presence of a 3-fold molar excess of ubiquitinPhospho-Ser65 
relative to Parkin, compared to ~0.2 without (Figure 5.2, left panel). In contrast, in the 
presence of a non-phosphorylatable S65A mutant of ubiquitin, no change in Parkin 
phosphorylation levels was detected (Figure 5.2, middle panel). Addition of increasing 
amounts of wild-type ubiquitin led to a moderate enhancement of Parkin phosphorylation 
due to PINK1-dependent generation of ubiquitinPhospho-Ser65 species during the kinase reaction, 
as confirmed by autoradiography (Figure 5.2, right panel). No enhancement of 
phosphorylation of Parkin S65A nor Ubl Parkin (both of which lack the phosphorylatable 
residue Ser65) by PINK1 in the presence of ubiquitinPhospho-Ser65 was observed (Appendix Figure 
1). This indicates that the ubiquitinPhospho-Ser65-mediated enhancement of Parkin 
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phosphorylation by PINK1 is specific to the Ubl domain Ser65 and does not involve 
phosphorylation of any additional sites on Parkin (Appendix Figure 1). 
 
Figure 5.2 UbiquitinPhosphoSer65 primes Parkin for phosphorylation by PINK1. 
The effects of ubiquitinPhospho-Ser65 (left), wild type (WT) (right) and Ser65Ala 
(S65A) (middle) ubiquitin on Parkin phosphorylation were investigated in a 
kinase assay. The indicated ubiquitin species were incubated with wild-type 
(WT) or kinase-inactive (KI) TcPINK1, Parkin and Mg2+ [γ-32P] ATP for 60 
min. Parkin concentration was kept constant, while ubiquitin concentration 
was varied, reaching the molar ratios indicated above the gel. Assays were 
terminated by the addition of LDS loading buffer and products were analysed 
by SDS/PAGE. Proteins were detected by Colloidal Coomassie Blue staining 
(top panel) and incorporation of [γ-32P] ATP was detected by autoradiography 
(bottom panel). Data show mean of two trials +/- standard deviation (s.d.), 
n=2 for each condition. 
5.2.2 Specificity of UbiquitinPhospho-Ser65-mediated effects 
To test whether ubiquitinPhospho-Ser65-dependent enhancement of Parkin phosphorylation by 
PINK1 was a specific event, I compared three different substrates of PINK1 (Parkin, the 
isolated Ubl domain of Parkin and GST-HAX1) in a kinase assay in the presence or absence 
of ubiquitinPhospho-Ser65 (Figure 5.3 A). HAX1 is a mitochondrial intermembrane protein, which 
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our lab has recently identified as a robust in vitro substrate of PINK1, although the 
physiological relevance of this phosphorylation has not yet been explored (Appendix Figure 
2, performed by Dr. Miratul Muqit). UbiquitinPhospho-Ser65 was found to only enhance the 
phosphorylation of full-length Parkin, and had no effect on the other two proteins tested, 
suggesting that ubiquitinPhospho-Ser65 does not affect PINK1 activity per se, but mediates a 
specific effect likely via direct interaction with full-length Parkin (Figure 5.3 A).  
The isolated Parkin Ubl domain phosphorylated at Ser65 (UblPhospho-Ser65) was also tested in a 
kinase assay with full-length Parkin (Figure 5.3 B). In contrast to ubiquitinPhospho-Ser65, addition 
of UblPhospho-Ser65 did not affect Parkin phosphorylation, indicating that this effect is phospho-
ubiquitin-specific (Figure 1C).  
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Figure 5.3 Selectivity of ubiquitinPhosphoSer65 enhanced Parkin phosphorylation.  
(A) Full-length Parkin is a specific target of ubiquitinPhospho-Ser65-mediated 
phosphorylation enhancement. Under similar conditions to Figure 5.2, the 
effects of ubiquitinPhospho-Ser65 on phosphorylation of various PINK1 substrates 
were assessed.  The kinase assays were set up with equimolar amounts of 
Parkin, GST-Ubl and GST-HAX1 (all expressed in E. coli) in the presence or 
absence of ubiquitinPhospho-Ser65 and wild-type (WT) TcPINK1. The incorporation 
of radioactive [γ-32P] ATP into substrate proteins was calculated and is 
displayed above the panels. Proteins were detected by Colloidal Coomassie Blue 
staining (top panel) and incorporation of [γ-32P] ATP was detected by 
autoradiography (bottom panel). Dashed lines indicate separate gels; asterisks 
denote the kinase band. Data show mean of two trials +/- s.d., n=2 for each 
condition. (C) UbiquitinPhospho-Ser65, but not UblPhospho-Ser65 enhances full-length 
Parkin phosphorylation by PINK1. Kinase assays in the presence or absence of 
ubiquitinPhospho-Ser65 or UblPhospho-Ser65 were carried out as in (A). Data 
representative of 2 independent experiments. 
5.2.3 The enhancement of ubiquitinPhosphoSer65-mediated phosphorylation of Ubl 
Ser65 is independent of ubiquitin chain topology and is achieved by mono-
ubiquitylated substrates 
Recent studies have demonstrated that in addition to phosphorylating monomeric ubiquitin 
PINK1 can phosphorylate polyubiquitin chains of different linkage types and lengths 
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(Ordureau et al., 2014, Wauer et al., 2015b, Okatsu et al., 2015). It was therefore important 
to investigate whether phosphorylated ubiquitin chains would have a similar effect as 
monomeric ubiquitinPhosphoSer65 in promoting Parkin phosphorylation by TcPINK1 (Figure 5.4 
A). I therefore set up kinase assays with ubiquitin dimers of each linkage type (Met1, Lys6, 
Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) or ubiquitin tetramers with Met1, Lys6, Lys11, Lys29, 
Lys33, Lys48 and Lys63 linkages (Kristariyanto et al., 2015b, Kristariyanto et al., 2015a) and 
equimolar amounts of wild-type Parkin and wild-type TcPINK1 (Figure 5.4 A). All linkage 
types were found to be phosphorylated, as judged by autoradiography, and led to a similar 
enhancement of Parkin phosphorylation by TcPINK1 as that observed following addition of 
monomeric ubiquitin (Figure 5.4 A).  
None of the reports describing ubiquitin phosphorylation by PINK1 at Ser65 have addressed 
whether PINK1 can efficiently phosphorylate monoubiquitin attached to substrate proteins; 
I therefore tested a model monoubiquitylated substrate in which ubiquitin has been C-
terminally fused to a Dac tag (a ~28.5 kDa fragment of E. coli penicillin binding protein 5 
comprising residues 37-297 that can be captured and released by binding to ampicillin-
Sepharose) (Lee et al., 2012a). To achieve this, I performed a kinase assay with TcPINK1 
and Parkin in the presence of monoubiquitin, Dac-ubiquitin or Dac tag alone (to control for 
any unspecific phosphorylation of the tag itself). This revealed that Dac-ubiquitin was readily 
phosphorylated by TcPINK1, and furthermore led to enhanced Parkin phosphorylation by 
PINK1 in a manner similar to monomeric ubiquitin (Figure 5.4 B). No phosphorylation 
activity was detected when the Dac tag alone was used, suggesting that the enhancement of 
Parkin phosphorylation was specific to ubiquitin phosphorylation by TcPINK1 (Figure 5.4 
B). 
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Figure 5.4 Ubiquitin dimers, tetramers and a mono-ubiquitylated substrate are 
capable of priming Parkin phosphorylation by PINK1. 
 (A) The effects of ubiquitin dimers of each linkage type (Met1 (M1), Lys6 
(K6), Lys11 (K11), Lys27 (K27), Lys 29 (K29), Lys33 (K33), Lys48 (K48) and 
Lys63 (K63), ubiquitin tetramers with M1, K6, K11, K29, K33, K48 and K63 
linkages and (B) the model mono-ubiquitylated substrate, Dac-ubiquitin (Dac-
ub) were assessed in a TcPINK1 kinase assay.  The indicated ubiquitin species 
were incubated with wild-type (WT) or kinase-inactive (KI) TcPINK1, Parkin 
and Mg2+ [γ-32P] ATP for 60 min. Assays were terminated by the addition of 
LDS loading buffer and products were analysed by SDS/PAGE. Proteins were 
detected by Colloidal Coomassie Blue staining (top panel) and incorporation of 
[γ-32P] ATP was detected by autoradiography (bottom panel).  
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5.3 Identification of Parkin histidine 302 and lysine 151 as key 
residues required for binding and maximal activation of Parkin by 
ubiquitinPhospho-Ser65  
5.3.1 Analysis of Parkin pocket mutants 
To better understand the mechanism of how ubiquitinPhospho-Ser65 promotes Parkin 
phosphorylation by PINK1, I next determined the ubiquitinPhospho-Ser65 binding site on Parkin. 
As mentioned in Section 5.1, inspection of the published truncated human Parkin structure 
(Wauer and Komander, 2013) revealed three putative phosphate-binding pockets (Figure 
5.1). Pocket 1 in UPD domain had been previously highlighted as a putative phosphate-
binding pocket (Wauer and Komander, 2013), but it was later demonstrated not to be 
required for Parkin binding to ubiquitinPhospho-Ser65 (Ordureau et al., 2014). To explore the 
potential contribution of residues forming these three pockets to ubiquitinPhospho-Ser65-mediated 
activation of Parkin, Parkin containing a single point mutant of each residue was expressed 
in E. coli and subsequently purified.  I then tested these point mutants in a PINK1 kinase 
assay in the presence of ubiquitinPhospho-Ser65 (Figure 5.5). All of the Pocket 1 mutants 
(Lys161Ala, Arg163Ala and Lys211Asn), as well as the Pocket 3 mutant (Arg455Ala), 
behaved like the wild-type Parkin (Figure 5.5). By contrast, the Pocket 2 mutant - His302Ala 
(H302A) mutation almost completely prevented the enhancement of Parkin Ser65 
phosphorylation by PINK1 (Figure 5.5). Furthermore, the Lys151Ala (K151A) mutation also 
disrupted the ability of ubiquitinPhospho-Ser65 to modify the PINK1-dependent phosphorylation 
of Parkin, albeit to a lesser extent (Figure 5.5). The remaining Pocket 2 mutants, Arg305Ala 
and Gln316Ala), displayed respectively either a modest effect or no effect on ubiquitinPhospho-
Ser65 mediated phosphorylation of Parkin Ser65 (Figure 5.5).  
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Figure 5.5 His302 and Lys151 are critical for mediating ubiquitinPhospho-Ser65 
enhanced phosphorylation of Parkin by TcPINK1.  
Wild-type (WT) full length Parkin or the indicated alanine mutant was 
incubated with wild-type (WT) TcPINK1, Parkin and Mg2+ [γ-32P] ATP in 
the presence or absence of ubiquitinPhosphoSer65. Proteins were detected by 
Colloidal Coomassie Blue staining (top panel) and Parkin phosphorylation 
levels assessed by incorporation of [γ-32P] ATP detected by autoradiography 
(bottom panel) and displayed above the panel. Data show mean of two trials 
+/- s.d., n=2 for each condition. 
5.3.2 Stability of His302Ala and Lys151Ala mutants 
To ensure that H302A and K151A mutations do not disrupt the Parkin:ubiquitinPhospho-Ser65 
interaction due to structural instability and/or unfolding caused by the mutations themselves, 
a thermal shift analysis was undertaken (performed by Dr. R. Julio Martinez-Torres). This 
demonstrated that the Parkin H302A and K151A mutants were as stable as the wild-type 
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protein, with no measurable change in thermal stability thus indicating no significant 
perturbation of fold or structural integrity (Figure 5.6).  
The analysis conducted utilised full-length Parkin, however, the high-resolution crystal 
structures of Parkin have been obtained using N-terminally deleted fragments of Parkin 
comprising the UPD-RBR domains (Riley et al., 2013, Spratt et al., 2013, Trempe et al., 
2013, Wauer and Komander, 2013). I am therefore unable to rule out the possibility that the 
topology of the ubiquitinPhospho-Ser65 pocket may be different in the structure of the full-length 
protein and might involve additional amino acids not evident from the UPD-RBR structures. 
Nevertheless, my analysis strongly suggests a key role for His302 and Lys151 in 
ubiquitinPhospho-Ser65 mediated effects on Parkin.  
 
Figure 5.6 Analysis of stability and UbiquitinPhosphoSer65 independent E3 ligase 
activity of Pocket 2 mutants of Parkin.  
Thermal denaturation curves obtained by differential scanning fluorimetry of 
wild-type (WT), His302Ala (H302A) and Lys151Ala (K151A) mutant Parkin. 
Results are displayed as the differential of the fluorescence in units divided by 
the differential of the temperature, plotted against temperature. Inset: 
Summary of melting points (Tm), indicated by the minimum of each curve, of 
each protein as follows: WT (59oC); H302A (59.5oC) and K151A (59.5oC). 
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5.3.3 The role of Pocket 2 residues in ubiquitinPhospho-Ser65 induced Parkin 
activation 
It was next important to test the effect of the H302A and K151A mutations on the 
ubiquitinPhospho-Ser65-mediated activation of Parkin. I addressed this by employing Parkin E3 
ligase assays as described in Section 2.2.28.2. Wild-type Parkin as well as the Pocket 2 point 
mutants (K151A, H302A, R305A and Q316A) were tested in ubiquitylation assays in the 
presence or absence of ubiquitinPhospho-Ser65. Parkin activity was assessed by monitoring the 
formation of free polyubiquitin chains, Miro1 multi-monoubiquitylation and Parkin auto-
ubiquitylation.  
Wild-type Parkin displayed activity only when ubiquitinPhospho-Ser65 was present, in agreement 
with previous data (Figure 5.7 A, lanes 1-2). Consistent with the phosphorylation assay 
analysis, a large reduction in Parkin activation by ubiquitinPhospho-Ser65 was detected following 
mutation of His302 to alanine, as judged by a complete loss of Miro1 ubiquitylation and 
substantial decrement in free poly-ubiquitin chain formation and Parkin autoubiquitylation 
(Figure 5.7 A, lanes 5-6). In addition, the K151A mutant exhibited a partial reduction in 
Parkin activity, as judged by Parkin autoubiquitylation and free poly-ubiquitin chain 
formation (Figure 5.7 A, lanes 3-4), the R305A mutant exhibited only modest negative effects 
on Parkin activation upon addition of ubiquitinPhospho-Ser65 (Figure 5.7 A, lanes 7-8), and finally 
Q316A behaved like the wild-type protein.  
In contrast, when the E3 ligase activity assay was performed in conjunction with 
phosphorylation by TcPINK1 (as described previously) under which conditions activation is 
imparted by TcPINK1-directed Parkin Ubl Ser65 phosphorylation, the activity of the H302A 
mutant was similar to that of the wild-type protein (Appendix Figure 3). These data suggest 
that H302A mutation is not causing large perturbations in the conformation of Parkin and 
instead is likely selectively affecting the ubiquitinPhospho-Ser65 interaction (Appendix Figure 3). 
The non-phosphorylatable S65A ubiquitin mutant was included in this experiment in order 
to discriminate the effects mediated by UblPhospho-Ser65 from those induced by ubiquitinPhospho-
Ser65 (Appendix Figure 3).  
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I also assessed Pocket 2 mutations for their impact on ubiquitinPhospho-Ser65-dependent ubiquitin 
discharge from the loaded E2 enzyme UbcH7. The reactions were assembled as described in 
Section 2.2.28.3. Equimolar amounts of each of the Parkin mutants as well as the wild-type 
protein were tested with ubiquitin or ubiquitinPhospho-Ser65. Whilst addition of ubiquitinPhospho-
Ser65 but not ubiquitin led to maximal E2-ubiquitin discharge by wild-type Parkin (Figure 5.7 
B, lanes 4 and 5), this was completely disrupted by the H302A mutation (Figure 5.7 B, lanes 
8 and 9) and partially by mutation of K151A (Figure 5.7 B, lanes 6 and 7) and Arg305Ala 
(Figure 5.7 B, lanes 10 and 11). The Gln316Ala mutant was largely unaffected (Figure 5.7 
B, lanes 12, 13). Consistent with their critical regulatory role, the His302 and Lys151 residues 
are highly conserved in multiple species of Parkin (Figure 5.7 C). 
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Figure 5.7 Parkin H302A and K151A mutants disrupt ubiquitinPhospho-Ser65 
mediated Parkin activation 
(A) The activity of wild-type (WT) Parkin and putative Pocket 2 mutants 
(K151A, H302A, R305A, Q316A) were assessed using ubiquitylation assays. 
Each reaction contained 0.05 mM ubiquitin comprising 25 μg of FLAG-
ubiquitin mixed with 5 μg of ubiquitinPhospho-Ser65 or wild-type ubiquitin. E3 ligase 
activity was evaluated by immunoblotting. Data representative of 5 
independent experiments. (B) H302A and K151A mutations hinder Parkin’s 
ability to interact with ubiquitinPhospho-Ser65 and discharge ubiquitin from a loaded 
E2.  Wild-type (WT) Parkin and pocket 2 mutants were assessed for their 
ability to discharge ubiquitin from a loaded UbcH7 (UbcH7-ub) enzyme with 
or without ubiquitinPhospho-Ser65 or non-phospho-ubiquitin. The activity was 
assessed by change in UbcH7 (E2):UbcH7-Ub (E2-Ub) ratio. The quantification 
of Coomassie bands was performed by LICOR and is presented above the panel. 
Data show mean of three trials +/- s.d., n=1 for each condition. (C) Parkin 
His302 and Lys151 are highly conserved across multiple species. Sequence 
alignment of residues around Lys151 and His302 in human Parkin and a variety 
of lower organisms showing high degree of conservation.  
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5.3.4 Analysis of Parkin disease mutants 
Whilst His302 and Lys151 have not been identified as mutated in human patients with 
Parkinson’s disease, a number of disease mutations lie in close structural proximity to these 
residues, including the RING1 mutant R275W, which was previously shown to be inactive 
(Section 3.4). I therefore investigated a panel of disease mutants, as described in Section 3.4, 
including R275W for their ability to interact with ubiquitinPhospho-Ser65 and analysed their levels 
of PINK1-mediated Ser65 phosphorylation. I conducted a kinase assay with each of the 
mutants, as well as wild-type Parkin and TcPINK1, in the presence or absence ubiquitinPhospho-
Ser65 (Figure 5.8). This resulted in the identification of three disease mutants that prevented 
ubiquitinPhospho-Ser65-enhanced Parkin Ser65 phosphorylation: K27N and A46P, which lie within 
the Ubl domain; and G430D, which lies within the RING2 domain, (Figure 5.8). However, 
the basal phosphorylation of these mutants in the absence of ubiquitinPhospho-Ser65 was 
substantially lower than that of wild-type Parkin; it is therefore possible to speculate that 
these mutations trap Parkin in a conformation that leads to a decrease in Ubl domain 
accessibility and a subsequent reduction in phosphorylation. Conversely, the R33Q mutant, 
which I found previously to be better phosphorylated than wild-type Parkin (Section 3.4), 
potentially due to disruption of Ubl-mediated autoinhibition, showed only a moderate change 
in phosphorylation by PINK1 upon addition of ubiquitinPhospho-Ser65 when compared to wild-
type (Figure 5.8).  
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Figure 5.8 Identification of Parkinson’s disease associated mutants that disrupt 
ubiquitinPhospho-Ser65 enhanced phosphorylation of Parkin by TcPINK1.  
Schematic of Parkin domain and location of disease-associated Parkin mutants 
(Upper panel). Wild-type (WT) full-length Parkin or the indicated disease 
point mutant was incubated with wild-type MBP-TcPINK1 and Mg2+ [γ-32P] 
ATP in the presence or absence of ubiquitinPhosphoSer65. Proteins were detected 
by Colloidal Coomassie Blue staining (top panel) and Parkin phosphorylation 
levels assessed by incorporation of [γ-32P] ATP detected by autoradiography 
(bottom panel) and displayed above the panel (Lower Panel). 
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5.4 Parkin His302 and Lys151 are necessary for efficient binding to 
ubiquitinPhospho-Ser65 
5.4.1 Isothermal titration calorimetry analysis of Parkin binding to 
ubiquitinPhospho-Ser65 
To demonstrate direct involvement of the identified Pocket 2 residues in the binding of 
ubiquitinPhospho-Ser65, isothermal titration calorimetry (ITC) analysis of ubiquitinPhospho-Ser65 
binding to full-length wild-type Parkin and the two most deleterious point mutants, H302A 
and K151A, was conducted by Dr. R. Julio Martinez-Torres (Figure 5.9). Similar to the 
findings of a recent study (Ordureau et al., 2014), wild-type Parkin bound to ubiquitinPhospho-
Ser65 with a Kd of 156 nM (Figure 5.9 A & B, left panel). In contrast, the K151A mutant was 
found to bind ubiquitinPhospho-Ser65 with 45-fold lower affinity (Kd of ~7M) than wild-type 
Parkin (Figure 5.9 A & B, middle panel), and the H302A mutant exerted an even more 
dramatic effect, with a 265-fold reduction in the affinity of binding to ubiquitinPhospho-Ser65 (Kd 
of ~42M) when compared to wild-type (Figure 5.9 A & B, right panel). Overall, these data 
indicate that residues H302 and K151 are required for optimal binding of ubiquitinPhospho-Ser65 
to Parkin. 
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Figure 5.9 Parkin His302 and Lys151 are required for optimal binding with 
UbiquitinPhospho-Ser65.  
(A) Isothermal Calorimetry analysis of Parkin WT (left), K151A mutant 
(middle) and H302A mutant (right) with UbiquitinPhospho-Ser65. (B) Table 
showing the Kd values (in M), H values (in Kcal mol-1), S values (in Kcal 
mol-1 deg) and –TS (in Kcal mol-1) derived from the graphs. Data 
representative of 2 independent experiments. 
5.4.2 Gel filtration analysis of Parkin interaction with phosphorylated 
ubiquitin species 
A complementary gel filtration analysis was undertaken to assess heterodimeric complex 
formation of wild-type Parkin with ubiquitinPhospho-Ser65 (performed by Dr. Axel Knebel). N-
terminal Dac-tagged ubiquitin (described in Section 5.2) was used, since it retains monomeric 
properties and is of a greater molecular weight than untagged ubiquitin, therefore it will 
produce a discernible increase in elution time upon binding to Parkin , which is necessary to 
determine if complex formation has occurred (Lee et al., 2012b). Dac-ubiquitinPhospho-Ser65 was 
produced in manner similar to that described in Section 4.6. Dac-ubiquitin was first 
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phosphorylated by Pediculus humanus corporis PINK1 (PhcPINK1) and then the 
phosphorylated and non-phosphorylated forms were separated by ion-exchange 
chromatography. 100 g of Dac-Ubiquitin or Dac-Ubiquitinphospho-Ser65 were incubated with or 
without 100 g of wild-type (WT), H302A or S65A Parkin for 30 min and subjected to size 
exclusion chromatography using a Superdex 200 Increase (10/300 GL) column. 250 l of 
purified protein at a concentration of 0.8 mg/ml was injected on to the column (Figure 5.10). 
Dac-ubiquitin, Dac-Ubiquitinphospho-Ser65, wild-type as well as H302A and S65A Parkin were 
also run alone to determine their individual elution profiles (Figure 5.10 A, B, C, D & I 
respectively). When wild-type Parkin was incubated with Dac-ubiquitin, no strong interaction 
could be seen between the two proteins, as two distinct peaks corresponding to those of the 
monomeric proteins were observed (Figure 5.10 E). In contrast, the binding of Dac-
ubiquitinPhos-Ser65 to wild-type Parkin resulted in a decrease in the elution time and an increase 
in the area of the Parkin peak, indicating heterodimer formation (Figure 5.10 F). The non-
phosphorylatable S65A Parkin mutant behaved in a similar way to wild-type Parkin; two 
separate peaks were observed following incubation with Dac-ubiquitin (Figure 5.10 J), 
however heterodimer formation was seen upon incubation with Dac-ubiquitinPhos-Ser65 (Figure 
5.10 K). No evidence was found for binding between Parkin H302A mutant and Dac-
ubiquitinPhos-Ser65 or Dac-ubiquitin, as judged by the presence of 2 separate protein elution 
peaks corresponding to the monomeric proteins in both cases (Figure 5.10 G & H 
respectively). 
 Overall, these binding studies indicate a critical involvement of His302 and Lys151 in 
ubiquitinPhospho-Ser65 binding, and suggest that these residues may lie within the ubiquitinPhospho-
Ser65 binding pocket of Parkin.  
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Figure 5.10 Analysis of heterodimer formation between Ser65-phosphorylated 
Dac-ubiquitin and Parkin using gel filtration chromatography.  
100 g of Dac-Ubiquitin or Dac-UbiquitinphosphoSer65 (both ~38.3 kDa) were 
incubated with or without 100 g of wild-type Parkin (WT) or Parkin 
His302Ala (H302A) (both ~51.6kDa) for 30 min and subjected to 
chromatography on a Superdex 200 Increase column (Ge-Healthcare Life 
Sciences). Parkin eluted at 13.8 ml and Dac-Ubiquitin at 15.1 ml. The dimer 
eluted at 12.9 ml. The x-axis is ml elution volume and the Y-axis is arbitrary 
milli absorption Units. (A) Profile of Dac-ubiquitin. (B) Profile of Dac-
UbiquitinphosphoSer65. (C) Profile of WT Parkin. (D) Profile of Parkin H302A 
mutant. (E) Profile of WT Parkin and Dac-ubiquitin. (F) Profile of WT Parkin 
and Dac-Ubiquitin phosphoSer65. (G) Profile of H302A Parkin and Dac-
UbiquitinphosphoSer65. (H) Profile of H302A Parkin and Dac-ubiquitin. (I) Profile 
of S65A Parkin. (J) Profile of S65A Parkin and Dac-Ubiquitin. (K) Profile of 
S65A Parkin and Dac-Ubiquitinphospho Ser65.  
5.5 Evidence that UbiquitinPhospho-Ser65 influences Parkin Ser65 
phosphorylation in cells  
5.5.1 His302Ala mutation causes a reduction in cellular ParkinPhospho-Ser65 levels 
I next explored whether the H302A mutation had any effect on Parkin phosphorylation in 
cells. To address this, I transiently overexpressed wild-type, S65A and H302A Parkin in wild-
type HeLa as well as PINK1 knock-out HeLa cells (Narendra et al., 2013a). I included an 
untransfected control to ensure the specificity of the antibodies utilised. 24 hours after 
transfection, cells were treated with 10 M CCCP or DMSO for 6 hours. CCCP was used to 
depolarise the mitochondria and stabilise and activate PINK1.  After treatment, the cells 
were lysed and extracts analysed by immunoblotting with a phospho-specific antibody raised 
against a previously characterised Parkin Ser65 epitope (Section 3.2). Consistent with the in 
vitro analysis (Figure 5.5), the level of Parkin phosphorylation was substantially diminished 
in cells expressing H302A Parkin (Figure 5.11, lanes 7-9) compared to wild-type Parkin 
(Figure 5.11, lanes 1-3). Antibody specificity was confirmed by the absence of Parkin Ser65 
phosphorylation signal in cells expressing the S65A Parkin mutant (Figure 5.11, lanes 4-6) as 
well as in untransfected cells (Figure 5.11, lanes 10-12). The strict dependence of the Parkin 
Ser65 site on active PINK1 was also demonstrated by the lack of Parkin phosphorylation at 
Ser65 in PINK1 knock-out cells (Figure 5.11, bottom).  
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5.5.2  His302Ala mutation diminishes Parkin activity in cells 
Under similar conditions, I investigated the requirement of His302 for optimal Parkin E3 
ligase activity in wild-type HeLa cells stimulated with either CCCP or DMSO. Previous mass 
spectrometric analysis has identified numerous mitochondrial proteins as Parkin substrates, 
including the Fe-S cluster-containing protein CISD1 (Sarraf et al., 2013). I chose to monitor 
the ubiquitylation of this protein as a marker of Parkin E3 ligase activity in cells. The cells 
 
Figure 5.11 Parkin H302A mutant displays a marked decrease in Parkin Ser65 
phosphorylation upon PINK1 activation.  
Wild-type HeLa (upper panel) or PINK1 knock-out HeLa cells (lower panel) 
were transfected with untagged wild-type (WT), Ser65Ala (S65A) or H302A 
mutant Parkin and stimulated with 10 μM of CCCP or DMSO for 6 h in 
triplicates. The lysates were subjected to immunoblotting as follows: Parkin 
Ser65 phosphorylation (anti-phospho-Ser65 antibody, 1:1000), Parkin (anti-
Parkin antibody SantaCruz, 1:1000), Actin (anti-actin antibody Sigma, 1:5000) 
and PINK1 (anti-PINK1 antibody, 1:1000). Data representative of 3 
independent experiments. 
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were transfected as described above, and a Cys431Phe disease mutant of Parkin was also 
included. As mentioned previously, Cys431 is the catalytic cysteine, and I have previously 
shown that mutating it to phenylalanine causes a complete loss of Parkin activity in vitro 
(Figure 3.15, Chapter 3). It therefore serves as a good negative control in this cell-based 
experiment. Cells were stimulated for 6 hours with CCCP or DMSO, followed by harvesting 
in PBS supplemented with 200 mM chloroacetamide. A membrane fraction, enriched in 
mitochondria, was prepared, as described in Section 2.2.11. Ubiquitylated proteins were then 
selectively pulled down from 1 mg of lysate using tandem ubiquitin binding entity (TUBE) 
technology (Hjerpe et al., 2009), in which the ubiquitin associated (UBA) domain of 
ubiquilin1 was expressed in 4 tandem repeats with an N-terminal Halo tag. This was coupled 
to Halo beads followed by pulldowns from the membrane fractions. The resulting proteins 
were analysed by immunoblotting (Figure 5.12). 
Upon stimulation with CCCP, a clear poly-ubiquitylation signal of CISD1 was observed in 
mitochondrial extracts of cells expressing wild-type but not the catalytically inactive C431F 
RING2 mutant of Parkin (Figure 5.12). A dramatic reduction in CISD1 poly-ubiquitylation 
was detected in cells expressing the H302A mutant (Figure 5.12, lane 3), confirming that 
binding involving His302 is essential for optimal Parkin activation in cells, consistent with 
the in vitro analysis of the H302A mutant (Figure 5.5). A significant reduction in CISD1 
poly-ubiquitylation levels was also detected in cells expressing the Parkin S65A mutant 
(Figure 5.12, lane 2) providing further evidence for the critical role of Ubl Ser65 
phosphorylation in the activation of Parkin E3 ligase activity in cells. CISD1 ubiquitylation 
was absent in cells stimulated with DMSO. 
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Figure 5.12 Parkin His302 is required for optimal activation of Parkin ubiquitin 
E3 ligase activity at mitochondria in response to PINK1 activation by CCCP.  
Wild-type HeLa cells were transfected with untagged wild-type (WT), Ser65Ala 
(S65A), His302Ala (H302A) or Cys431Phe (C431F) mutant Parkin and 
stimulated with 10 μM of CCCP or DMSO for 6 h. Mitochondrial enriched 
extracts were incubated with a ubiquitin binding resin derived from His-Halo-
Ubiquilin1 UBA-domain tetramer (UBAUBQLN1). Captured ubiquitylated 
proteins were subjected to immunoblotting with CISD1 (1:1000) and ubiquitin 
(1:1000) antibodies. In parallel mitochondrial input extracts were 
immunoblotted with Tomm70 antibody (1:1000).  
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5.5.3 ParkinPhosphoSer65 is tethered to mitochondria in cells after stimulation 
with CCCP 
Multiple groups have reported PINK1-dependent phosphorylation of ubiquitin on 
mitochondrial membranes, leading to the hypothesis that ubiquitinPhospho-Ser65 acts as a Parkin 
acceptor/receptor on the mitochondria and drives Parkin mitochondrial recruitment (Okatsu 
et al., 2015, Ordureau et al., 2014). To address how a decrease in ubiquitinPhospho-Ser65 binding 
would affect Parkin phosphorylation at the mitochondria, I established an 
immunofluorescence assay using a recently generated highly sensitive monoclonal anti-
phospho-Parkin Ser65 antibody. I initially generated inducible FlpIn TRex HeLa cells stably 
overexpressing wild-type Parkin and the S65A, H302A and C431F Parkin point mutants. 
Cells were plated on glass coverslips, protein expression was induced using doxycycline and 
PINK1 activation was stimulated using CCCP, with DMSO as a negative control. Total 
Parkin, Parkin phospho Ser65 and mitochondrial distribution was monitored using 
immunofluorescent probes, as described in Section 2.2.22. Upon stimulation of cells expressing 
wild-type Parkin with 10 M CCCP, a striking accumulation of Parkin Ser65 phosphorylation 
on the mitochondria, as judged by staining with the mitochondrial dye Mito-ID red, was 
observed (Figure 5.13, top row). Furthermore, the mitochondria appeared to be clustered 
around the nucleus in a peri-nuclear distribution (Figure 5.13, top row). The high specificity 
of the phospho-antibody was confirmed by an absence of Parkin Ser65 phosphorylation signal 
in S65A Parkin-expressing cells (Figure 5.13, third row). Consistent with the western blot 
analysis (Figure 5.11) a large reduction of Parkin Ser65 phosphorylation in cells expressing 
H302A Parkin was detected. In addition, the Ser65-phosphorylated H302A Parkin signal was 
diffuse within the cytosol, in agreement with requirement of ubiquitinPhospho-Ser65 binding ability 
for mitochondrial translocation (Figure 5.13, fourth row). Finally, there was a substantial 
reduction in total Parkin translocation in cells expressing the C431F mutant, however, Parkin 
still became phosphorylated and the ParkinPhospho-Ser65 signal was mainly confined to 
mitochondria, albeit at levels significantly lower than wild-type Parkin (Figure 5.13, fifth 
row).  
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Figure 5.13 Parkin H302A mutant disrupts mitochondrial accumulation of 
Parkin Ser65 phosphorylation. 
Wild-type HeLa cells stably expressing untagged wild-type (WT) (top row and 
second row), Ser65Ala (S65A) (third row) or His302Ala (H302A) (fourth row) 
mutant Parkin were stimulated with 10 μM of CCCP for 6 h. HeLa cells 
expressing WT Parkin were also treated with DMSO for 6h (second row). Cells 
were stained for Parkin Ser65 phosphorylation (anti-phospho-Ser65 antibody) 
or total Parkin (anti-Parkin antibody); mitochondria were labelled using MITO-
ID® Red. Data representative of 4 independent experiments. 
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5.6 Analysis of Ubl domain interaction with Ubl Parkin: regulation 
by UbiquitinPhospho-Ser65 
5.6.1 UbiquitinPhospho-Ser65 disrupts Ubl binding to Parkin  
To probe the mechanism by which ubiquitinPhospho-Ser65 enhances Parkin Ser65 phosphorylation, 
the crystal and NMR structures of the Ubl domain and full-length Parkin were examined 
(Sakata et al., 2003, Tashiro et al., 2003, Tomoo et al., 2008, Riley et al., 2013, Spratt et al., 
2013, Trempe et al., 2013, Wauer and Komander, 2013). Structural analysis of the Ubl domain 
revealed that Ser65 resides in a loop adjacent to the fifth -strand that exhibits conformational 
flexibility (Sakata et al., 2003, Tashiro et al., 2003, Tomoo et al., 2008) and may only be 
partially surface accessible in the full-length structure. The Ubl domain itself binds to the 
RING1 domain (Trempe et al., 2013) and can interact with Ubl Parkin in trans (Chaugule 
et al., 2011). It is therefore plausible that ubiquitinPhospho-Ser65 binding might alter the 
interaction between the Ubl domain and the C-terminal domain in a way that renders Ser65 
of the Ubl domain more accessible for phosphorylation by PINK1.  
In order to address this possibility, an Alphascreen in vitro binding assay was developed by 
Dr. Jinwei Zhang, in collaboration with members of the Drug Discovery Unit (University of 
Dundee). This robustly quantified the interaction between the Ubl domain (GST-Ubl, 
residues 1-76) and a C-terminal fragment of Parkin that contains the RING1 domain (Parkin 
80-465-biotin). The proteins were first expressed in E. coli (Appendix Figure 4) followed by 
binding to streptavidin coated donor beads (GST-Ubl) and glutathione coated acceptor beads 
(Parkin-80-465-biotin). Binding was established by monitoring the proximity-based 
luminescent signal and the optimal assay conditions were determined by titrating GST-Ubl 
at concentrations from 0-300 nM against Parkin-biotin at concentrations from 0-300nM. Cross 
titration analysis revealed the strongest binding signal was detectable at concentrations of 10 
nM Parkin (80-465)-biotin and 10 nM GST-Ubl.  
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These optimised conditions were then used to determine whether ubiquitinPhospho-Ser65 may 
influence the interaction between the Ubl domain and the rest of Parkin (Figure 5.14, 
performed by Dr. Scott Wilkie). The addition of increasing amounts of ubiquitinPhospho-Ser65, 
but not non-phosphorylated ubiquitin, led to dose-dependent disruption of GST-Ubl (1-76) 
binding to Parkin (80-465)-biotin with an IC50 of ∼0.2 M (Figure 5.14 A & E). This strongly 
suggested that upon binding to Parkin, ubiquitinPhospho-Ser65 disrupts the interaction of the Ubl 
domain with the Parkin C-terminal domain.  
The role of residue His302 in the ubiquitinPhospho-Ser65-mediated disruption of Ubl binding was 
next addressed. The binding of GST-Ubl to the Parkin H302A mutant was insensitive to 
increasing amounts of ubiquitinPhospho-Ser65 (Figure 5.14 B & E), in agreement with residue 
His302 playing an essential role in the binding of ubiquitinPhospho-Ser65 and promotion of PINK1-
mediated Parkin phosphorylation and the subsequent activation of Parkin. The activity of 
BAP tagged Parkin (80-465) wild-type and the H302A mutant was tested in parallel to that 
of Ubl Parkin to ensure that their activity is intact and any effects detected in the 
Alphascreen assay are not due to protein instability (Appendix Figure 3). Both BAP-tagged 
versions of Parkin displayed a similar activity to that of wild-type Ubl Parkin (Appendix 
Figure 3).  
To assess any interplay between ubiquitinPhospho-Ser65 and Ser65-phosphorylated Ubl domain 
(UblPhospho-Ser65) in the activation of Parkin, UblPhospho-Ser65 was generated, as described in Section 
2.2.30.1 to a stoichiometry of phosphorylation of ~90%, and Alphascreen assays were 
undertaken using this protein in addition to wild-type and H302A Parkin. The ability of 
UblPhospho-Ser65 to disrupt the GST-Ubl:Parkin (80-465) biotin interaction was tested, and under 
similar assay conditions, the ability of UblPhospho-Ser65 to disrupt the GST-Ubl:Parkin WT 
interaction was greatly reduced compared to that of the untagged Ubl domain or 
ubiquitinPhospho-Ser65. The mild disruptive effect observed is likely to be due to the presence of 
unphosphorylated Ubl (10%) present in the UblPhospho-Ser65 sample (Figure 5.14 C & E) and 
is consistent with the lack of effect of UblPhospho-Ser65 in promoting PINK1-dependent 
Chapter 5: Elaboration of molecular interaction of phosphorylated ubiquitin and Parkin 
159 
 
phosphorylation of Parkin (Figure 5.3). Similarly, UblPhospho-Ser65 was only able to weakly 
disrupt the GST-Ubl to Parkin H302A interaction (Figure 5.14 D & E), which is again likely 
to be due to unphosphorylated Ubl in the UblPhospho-Ser65 sample.  
 
Figure 5.14 UbiquitinPhospho-Ser65-mediated disruption of binding between the  
Ubl domain and Ubl Parkin is dependent on residue His302.  
An AlphaScreenTM binding assay of Parkin Ubl domain and C-terminus of 
Parkin was established. GST-Ubl (residues 1-76) and wild-type C-terminal 
Parkin-Biotin (residues 80-465) were incubated with streptavidin-coated donor 
beads and Glutathione acceptor beads for 60 min. (A, B) Phosphorylated 
(ubPhosSer65) and wild-type (ub) ubiquitin was tested with wild-type (wt) (A), or 
H302A Parkin (B). (C, D) Phosphorylated (UblPhosSer65) or wild-type Ubl 
domain was tested with wild-type (C) or H302A Parkin (D). (E) Table showing 
the IC50 values (in nM) derived from graphs. ND indicates incomplete inhibition 
of the  interaction. Data show mean of one trial +/- s.d., n=3 for each condition 
(A-D). 
Chapter 5: Elaboration of molecular interaction of phosphorylated ubiquitin and Parkin 
160 
 
5.7 Purified Ser65–phosphorylated Parkin exhibits constitutive 
activity that is no longer sensitive to UbiquitinPhospho-Ser65  
All the data presented so far indicate that binding of ubiquitinPhospho-Ser65 to Parkin may 
represent a critical first step in the Parkin activation cascade. This suggests that the ensuing 
Parkin Ubl Ser65 phosphorylation by PINK1 is likely to represent the critical effector step 
leading to activation of Parkin E3 ligase activity. To obtain further experimental evidence 
for this model, I investigated whether near-maximally phosphorylated purified Ser65–
phosphorylated Parkin (ParkinPhospho-Ser65) could be further activated by addition of 
ubiquitinPhospho-Ser65. His-SUMO tagged full-length Parkin was purified from E. coli, captured 
on Ni-NTA-agarose and phosphorylated by MBP-TcPINK1 before the His-SUMO-tag was 
removed and Parkin was purified via nickel affinity and size exclusion chromatography 
(performed by Dr Axel Knebel). Under super-saturating phosphorylation conditions, a 
heterogeneous mixture containing approximately 60% phosphorylated Parkin was obtained, 
as confirmed directly by Aquapeptide analysis (performed by Dr. Julien Peltier, Figure 5.15).  
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Figure 5.15 Quantitative analysis of phosphorylation of full length Parkin at 
Ser65 using Aquapeptides for p-Ser65.  
Table summarising the peptides in wild-type Parkin (WT) (left), WT 
ParkinPhospho-Ser65 (P-Parkin WT) samples (middle), and H302A ParkinPhospho-Ser65 
(P-Parkin H302A) samples (right). LC-MS/MS spectra (left panel) of non-
phospho peptides of WT Parkin (top), P-Parkin WT (middle) and P-Parkin 
H302A (bottom). LC-MS/MS spectra (right panel) of phospho peptides of WT 
Parkin (top), P-Parkin WT (middle) and P-Parkin H302A (bottom).  
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5.7.1 Purified Ser65–phosphorylated Parkin is no longer sensitive to 
UbiquitinPhospho-Ser65  
Next, I compared the activity of ParkinPhospho-Ser65 and wild-type Parkin in the presence or 
absence of increasing amounts of non-phosphorylated ubiquitin or ubiquitinPhospho-Ser65. I 
assembled the ubiquitylation assays as described in Section 2.2.28.2: 0.05 mM Flag-ubiquitin 
was used in conjunction with the indicated amounts of untagged phospho or non-phospho 
ubiquitin. As previously described (Section 4.7), wild-type Parkin was inactive upon titration 
of ubiquitin, however, a dose-dependent increase in activity was observed when 
ubiquitinPhospho-Ser65 was added, as judged by the formation of free ubiquitin chains, Miro1 
ubiquitylation and Parkin autoubiquitylation (Figure 5.16). Strikingly, the purified 
ParkinPhospho-Ser65 was insensitive to both ubiquitin and ubiquitinPhospho-Ser65; it exhibited marked 
basal E3 ligase activity evidenced by free polyubiquitin chain formation, Miro1 multi-
monoubiquitylation and Parkin autoubiquitylation (Figure 5.16). The basal activity of 
ParkinPhospho-Ser65 was substantially greater than that of wild-type Parkin, based on levels of 
Miro1 ubiquitylation.  
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Figure 5.16 Phosphorylated Parkin at Ser65 exhibits significant constitutive 
activity.  
2 g of full-length wild-type (Parkin WT) or phosphorylated at Ser65 (P-Parkin 
WT) Parkin were analysed using E3 ligase assay with increasing amounts of 
non-phospho-ubiquitin or ubiquitinPhosphoSer65 as indicated. Parkin activity was 
evaluated by immunoblotting as follows: ubiquitin (anti-FLAG-HRP), Parkin 
(anti-Parkin antibody) and Miro-1 (anti-SUMO1 antibody). Data 
representative of 3 independent experiments. 
To test if the insensitivity to ubiquitinPhospho-Ser65 was a result of ParkinPhospho-Ser65 activity 
having reached a plateau, I set up a ubiquitylation assay using 10-fold less wild-type or 
phosphorylated Parkin in conjunction with increasing ubiquitinPhospho-Ser65 levels, as before 
(Figure 5.17). No change in ParkinPhospho-Ser65 activity was observed when ubiquitinPhospho-Ser65 
was added, whilst wild-type Parkin displayed a similar activity pattern to that seen at the 
higher concentration (Figure 5.17), suggesting that insensitivity may be an intrinsic trait of 
ParkinPhospho-Ser65.  
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Figure 5.17 A lower titre of Ser65-phosphorylated Parkin activity remains 
insensitive to ubiquitinPhospho-Ser65.  
0.22g of wild-type (Parkin WT) or Parkin phosphorylated at Ser65 (P-Parkin 
WT) were incubated in an E3 ligase assay supplemented with non-phospho-
ubiquitin or ubiquitinPhospho-Ser65 as indicated. Parkin activity was evaluated by 
immunoblotting as follows: ubiquitin (anti-FLAG-HRP antibody; 1:10000) and 
Miro-1 (anti-SUMO1 antibody; 1:2000).  
5.7.2 Time course analysis of ParkinPhospho-Ser65 activity 
Subsequently, I tested if ubiquitinPhospho-Ser65 sensitivity could be observed in a time-dependent 
fashion and has not been previously detected due to inadequacies in the dynamic range of 
the assay detection method or the reaction reaching a non-linear phase. To achieve this, I 
undertook a time course analysis of Parkin E3 ligase activity, wherein wild-type or 
phosphorylated Parkin protein was incubated with a fixed amount of FLAG-ubiquitin and 5 
g of untagged wild-type or phosphorylated ubiquitin. The reactions were allowed to continue 
for the times indicated (Figure 5.18). In agreement with the previous analysis, no 
enhancement of ParkinPhospho-Ser65 activity by ubiquitinPhospho-Ser65 could be observed at any of 
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the time points tested (Figure 5.18) as judged by free polyubiquitin chain formation and 
Parkin autoubiquitylation.  
 
Figure 5.18 Timecourse analysis of Ser65-phosphorylated Parkin activity in the 
presence or absence of ubiquitinPhospho-Ser65.  
2g of wild-type (Parkin WT) or Parkin phosphorylated at Ser65 (P-Parkin 
WT) were subjected to E3 ligase assays in the presence of non-phospho-
ubiquitin or ubiquitinPhospho-Ser65 as indicated. Reactions were terminated at the 
indicated timepoints by the addition of LDS loading buffer. Parkin activity was 
evaluated by immunoblotting as follows: ubiquitin (anti-FLAG-HRP 
antibody), and Parkin (anti-Parkin antibody). 
5.7.3 ParkinPhospho-Ser65 His302Ala mutant is constitutively active 
A ~90% phosphorylated H302A mutant Parkin was also generated by Dr. Axel Knebel (Figure 
5.15) and tested in the ubiquitylation assays. I assembled the E3 ligase assays in parallel with 
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wild-type as well as ParkinPhospho-Ser65 with or without ubiquitinPhospho-Ser65, as described in 
Section 2.2.28.2 (Figure 5.19).  Both ParkinPhospho-Ser65 and the ParkinPhospho-Ser65 H302A mutant 
displayed similar levels of activity independent of ubiquitinPhospho-Ser65, providing further 
evidence that the H302A mutation is not significantly perturbing the structural fold and 
integrity of Parkin.  
 
Figure 5.19 Purified Ser65-phosphorylated Parkin H302A exhibits constitutive 
E3 ligase activity that is insensitive to ubiquitinPhospho-Ser65.  
2 g of full-length wild-type (P-Parkin WT) or H302A (P-Parkin H302A) 
Parkin phosphorylated at Ser65 were subjected to E3 ligase assays 
supplemented with non-phospho-ubiquitin or ubiquitinPhospho-Ser65 as indicated. 
Parkin activity was evaluated by immunoblotting as follows: ubiquitin (anti-
FLAG-HRP antibody), Parkin (anti-Parkin antibody) and Miro-1 (anti-
SUMO1 antibody).  
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5.7.4 ParkinPhospho-Ser65 loses activity upon dephosphorylation by calf alkaline 
phosphatase 
 To confirm that the constitutive activity of ParkinPhospho-Ser65 was caused by phosphorylation 
rather than structural instability caused by the phosphorylation and subsequent 
repurification conditions, I treated ParkinPhospho-Ser65 with increasing amounts of calf alkaline 
phosphatase, and a subsequent dose-dependent reduction in its activity was observed, as 
indicated by diminishing free polyubiquitin chain formation and Parkin autoubiquitylation, 
which  correlated with the decreased phosphorylation at Parkin Ser65 (Figure 5.20). 
 
Figure 5.20 Dephosphorylation of Parkin at Ser65 leads to reversal of Parkin E3 
ligase constitutive activity. 
 1 μg of full-length Parkin phosphorylated at Ser65 was subjected to increasing 
amounts of alkaline phosphatase as indicated. Reactions were then incubated 
with ubiquitylation assay components (E1 and UbcH7) in the presence of 0.05 
mM FLAG-ubiquitin. Reactions were terminated after 60 min by the addition 
of LDS loading buffer. The effects on Parkin E3 ligase activity were evaluated 
by ubiquitin chain formation ubiquitylation and Parkin autoubiquitylation 
evaluated by immunoblotting as follows: ubiquitin (anti-FLAG-HRP 
antibody), Parkin (anti-Parkin antibody). The degree of Parkin Ser65 de-
phosphorylation was monitored using anti-pSer65 Parkin antibody. Data 
representative of 4 independent experiments. 
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5.8 Discussion and Summary 
Parkin was historically reported to be a constitutively active RING E3 ligase, later found to 
interact with another PD-linked protein PINK1. During the last 4 years, the field of PINK1 
and Parkin study has undergone a ‘violent intellectual revolution’ (Kuhn, 1962) that has not 
only refuted the initial conclusions, demonstrating Parkin to be a tightly-regulated 
autoinhibited E3 ligase (Okatsu et al., 2015, Shiba-Fukushima et al., 2014, Ordureau et al., 
2014, Chaugule et al., 2011), but also uncovered a multi-dimensional regulatory mechanism 
underpinning this previously enigmatic relationship. This chapter presents recent insights 
into the cogs of the complicated machinery, uncovering the regulation of Parkin in the context 
of mitochondrial health.  
It was previously known that upon mitochondrial damage, PINK1 becomes stabilized on the 
mitochondrial membrane via association with the TOM complex (Lazarou et al., 2012), 
followed by its activation, Parkin recruitment (Geisler et al., 2010, Narendra et al., 2010, 
Vives-Bauza et al., 2010) and activation (Matsuda et al., 2010) as well as substrate 
ubiquitylation. More specifically, following PINK1 activation, Parkin and ubiquitin were 
found to be phosphorylated at Ser65 (Kondapalli et al., 2012, Shiba-Fukushima et al., 2012, 
Koyano et al., 2014, Kane et al., 2014, Kazlauskaite et al., 2014c) and ubiquitinPhospho-Ser65 was 
shown to subsequently enhance Parkin activity (Figure 5.21 A). Several recent studies have 
revealed that ubiquitinPhospho-Ser65 acts as Parkin receptor on the mitochondria (Shiba-
Fukushima et al., 2014, Okatsu et al., 2015) and contributes to a feed-forward cascade, 
wherein autoinhibited Parkin continuously samples the mitochondrial membrane and upon 
membrane depolarisation becomes activated via phosphorylation at Ser65 by PINK1 (Figure 
5.21 B). Activated Parkin is then able to ubiquitylate outer mitochondrial membrane 
proteins, which can then be phosphorylated by PINK1, further enhancing recruitment of 
Parkin (Ordureau et al., 2014) (Figure 5.21 B). My discoveries presented in this chapter, 
together with a recent structural paper (Wauer et al., 2015a), add missing details into the 
picture.  
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Figure 5.21 Regulation of Parkin E3 ligase activity by PINK1-mediated 
phosphorylation 
A PINK1 mediates phosphorylation of Parkin and ubiquitin at Ser65, 
phosphorylation of ubiquitinPhospho-Ser65 bound Parkin is largely enhanced. B 
Upon mitochondrial membrane depolarization, PINK1 gets stabilized on the 
OMM, where it phosphorylates ubiquitin at Ser65 on the ubiquitylated OMM 
proteins. Cytoplasmic Parkin samples the mitochondrion and gets recruited by 
binding to ubiquitinPhospho-Ser65 when it itself gets phosphorylated at Ser65 and 
fully activated. This leads to further ubiquitylation of OMM and cytoplasmic 
proteins and subsequent recruitment of mitophagy machinery. 
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Firstly, upon binding to full-length Parkin, ubiquitinPhospho-Ser65 enhances Ubl Ser65 
phosphorylation by PINK1 in a highly specific manner (Figure 5.2 & Figure 5.3). Notably, 
all species of dimeric and tetrameric ubiquitin tested, as well as a model mono-ubiquitylated 
substrate (Figure 5.4) could be phosphorylated by PINK1 to a similar, if not equivalent, 
extent and led to increased Parkin phosphorylation, suggesting that this is a wide-spread 
effect. This is particularly interesting since Parkin has been demonstrated by myself and 
others to form multiple ubiquitin chain linkages (Chapter 3) (Ordureau et al., 2014). It will 
be necessary in future to understand how uniform the phosphorylation of each of the linkages 
is in vivo as well as to determine the biological outcomes of these phosphorylation events. 
Given that ubiquitin phosphorylation is not as yet a well understood phenomenon, it will be 
important to search for phospho-ubiquitin specific adaptor proteins and to learn if ubiquitin 
chain topology-driven cellular events are similarly controlled and effected once one or more 
phospho moieties are present. It would also be insightful to assess whether (multi)-
monoubiquitylated and polyubiquitylated substrates of Parkin such as Miro1/2 or 
Mitofusin1/2 (Sarraf et al., 2013, Kazlauskaite et al., 2014b) become phosphorylated at 
ubiquitin Ser65, and if so whether this plays a role in aiding Parkin activation. Finally, it will 
be critical to define the interactions and timeline of PINK1 phosphorylation of free and 
substrate-bound mono- and poly- ubiquitin and how the PINK1-modified ubiquitome lead to 
altered cellular function and mitochondrial quality control. 
In addition, His302 and Lys151 in Parkin were defined as critical residues for ubiquitinPhospho-Ser65 
binding. The results presented in this chapter clearly show the direct involvement of both 
residues in direct binding between Parkin and phospho-ubiquitin (Figure 5.9), as well as the 
functional impairment upon mutation of these residues to alanine (Figure 5.5 & Figure 5.7). 
The importance of His302 was also confirmed in cell studies, where a loss of Parkin 
phosphorylation as well as activity were observed when the Parkin H302A mutant was 
analysed (Figure 5.11 & Figure 5.12). Whilst my study did not define the entire phospho-
ubiquitin binding site, several recent papers have provided structural insights into 
ubiquitinPhospho-Ser65 binding to Parkin (Wauer et al., 2015a, Kumar et al., 2015, Sauve et al., 
2015). It was revealed that in addition to RING1 domain, Ubl interacts with IBR and REP 
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(Sauve et al., 2015, Kumar et al., 2015). It was demonstrated that besides Lys151 and His302, 
Arg305, Ala320 and Gly284 are important for ubiquitinPhospho-Ser65-mediated Parkin activation 
(Wauer et al., 2015a, Sauve et al., 2015). In addition, it was shown that binding of 
phosphorylated ubiquitin destabilizes the Ubl interaction with the RING1-IBR-RING2 
catalytic core of Parkin, leading to displacement of the Ubl domain and it being rendered 
more accessible for PINK1 phosphorylation (Wauer et al., 2015a, Sauve et al., 2015). These 
results agree well with the Alphascreen data presented in this chapter (Figure 5.14), which 
display a loss of interaction between the Ubl domain and Ubl Parkin in trans upon binding 
of ubiquitinPhospho-Ser65. The Alphascreen technology could therefore be exploited as a tool for 
high-throughput screening of Parkin activators; candidate molecules could be screened for 
their ability to disrupt the in trans interaction between the Ubl domain and Ubl Parkin, 
thereby mimicking the effects of phosphorylated ubiquitin.   
Immunocytochemistry has been an invaluable tool in studying PINK1-Parkin mitochondrial 
dynamics in the past as well as in the present. Results displayed in Figure 5.13 confirm the 
essential role of ubiquitin phosphorylation in Parkin recruitment to the mitochondrial 
membrane. However, this data also illuminates several other important points: Parkin 
phosphorylation by PINK1 is highly specific, as no signal could be detected when cells were 
treated with DMSO and only extremely low levels of signal were observed after CCCP 
treatment when a Parkin S65A mutant was used. In addition, once the H302A mutant was 
analysed, I observed that it was still becoming phosphorylated although no retention on the 
mitochondrial membrane could be detected. This might reflect the decreased binding 
efficiency between H302A Parkin and ubiquitinPhospho-Ser65 (>250 times lower than wild-type 
Parkin, Figure 5.9) and therefore a much more transient state of interaction. Alternatively, 
this could be a result of dynamic Parkin sampling of the mitochondrial surface after PINK1 
activation and the lack of the key element required for binding to phosphorylated ubiquitin. 
Lastly, a very important observation comes from the C431F mutant. Most of the studies 
analysing Parkin recruitment to the mitochondrial membranes look at the shift in the global 
cytosolic Parkin levels to a membrane-retained form. However, analysis of the C431F mutant 
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suggests that this approach is insufficient. While no change in global Parkin distribution of 
the C431F mutant could be observed when the total Parkin antibody was used (similar to 
previously published studies (Ordureau et al., 2014, Kane et al., 2014, Koyano et al., 2014, 
Fiesel et al., 2015)), ParkinPhospho-Ser65 staining reveals a clear cluster of Parkin C431F tethered 
to the mitochondria. This data raises questions regarding the sequence of events in the Parkin 
recruitment cascade – while Ordeau and colleagues claim that Parkin activity is a prerequisite 
for mitochondrial translocation (Ordureau et al., 2014), their interpretation is based on 
inspection of total Parkin levels. The data presented in Figure 5.13 throw these results into 
question, since the signal from the catalytically dead phosphorylated Parkin C431F is located 
exclusively on the mitochondria. It will therefore be extremely important to develop tools 
that enable the scientific community to look at this signalling cascade in much greater and 
finer detail – a detailed study on ubiquitin phosphorylation combined with Parkin 
phosphorylation will need to be conducted in a way that examines these events as they occur 
in both time and space, which would make it possible to more firmly determine the sequence 
of events. This finding also raises the question of other E3 ligases present on the mitochondria 
and their contribution to the signalling cascade. In addition, Okatsu and colleagues have 
revealed that free ubiquitin can be phosphorylated and diffuse throughout the cell (Okatsu 
et al., 2015); it will therefore be important to test whether Parkin perhaps gets activated to 
differing levels in different subcellular locations, and if so, whether this also contributes to 
the maintenance of cell health in the same way as mitophagy. 
Finally, a question as to the distinct function of the two phosphorylation events remains only 
partially answered. The results presented in the last part of this chapter strongly argue in 
favour of Parkin phosphorylation being the main E3 ligase activating event (Figure 5.16, 
Figure 5.17, Figure 5.18, Figure 5.19 & Figure 5.20), in agreement with other reports 
(Ordureau et al., 2014, Shiba-Fukushima et al., 2014). However, multiple studies have 
displayed in vitro ubiquitinPhospho-Ser65-driven Parkin activation (Kane et al., 2014, Koyano et 
al., 2014, Kazlauskaite et al., 2014c). The structure of ubiquitinPhospho-Ser65 bound to Pediculus 
humanus Parkin has revealed that while several autoinhibitory surfaces have been dismantled, 
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the catalytic cysteine remains obscured (Wauer et al., 2015a). It will therefore be important 
to reconcile these data and reach an in-depth understanding of each contributing factor in 
this signalling cascade. 
 
 
  
Appendix 
174 
 
6 Appendix 
 
Figure 6.1 UbiquitinPhosphoSer65 specifically promotes Parkin Ser65 phosphorylation 
by PINK1.  
The effect of ubiquitinPhosphoSer65 on the ability of TcPINK1 to phosphorylate wild-
type (WT), S65A, and Ubl-deleted (Ubl; residues 80-465) Parkin was 
investigated in a kinase assay. The indicated Parkin species was incubated with 
or without ubiquitinPhosphoSer65in a kinase assay analysed by SDS/PAGE. Proteins 
were detected by Colloidal Coomassie Blue staining (top panel) and incorporation 
of [γ-32P] ATP was detected by autoradiography (bottom panel). 
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Figure 6.2 The mitochondrial protein HAX1 is phosphorylated by TcPINK1 in 
vitro.  
GST-HAX1 (full length) (2 μM) was incubated in the presence of full-length wild-
type TcPINK1 (1–570) and kinase inactive TcPINK1 (D359A) and Mg2+ [γ-32P] 
ATP. Assays were terminated by addition of LDS loading buffer and separated 
by SDS-PAGE. Proteins were detected by Colloidal Coomassie Blue staining 
(upper panel) and incorporation of [γ-32P] ATP was detected by autoradiography 
(lower panel). 
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Figure 6.3 Parkin H302A does not disrupt E3 ligase activity  
Full-length wild-type (WT), H302A or Ubl WT, BAP-tagged WT (BAP-WT) 
or BAP-tagged H302A (BAP-H302A) Parkin was incubated in presence or 
absence of wild-type (WT) or kinase-inactive (KI) PINK1 in a kinase reaction as 
indicated. Ubiquitylation reactions were then initiated by addition of 
ubiquitylation assay components, including 0.05 mM Flag-ubiquitin. Reactions 
were analysed by immunoblotting. Ubiquitin and Parkin were detected using anti-
FLAG and anti-Parkin antibodies, respectively.  
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Figure 6.4 Expression of proteins utilised in Alphascreen binding assay. 
 2g of the following proteins were analysed by SDS/PAGE and proteins were 
detected by Colloidal Coomassie Blue. Parkin Ubl (residues 1-76), GST-Parkin 
Ubl, Parkin (80-465), Parkin (80-465)-biotin affinity peptide (BAP), Parkin (80-
465)-biotin.  
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